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Computers are incredibly fast, accurate and stupid.
Human beings are incredibly slow, inaccurate and brilliant.
Together they are powerful beyond imagination.
A. Einstein
I tried to do my best...
v
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Introduction
P-glycoprotein is an ATP-dependent eux transport protein which is highly
expressed in many human tissues such as the intestinal epithelium and the
blood-brain barrier, and is over-expressed in many cancer cells.1 This trans-
porter carries a wide variety of chemically unrelated compounds. It binds
them within the cell lipid membrane, and 
ips them to the outer lea
et or
exports them to the extracellular medium.2 Since P-glycoprotein aects the
distribution of many drugs, assessing the interactions between drugs and P-
glycoprotein at an early stage of drug development is important.
It has been shown that the binding of a drug to the transporter occurs in a
two-step process.3{5 (i) The drug partitions from the extracellular environment
to the lipid membrane, and after diusion to the inner cytosolic lea
et of
the bilayer (Figure 1, arrow 1), (ii) it binds to P-glycoprotein most likely via
hydrogen bond formation (Figure 1, arrow 2).
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Figure 1: Two-step transport mechanism of P-glycoprotein. The drug has
rst to partition from extracellular or intracellular aqueous environ-
ment into the inner lea
et of the lipid bilayer (1), and then from
the lipid to the transporter (2) (taken from ref.6).
Dierent methods have been used to assess the lipid-water partition coef-
cient, such as isothermal titration calorimetry, and lipid monolayer insertion
measurements. However, the lipid-water partition coecient depends on the
lipid used, and in turn on the lateral packing density of the lipid layer. There-
fore an approach based on surface activity measurements was developed, which
allows the prediction of the lipid-water partition coecient for membranes of
dierent lateral packing densities.7 Measurements of the surface pressure of
1
2the drug in buer solution as a function of concentration (Gibbs adsorption
isotherm) yields the air-water partition coecient (Kaw ), the critical micellar
concentration (CMC), and the cross-sectional area of the compound (AD),
provided experiments are performed under conditions of minimal electrostatic
repulsion. Since air has a dielectric constant close to that of the lipid core
region of a membrane, there is a direct relationship between the partition
of a drug into the air-water interface, and the partition into the lipid-water
interface.8 The cross-sectional area, as well as the lipid-water partition coef-
cient (and by extension the air-water partition coecient), are thus crucial
parameters to assess the binding and diusion of a drug into a lipid bilayer.
In a rst part of the thesis, I focused on the membrane binding step. Since
the cross-sectional area of a compound is a crucial parameter for drug parti-
tioning into the lipid bilayer, the quality of the data obtained by mean of surface
activity measurements are most important. For this purpose, in a rst step,
I improved the calibration of the experimental settings, by assessing several
factors like the evaporation or the solvent eect. In a second step, I developed
computer routines for unbiased evaluation of these measurements. In a third
step, I developed an algorithm to calculate the cross-sectional area of a com-
pound oriented at a hydrophilic-hydrophobic interface; this algorithm has been
calibrated on a set of measured data, in order to nd from a conformational
ensemble the conformation of the membrane-bound drug.
In a second part of the thesis, I focused on the binding of a drug to
P-glycoprotein. P-glycoprotein is monitored essentially by three types of as-
says, (i) the measurement of ATP hydrolysis activity of the transporter, (ii)
a competition assay against calcein-AM, and (iii) a transcellular transport as-
say through polarized P-glycoprotein over-expressing cell monolayer. Based
on a modular binding approach to assess the two-step binding of a drug to
P-glycoprotein (Figure 1),5 I developed several rules to predict the outcome
of these experimental assays. Each rule, predicting one particular assay, has
been tested on experimental datasets.
In a third part of the thesis, I developed a working interface to handle
multiple structures of compounds, to calculate the new descriptors involved in
the two-step binding of drugs to P-glycoprotein (membrane partitioning, and
binding to the transporter), and to calculate the outcome of the prediction
rules. Moreover the working interface has been designed in a way the user can
easily dene new rules, or even introduce a new multidrug transporter (e.g.
the multidrug transporter MRP1).
Starting from well characterized physical-chemical parameters, I developed
a coherent ensemble of descriptors to assess by a rule-based approach the
thermodynamics and kinetics of P-glycoprotein activation. This ensemble has
been embedded in a customizable working interface, allowing easy evaluation
of the in silico predictions.
Chapter 1
Assessment of the
cross-sectional area
1.1 Introduction
1.1.1 Experimental part
For accurate use of the two monolayer Langmuir troughs (20 mL and 3 mL)
a calibration is required. It has been shown9 that several parameters have to
be taken into account, like the evaporation of the liquid, the in
uence of the
injected volume and the in
uence of the solvent in which the tested compound
is dissolved. These factors have an important impact on the measured surface
pressure. By making measurements over a broad concentration range, or
successive measurements with dierent concentrations containing overlapping
regions, we noted that the corrections applied to the data obtained in the
3 mL trough were not optimal. Indeed, as depicted in Figure 1.5, we could
not see an overlap in the surface pressure for two identical concentrations
when two dierent stock solutions with a low and a high concentration were
used, especially for large injected volumes.
In order to enhance the accuracy of the data evaluation, we improved the
correction factors with respect to the following points:
 temperature dependant evaporation of the buer,
 in
uence of the total volume (buoyancy) on the measured surface pres-
sure, and
 in
uence of the solvent (water, methanol, DMSO) on the measured
surface pressure.
3
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1.1.2 Computational part
The need of a software for a more eective evaluation of the monolayer data
has become important with the multiplication of the measurements made in
both 3 mL and 20 mL troughs. For this purpose, we developed a way to
automatize the selection of the quasi-linear part of the  = f (log(C)) plot
(Gibbs adsorption isotherm), in order to remove the bias inherent to the manual
selection of these points.
We then nalized a method to determine the critical micellar concentration
(CMC) in an automatical way.
Finally, we improved the determination of the averages of the measured
surface pressures and the injection times of the raw data given by the automatic
recorder coupled to the 3 mL trough.
1.2 Experimental part: calibration of the monolayer
troughs
1.2.1 Correction factor for the water evaporation
Fischer9 showed that in the 20 mL trough, the injected amount exactly com-
pensates the evaporation, as long as the injections are made every 30 minutes.
For the 3 mL trough, we could see that the evaporation and the injected volume
did not compensate each other. In order to estimate the evaporation in the
3 mL trough, we placed the trough covered with a plastic hood and lled with
3 mL of buer solution (50 mM TRIS, 114 mM NaCl, pH 7.4) on an analytical
balance at room temperature (21:5 C), with a standard lter paper plunged
into the buer to mimic the usual conditions of experiment. Figure 1.1(a)
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Figure 1.1: Evaporation in the 3 mL monolayer trough: (a) shows the ab-
solute volume decrease with the time at 21:5 C; (b) shows the
relative evaporation of the water.
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shows the linear decrease of the total volume with time (a measurement was
made every minute during 20 minutes and every ve minutes during additional
70 minutes). By calculating the relative evaporation per minute:
relative evaporation =
1
2

(
Vi+1   Vi
ti+1   ti +
Vi   Vi 1
ti   ti 1
)
; (1.1)
where Vi is the measured volume at time ti , Vi+1 the volume at time ti+1,
and Vi 1 the volume at time ti 1, it appears that the volume decrease in the
trough is constant after 15 minutes, as shown in Figure 1.1(b). The average
evaporation was estimated as -0.37 L/min at 21:5 C (dotted line) and -
0.45 L/min at 24:5 C (dashed line) over a period of 90 minutes (average
duration of an experiment).
The in
uence of the presence of a monolayer of drugs on the surface of
the buer on the evaporation was also measured. As an example for a surface
active compound, we used the local anesthetic dibucaine and applied it at a
concentration of 1 mM (by adding 100 L of a stock solution of 31 mM dibu-
caine prepared in pure water in 3 mL of buer solution), which elicits around
half maximum surface pressure. The negative control was 100 L of pure
water in 3 mL of buer solution. The results of this experiment, shown in
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Figure 1.2: Relative evaporation in the 3 mL monolayer trough without ()
and with () 1 mM of dibucaine
Figure 1.2, demonstrate that there is a perceptible in
uence of the presence
of a drug monolayer at the air-water interface on the water evaporation. It is,
however, small enough to be neglected.
The in
uence of stirring the buer on evaporation was determined by us-
ing the same setup as before but applying in addition the stirring device. To
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avoid disturbances by vibrations, the experiment was performed outside of the
analytical balance because of its high sensitivity. The weight of the trough
was measured every 5 minutes during 65 minutes. The measurement was
performed twice at 23:5 C, with 100 L of pure water (control) and with
100 L of dibucaine (nal concentration: 1 mM). The results are shown in
Figure 1.3. The average evaporation without drug (-0.304) is very close to
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Figure 1.3: Relative evaporation in the 3 mL monolayer trough under stirring
condition, without () and with () 1 mM of dibucaine. The
dashed line corresponds to the average of all values.
the one with drug (-0,319), conrming the negligible impact of a monolayer
of surface-active compound at the air-water interface of the 3 mL trough.
Interestingly, the stirring seems to decrease the evaporation by 30%.
As a consequence of these observations, the only parameters taken into
account for the evaporation are:
temperature of the local environment (room temperature), and
elapsed time between each injection.
These two parameters are important for the accuracy of our measurements,
but the total volume and the solvent in which the compounds are dissolved
are even more crucial as shown below.
1.2.2 Correction factor for the liquid level
We then tested the in
uence of the injected amount of a stock solution on the
surface pressure, , particularly in the 3 mL trough. An increase of the volume
1.2. EXPERIMENTAL PART 7
will lead to a change in the buoyancy force exerted on the lter paper. The
impact of the variation of total volume on the measured surface pressure was
determined by adding increasing amounts of water to 3 mL of buer (50 mM
TRIS, 114 mM NaCl, pH 7.4) every 5 minutes. Figure 1.4 shows that the
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Figure 1.4: Eect of addition of water to 3 mL of buer on the measured
surface pressure.
increase of the total volume has a linear correlation with the increase of the
measured surface pressure in the 3 mL trough. We went up to an addition
of 1920 L, a volume which is never reached experimentally. The linear t of
these data points leads to equation 1.2:
 = 1:976  10 3  V   5:928: (1.2)
The previously dened evaporation parameter was applied to the measured
surface pressure. This equation will be used as an additional correction factor
for the measured surface pressure.
These correction factors for evaporation and liquid level lead to a better eval-
uation of the surface pressure measurements, as shown in Figure 1.5: the
data evaluated with the new corrections (open symbols) are much closer to
the linear t (dotted line) of the surface pressure measurements than the data
evaluated previously.9
1.2.3 Correction factor for the solvent
Many compounds are not well soluble in water, and therefore stock solutions
have to be prepared in an organic solvent, usually methanol or DMSO. We
measured the eect of methanol in the 20 mL trough (T. Alt and X. Li-
Blatter, unpublished results), as well as in the 3 mL through. The troughs
8 CHAPTER 1. ASSESSMENT OF THE CROSS-SECTIONAL AREA
1E-5 1E-4 1E-3 0,01 0,1
0
5
10
15
20
25
 (m
N
/m
)
Log(C) (M)
 previous corrections
 New corrections
Figure 1.5: Comparison between previous9 corrections () and the new de-
ned corrections () for the  = f (log(C)) plot of methyl-
cyclodextrin in the 3 mL trough; the dotted line represents the
linear t of the new corrected data.
were lled with buer (50 mM TRIS, 114 mM NaCl, pH 7.4). The results
are shown in Figure 1.6. Both sets of data could be tted with the extended
Langmuir model:
 =
(
a  b  V 1 c
1 + b  V 1 c
)
; (1.3)
where  is the surface pressure in mN/m, V, the total injected volume in
L and a, b and c are variable parameters. The t parameters obtained
were a = 45:92, b = 1:92  10 3, c = 6:91  10 2 and a = 11:66, b = 2  10 5,
c =  5:81  10 1 for the 3 mL (Figure 1.6(a)) and the 20 mL trough (Fig-
ure 1.6(b)), respectively. To check the relevancy of the correction factor, we
compared previous results obtained with the same compound (amitriptyline,
chlorpromazine) dissolved either in water or in methanol (data not shown). We
obtained identical  = f (log(C)) plots by subtracting the correction factor
from the methanol data set.
For the DMSO, the same approach was made, with the same buer. Data
for the 20 mL trough measurement were taken from a previous experiment
(T. Alt and X. Li-Blatter, unpublished results). The two results are shown in
Figure 1.7(a) for the 3 mL trough and in Figure 1.7(b) for the 20 mL trough.
The DMSO eect on the 3 mL trough was also tted with equation 1.3.
However, the eect of the DMSO on the 20 mL trough could not be tted
with the extended Langmuir model; the only satisfying tting model was the
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Figure 1.6: Eect of methanol on the measured surface pressure: (a) shows
the eect on the 3 mL trough; (b) shows the eect on the 20 mL
trough; the dotted curves represent the extended Langmuir model
t.
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Figure 1.7: Eect of DMSO on the measured surface pressure: (a) shows
the eect on the 3 mL trough; (b) shows the eect on the 20 mL
trough; the dotted curves represent the extended Langmuir model
t (a), and the Lorenz model t (b).
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Lorenz model:
 = 0 +
2A

w
4(V   Vc)2 + w2 ; (1.4)
where  is the surface pressure in mN/m, V the total injected volume in L
and 0, A, w and Vc four variable parameters. The t parameters obtained
were 0 =  2:36, A = 5:14  104, w = 1:94  103 and Vc = 2:42  103.
1.3 Computational part
1.3.1 Automatic evaluation of -Log(C) plots
After having establish consistent correction factors for the evaluation of the
measured surface pressures, the next step was to develop a software to fa-
cilitate the analysis of the  = f (log(C)) plots. The objective was also to
remove the bias induced by the manual selection of the quasi-linear part of
these plots. Indeed, it can be very dicult to choose by eye the best quasi-
linear part, and this method will not be reproducible and user-independent.
The most logical approach was to develop an automatized system which
would select the best quasi-linear part of the  = f (log(C)) plot in a rational
way. Thus, a Microsoftr Excel macro was programmed to full this task.
Figure 1.8: User interface of the Pi-Log(C) automation Excel macro
The user interface shown in Figure 1.8 allows a choice of the range of con-
centrations and surface pressure () measurements, and two dierent methods
of calculation for the automatic evaluation, which will be described further be-
low. The "More\ button opens a second panel, in which one can manually
choose the quasi-linear part of the plot and the surface pressure where the
CMC is reached, in case the program was unable to determine these parame-
ters.
The automatic selection of the quasi-linear part will be discussed in the
rst section, and some other features will be described in the second section.
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Automatic determination of the linear part
Here we will describe brie
y how the Excel macro determines the "best\ quasi-
linear part of the plot; two methods for evaluation, "derivative\ (A) and "min-
imax\ (B), were developed. "n\ represents the total number of data points
(i.e. the number of distinct concentrations for which a surface pressure was
measured). A datapoint is given by the log of a concentration and its cor-
responding measured surface pressure, and is abbreviated as "point\. The
method described below is the "derivative\ method (A).
1. Calculate the derivative for each point from 2 to n   1
2. Set the derivative of the rst and last point to 0
3. Calculate the sum of the derivatives for each group of k points (3  k 
n) as dened below:
3 points:
3∑
i=1
@i ;
4∑
i=2
@i ; : : : ;
k+2∑
i=k
@i ; : : : ;
n∑
i=n 2
@i
4 points:
4∑
i=1
@i ; : : : ;
k+3∑
i=k
@i ; : : : ;
n∑
i=n 3
@i
...
n points:
n∑
i=1
@i
(1.5)
4. Select for each group of k points (3  k  n) the one which has the
highest sum (i.e. the steepest part of the plot)
5. Calculate for the selected groups of 3 to n points their r2 (correlation
coecient)
6. Adjust all calculated r2 to a base 100 where 0 is the lowest r2 and 100
the highest r2
7. Choose the group which has the highest k and for which r2 is superior
or equal to 90
This group of k points represents the steepest part of the  = f (log(C)) plot
and shows a good ratio between the correlation coecient and the number of
points.
A second possibility of evaluation is the "minimax\ method (B) which
works on the same basis as the one described above (A), but the weighting of
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all p points (1  p  n) is not dened as their derivative, but as follows:
If p > (min + max) / 2 Then
weight(p) = max - p
Else
weight(p) = p - min
End If
(1.6)
with min and max the lowest and the highest measured value, respectively.
This method can be useful for example when the shape of the  = f (log(C))
plot is sigmoidal; in this case, the "derivative\ method is unable to determine
a relevant group of point, whereas the "minimax\ method can lead to useful
data.
Other features
Besides the automatic determination of the linear part of the  = f (log(C))
plot, the Excel macro contains other features which improve the evaluation of
data as outlined below:
Figure 1.9: Progress window of the Pi-Log(C) automation Excel macro
Progress window: The user is informed of the calculation process in real time
during the computation and can stop it at any time, as shown on the
screen capture above (Figure 1.9).
Cross-sectional area: Using the slope of the linear part of the plot chosen with
the method described above, the macro calculates the cross-sectional
area (AD) of the tested compound. From AD, it can directly calculate
the air-water partition coecient (Kawcalc ) and the lipid-water partition
coecient (Klwcalc ).
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CMC: The macro is able to determine automatically if the concentration
range used for the measurement was large enough to reach the critical
micellar concentration and it species also the CMC value, if required. In
this case, the whole macro is automatically run again by giving a weight
of zero to the datapoint which is closest to the CMC. Indeed, it often
appears that the measured surface pressure slightly "jumps\ just before
reaching the CMC, leading to a non-optimal determination of the quasi-
linear part of the  = f (log(C)) plot. By weighting the last datapoint
before CMC to zero, this point will have less chance to be included in
the quasi-linear part of the  = f (log(C)) plot, especially in the case of
a surface pressure jump. Consequently, dierent Kaw and AD (K
0
awcalc
and A0Dcalc ) will be calculated. The average of the two values (resp.
(Kawcalc + K
0
awcalc )=2 and (ADcalc + A
0
Dcalc )=2) and the corresponding
standard deviations will be displayed on the Excel sheet.
Figure 1.10: Screen capture of the graphic displayed by the Pi-Log(C) au-
tomation Excel macro
Graphic: The macro draws an explicit  = f (log(C)) graphic () showing
the best linear part chosen by the macro () and the CMC if required
(see Figure 1.10). The graphic also shows the numerical values for AD
and CMC.
Chemical structure: If the chemical structure of the tested compound is
present in a predened folder, it is added to the output worksheet.
Future enhancements: The macro is structured in a way that it is easy to add
some new modules (functionalities), like the calculation of the surface
concentration (Csub) of the compound.
This Excel macro strongly simplies the evaluation of the surface pressure
measurements, without the inconvenience of many automated systems: it has
not become a black box where the user only sees the output, as he always
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keeps the control on the crucial part of the automation which is the selection
of the quasi-linear part of the  = f (log(C)) plot.
1.3.2 Automatic data extraction for the 3 mL trough
For the monolayer measurements, we either use a 20 mL trough which is
coupled to a mechanical recorder, or a 3 mL trough which is connected to a
computer for the recording of the surface pressure. Both troughs are covered
with a hood to lower the evaporation eect. The electronic data acquisition
for the 3 mL trough gives an output le containing a large data table with
the surface pressure measured in real-time during the whole experiment. The
interval between two data acquisitions can be congured and is usually set
to 3 seconds; as a consequence, a measurement of an average duration (i.e.
1h30) will generate 1800 data points.
As the injection is not yet automatic, the elapsed time between each injec-
tion is not recorded, therefore the user has to nd out the injection steps in this
large data table. He also has to calculate an average value of the equilibrated
part of the surface pressure for each concentration, to take into account the
background noise generated by interferences with the magnetic stirrer.
This task is of course very time consuming, therefore it was important
to develop an automated method to extract the injection times (to take into
account the evaporation of the buer, see chapter 1.2.1 on page 4) and the
average surface pressures for each concentration.
Extraction of injection times and surface pressures
The rst user interface shown in Figure 1.11(a) allows the selection of the
whole data table. The user can also select the sensitivity for the extraction
of the injection times and surface pressures, to handle the importance of the
background noise. From one measurement to the other, the background noise
can vary, and if the sensitivity isn't high enough, some injections will not be
found by the PiXtract macro. During the calculation, the progress window
(Figure 1.11(b)) is displayed to inform the user on the task progress in real
time.
The data are rst smoothed to lower the background noise, and then
derived to reveal the injection peaks. The smoothing works by averaging the
14 surrounding points weighted according to a gaussian distribution, in order
to get rid of the periodic noise due to the stirring device.
Then, the injection times are extracted (from one peak of injection to the
other). Afterwards, the surface pressure of each injection is dened as an
average of measured surface pressures, from the injection peak towards the
previous injection peak until the measured surface pressure is lower or higher
than a threshold dened from global background noise.
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(a) (b)
Figure 1.11: User interface (a) and progress window (b) of the PiXtract Excel
macro
Renement of the extracted data
The second user interface (Figure 1.12) is displayed when the calculation is
over, simultaneously with the graphic shown in Figure 1.13. This graphic
presents the injection peaks found by the Excel macro, and the user can either
add or remove some injection steps intuitively; the selected steps are displayed
in real time on the graphic. If the global threshold was too high (too many
peaks found) or too low (not enough peaks found), the Excel macro can be
run again with a dierent sensitivity. When the correct peaks are selected,
the user can rerun the Excel macro with a higher sensitivity to improve the
calculated average of the surface pressure.
Later on, the user can set the duration between the beginning of the exper-
iment and the start of the recording (to take into account the real evaporation)
and also deduct the baseline from all data. Finally, the data (surface pressures
and time between each injection) can be pasted into the worksheet described
in section 1.3.1 on page 10. The two Excel macros are intimately coupled for
better eciency in the data evaluation. Moreover, the exact determination of
the injection times allows a more accurate estimation of the evaporation of
the water.
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Figure 1.12: Second user interface of the PiXtract Excel macro
Figure 1.13: Screen capture of the graphic displayed by the PiXtract Excel
macro
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1.3.3 Calculation of the cross-sectional area
This section has been thoroughly described in ref.10 (cf. Appendix).
1.4 Conclusion
In a rst step, we assessed new correction factors for the solvent evaporation,
the liquid level, and the in
uence of the solvent on the measured surface
pressure. In a second step, the PiXtract Excel macro was developed, in order
to precisely evaluates the raw data generated by the automatic recorder of
the 3 mL trough (injection times, surface pressure reached at the equilibrium
before the next injection). Finally, the Pi-Log(C) automation Excel macro was
programmed to provide a more accurate and unbiased evaluation of the  =
f (log(C)) plot. This may lead to a better reproducibility of our experiments
and a decrease of the margin of error.
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Chapter 2
Prediction of P-glycoprotein
interaction
2.1 Introduction
During the development of a new pharmaceutical compound, the pharmacoki-
netics of the drug has to be assessed precisely;11 this will be directly related
to the plasma, as well as the concentration of the drug at the target site.
Achievement of required concentration might be hindered at dierent steps of
the disposition of the drug within the organism:12
Absorption The rst step of the disposition of the drug is the absorption,
which will critically in
uence its bioavailability. Several parameters have to
be fullled in order to get the compound in a sucient concentration into
the bloodstream: the compound has to be soluble, chemically stable in the
stomach if the compound is orally taken, and it has to be able to cross the
intestinal barrier.
Distribution Once the drug is present in the bloodstream, it has to reach its
eector site (target) and distribute into tissues and organs. To this purpose
the compound might have to cross several barriers, such as the blood-brain
barrier.
Metabolization The organism has several ways to eliminate any exogenous
material, as a drug. One of the best investigated ways is the metabolism by
enzymes present in the liver, the cytochromes P450 family. The drugs' half-
time in the organism is thus a crucial parameter to assess its bioavailability.
Elimination The last step of the disposition of the drug is its elimination:
the drug, metabolized or not, will be removed from the organism by excretion,
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usually through the kidneys or in the feces. Since multidrug transporters are
expressed in the kidneys, they might play an important role by increasing the
clearance of the drug.13, 14 Moreover since metabolites of the drug might
also have a pharmacological activity or toxicity, their elimination is also an
important factor to assess.
2.1.1 Multidrug transporters
During absorption and distribution, the drug might thus have to cross several
barriers, such as the intestinal barrier (IB) or the blood-brain barrier (BBB).
Several factors might prevent the diusion of the drug through these barriers.
First of all the compound must achieve passive diusion, thus if it is highly
charged or too large it will not be able to diuse or diuse only slowly.15, 16
Secondly, these barriers have a high expression level of a wide variety of mul-
tidrug transporters,17{19 some of them are localized in the apical side of the
epithelial cells, others on the basolateral side (Figure 2.1(a)).
These multidrug transporters have a high sequence homology (Figure 2.1(b))
and share similar properties: they have two transmembrane domains consti-
tuted of 6 membrane-spanning -helices providing specicity for the substrate
(Figure 2.2, orange and pink), and two nucleotide-binding domains, which
bind ATP and uses the energy of ATP hydrolysis to drive the transport of a
wide panel of structurally unrelated molecules across the cell membrane (Fig-
ure 2.2, green and limon).20, 21 The best characterized member of the ATP-
binding cassette (ABC) multidrug transporters is the P-glycoprotein, which
has a molecular weight of 170kDa and is encoded by the MDR1 gene, is
mainly expressed in the intestinal epithelium and the blood-brain barrier where
it might reduce the diusion of the drugs into the organism, and the kidneys
and the liver where it plays an important role in the clearance of drugs. It
is also highly expressed in many cancer cells, to which it confers multidrug
resistance.22 However the three-dimensional structure of P-glycoprotein has
not been resolved yet.
2.1.2 P-glycoprotein
P-glycoprotein recognizes a wide spectrum of chemically diverse molecules,
that are hydrophobic and may carry a positive charge at physiological pH; they
are e.g. anticancer drugs (vinca alkaloids, anthracyclines, epipodophyllotox-
ins, taxoids. . . ), therapeutic agents like HIV-protease inhibitors, or cyclic pep-
tides.24{26 A drug that will be recognized and translocated by P-glycoprotein
(or any other multidrug transporter) will not be able to reach its target if the
targeted organ is protected by a high expression level of the transporter, or
if the drug is in a decreased concentration.27, 28 On the other hand, a com-
pound having a high anity for the transporter may change the bioavailability
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(a)
(b)
Figure 2.1: Multidrug transporters: (a) schematic representation of trans-
porters involved in intestinal transport through enterocytes
(adapted from http://bigfoot.med.unc.edu/watkinsLab); (b)
Phylogenetic tree of some selected transporters.
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Figure 2.2: Homology model of the transporter P-glycoprotein.23 The two
transmembrane domains are shown in orange and pink, and the
two nucleotide binding domains in green and limon.
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of another co-administrated drug that was usually euxed by P-glycoprotein,
leading to unexpected side-eects.29
It is therefore crucial, in an early stage of the development of a new drug, to
nd out if it is a potential substrate or inhibitor of P-glycoprotein, to optimize
the bioavailability of the drug, and to avoid any unwanted toxicological eect
that may occur with co-administration of other substances.
It has been proposed that P-glycoprotein has two binding regions, one
activating binding region occupied at low substrate concentrations, and one
inhibitory binding region, occupied at high substrate concentrations.1, 30, 31
Binding of drug to the activating region will enhance P-glycoprotein activity
and thus ATP hydrolysis, whereas binding to the inhibitory region will reduce
P-glycoprotein activity.32{34
The putative transmembrane helices of P-glycoprotein have a high number
of residues with hydrogen bond donor side chains arranged in an amphipathic
manner.25 It has been suggested that the binding of the drug to the transporter
occurs via hydrogen bonds arranged in a particular spatial distance, called
type I and type II units, between hydrogen bond acceptors on the drug and
the hydrogen bond donor side chains of the transmembrane  helices of P-
glycoprotein.35
2.1.3 Assays to study the in
uence of P-glycoprotein
Some transgenic animal models have been established (like double knock-out
mice, since mice have two genes coding for P-glycoprotein, mdr1a and mdr1b)
to study the eect of the absence of P-glycoprotein on the bioavailability of
drugs.27 Moreover, several in vitro methods based on transgenic cells over-
expressing P-glycoprotein have been established.36 The following section will
enumerate and describe the most commonly used techniques.
ATPase activity assay As stated previously, P-glycoprotein needs ATP to
perform the transport of the drug out of the cell. Thus a process coupled to
drug eux will be hydrolysis of ATP, leading to apparition of ADP and inor-
ganic phosphate, Pi . However the hydrolyzing step will occur inside the cell,
which is rather dicult to monitor. The solution is to work with inside-out
vesicles: the cells are disrupted, then the membrane fragments containing the
P-glycoprotein are isolated with several centrifugation steps. Afterward, these
fragments will reassemble predominantly as inside-out (the nucleotide-binding
sites toward the exterior) vesicles. In those vesicles, the inorganic phosphate
will appear in the medium upon P-glycoprotein activation; a colorimetric reac-
tion is used to measure afterward the extravesicular Pi concentration.37, 38
Competition assay The competition assay uses a "pre
uorochrome\, the
calcein-AM, that is a known substrate for P-glycoprotein. Once in the cell,
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calcein-AM is hydrolyzed by endogenous esterases into calcein, which is a highly
negatively charged 
uorescent compound (Figure 2.3). Calcein will thus not be
able to leave the cell once hydrolyzed. In P-glycoprotein over-expressing cells,
calcein-AM will only poorly penetrate the cell due to its eux by the multidrug
transporter, leading to a slow apparition of 
uorescence. However upon co-
administration of another P-glycoprotein substrate, this drug will compete with
calcein-AM, leading to a higher diusion of the pre
uorochrome into the cell,
and thus a faster apparition of 
uorescence. This assay is carried out with
intact cells; a control might be performed with wild-type cells, leading to a
fast apparition of 
uorescence both without and with co-administration of a
second drug.39
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Figure 2.3: Non-
orescent calcein-AM hydrolyzed by esterases into 
uores-
cent and negatively charged calcein.
Transcellular transport assay The last kind of commonly used in vitro as-
says is the transcellular transport assay.40 It is performed using either wild-
type cells (e.g. porcine brain endothelial cells, PBEC), or transgenic cells
over-expressing P-glycoprotein (e.g. PBEC or Caco-2 cells). The cells are
grown on a polyethylene membrane lter (with pore size of 3m) coated with
collagen; this allows the cells to be polarized, and to express the multidrug
transporter on one side only, namely the apical side (corresponding to the lu-
men of the stomach, or the blood vessel at the blood-brain barrier, depicted as
donor compartiment in the model) (Figure 2.4). The cells will grow until con-
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Figure 2.4: Schematic view of the paracellular transport assay, compared to
the blood-brain barrier.36 PBEC stands for porcine brain endothe-
lial cells.

uence is reached, and the endothelial cells will build tight junctions between
them. The tested compound is then rst applied in the donor compartment
and the apparition of drug is monitored (usually by HPLC and mass spectrom-
etry) in the acceptor compartment (corresponding to the brain parenchyme at
the blood-brain barrier, or the blood at the intestinal barrier); this experiment is
called B!A. In a second experiment, the drug is applied in the acceptor com-
partment, and the apparition of drug is monitored in the donor compartment;
this experiment is called A!B.
If a drug is not a substrate for P-glycoprotein, the apparition of the drug
in both compartments will be identical, thus the ratio B!AA!B will be 1. Since
the transporter is expressed only in the apical side (towards the donor com-
partment), a substrate applied in the acceptor compartment the drug will be
euxed by the transporter, leading to no or a slow apparition of the drug in
the donor compartment. When applied to the donor compartment it will ac-
cumulate more rapidly in the acceptor compartment. Thus the ratio B!AA!B will
be larger than 1. A compound is generally dened as substrate if this ratio is
larger than 1.5.36
Cyctosensor microphysiometer In our group we use a new approach to
study the substrates of P-glycoprotein. It has been described previously that
the P-glycoprotein uses the energy of ATP hydrolysis to transport drugs out of
the cell.32 The use of ATP is directly correlated to the production of lactate,
and as a coupled phenomenon, an extrusion of a proton out of the cell.33 Thus
upon P-glycoprotein activation, the environmental medium will be acidied ;
this acidication can be assessed using a cytosensor microphysiometer, which
is a micro pH-meter. Results obtained with this method are comparable to
those obtained with the ATPase activity assay, however it has the advantage to
handle living cells instead of reconstituted inside-out membrane vesicles.33, 34
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2.1.4 Kinetic parameters of these models
The four assays described above allow the measurement of dierent kinetic pa-
rameters. A kinetic model was proposed by Litman et al. in 1997;30, 31 it states
that P-glycoprotein has two binding regions, one activating binding region and
one inhibitory binding region. At low drug concentration, the activating bind-
ing region will be occupied, leading to an increase of ATP hydrolysis. Drugs
enhancing ATP hydrolysis by P-glycoprotein are called intrinsic substrates.6 At
high drug concentration, the inhibitory binding region is likely to be occupied,
leading to a decrease in the ATP hydrolysis. Drugs causing a decrease in the
ATP hydrolysis already at low concentrations are called inhibitors.4 Moreover,
as described for the competition assay, if two dierent intrinsic substrates (like
calcein-AM and another substrate of P-glycoprotein) are applied simultane-
ously, the substrate with the higher binding anity to the transporter will
in
uence the bioavailability of the second drug;29 these compounds having a
high anity to P-glycoprotein are called modulators.4, 41 Modulators generally
enhance P-glycoprotein activity, and thus ATP hydrolysis.
ATPase activity assays can identify unambiguously intrinsic substrates,
modulators and inhibitors. Since this method monitors the ATP hydrolysis
resulting from P-glycoprotein activity, any drug that will interact with P-
glycoprotein in
uences the ATP consumption and thus the apparition of in-
organic phosphate. Moreover, since P-glycoprotein has a basal activity in the
absence of externally applied drug due to transport of endogenous substrate
or uncoupled cycling,42{44 even the eect of an inhibitor of P-glycoprotein will
be measurable, since inhibitors decrease the transporter activity.
Competition assays, using calcein-AM (or rhodamine 123), can be used to
detect modulators (compounds that will modulate the diusion of calcein-AM
into the cell, and thus lead to a faster apparition of 
uorescence of calcein),
or inhibitors of P-glycoprotein. This method only detects the modulators with
higher anity to P-glycoprotein than calcein-AM.
One should emphasize the dierence between intrinsic substrates and ap-
parent substrates. Apparent substrates are intrinsic substrates (leading to an
increase in the ATP consumption of P-glycoprotein), which give a value larger
than 1.5 in the B!AA!B ratio in transcellular transport assays.36 To be detected
by this method, the substrates of P-glycoprotein should be large enough (i.e.
cross-sectional area & 70 A2 for blood-brain barrier permeation), or highly
charged, in order to diuse slowly through the cell membrane.4, 7 Indeed in-
trinsic substrates having a small cross-sectional area might diuse too fast to
be eectively accumulated in the apical side (donor compartment), leading
thus to a ratio B!AA!B  1.6
Available data on P-glycoprotein interaction with drugs have to be consid-
ered carefully: considering the fundamental dierences in the setup and thus
the information collected with these assays, one might obtain various outcome
for one single drug, that has not been fully understood for a long time. This is
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mainly due to the dierence between intrinsic substrate and apparent substrate
explained above, the presence of two binding regions on P-glycoprotein leading
to inhibition at high substrate concentration, but also due to the dierence
in the lipid composition and the lateral packing density of membranes from
dierent cell lines used in these assays.6
2.2 Literature review of in silico prediction of P-glycoprotein
interaction
In the above section we described the in
uence that P-glycoprotein might
have on the absorption and distribution of a drug in the organism, and in
a more general manner on its bioavailability. Several in vivo, as well as in
vitro models and methods have been developed to assess the interaction of
drugs with P-glycoprotein; these methods are of particular interest especially
during the development of new pharmaceutical compounds, like anticancer or
antiviral drugs where numerous cases of resistance to the treatment due to
P-glycoprotein interaction have been reported.
Since these methods are poorly adapted to screening of a large number of
compounds, it has been a great challenge to develop relevant computational
tools to anticipate whether drug candidates are P-glycoprotein substrates,
modulators or inhibitors. Several tools based on dierent approaches have
been published, and the following section will shortly review these methods of
prediction of P-glycoprotein interaction.
2.2.1 Datasets used in the literature for models training
Building a new model to assess the interaction between P-glycoprotein and
drugs requires experimental data. It is therefore of importance to rst carefully
investigate by which technique the data used as training sets were obtained.
Some models are essentially based on the results of transcellular transport as-
say on Caco-2 cells or MDR1-MDCK cells (dog kidney epithelial cells),45{47
some others on competition assays48{51 or ATPase assays52, 53 and some mod-
els combine in vitro results from dierent experiments.54, 55 Some authors do
not describe the source of their experimental data, but dene P-glycoprotein
substrates as compounds being transported or inducing overexpression of the
multidrug transporter, whereas non-substrates are compounds specically de-
scribed as not being transported by P-glycoprotein.56{58 One can assume that
these authors use the results of transcellular transport assays and protein ex-
pression level analysis, however, they combine the results of two processes
which cannot be a priori mixed. Compounds inducing overexpression of P-
glycoprotein are likely to be intercalating agents or molecules interacting with
DNA, but they are not necessarily apparent substrates of P-glycoprotein.59
Since intercalating agents often contain one or several phenyl groups, which
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have been shows to be a frequent recognition element by the multidrug trans-
porter,35 the confusion between substrates and inducers is regularly observed.
2.2.2 Recent models for P-glycoprotein substrates prediction
In the last years, many models have been published, using dierent approaches
to assess the anity of drugs to P-glycoprotein. Most of them are using the
results of transcellular transport assays, however the results of ATPase activity
assays or competition assays are also employed. Three main approaches are
used for the prediction of substrates of P-glycoprotein.
Pharmacophoric model A pharmacophore corresponds to the essential fea-
tures (hydrophobic area, aromatic ring, hydrogen bond acceptors, hydrogen
bond donors, anions, cations etc.) of one or several molecules having the same
biological activity. The published pharmacophore models have several (usually
4) features, each feature having a specic spatial localization.45, 48{51, 53, 54, 60
Ekins et al.50, 51 collected data from dierent experiments and proposed one
pharmacophore for each type of experiment: one for inhibition of digoxin trans-
port by P-glycoprotein through Caco-2 cells (transcellular transport assay),
one for the inhibition of vinblastine binding (competition assay), one for the
accumulation of vinblastine in P-glycoprotein over-expressing cells (competi-
tion assay), and a fourth one for the calcein accumulation in the same cells
(competition assay). Garrigues et al.53 proposed two pharmacophores for
P-glycoprotein binding; both binding regions are bound together, one region
will bind one kind of small drugs (like bromocriptine), the second another kind
of small drugs (like tentoxin), and large drugs will bind using both binding
regions (like verapamil or vinblastine). Penzotti et al.52 generated 100 phar-
macophores of either 2 (8 models), 3 (39 models) or 4 (53 models) features;
88% of the pharmacophores contained at least one hydrogen bond acceptor
feature, 97% a hydrogen bond donor feature, and most of them a hydrophobic
group, and an aromatic ring. Moreover, 18% of the models contained either
type I or type II units,35 as described in section 3.2.9.
These models have all been established on relatively small datasets (no
more than 30 compounds, and 50 compounds for the training set in Penzotti
et al.,52 mainly collected from Seelig35), thus they might fail in predicting
substrates of P-glycoprotein of chemical families not represented in the orig-
inal training set. It might be surprising that the models proposed by Ekins
et al.50, 51 for the three competition assays are quite dierent, but this can
be explained by the small size of the experimental datasets; it highlights the
weaknesses of the pharmacophore approach. This is also visible in the external
validation (screening of an external database) of the model proposed by Ecker
et al.,60 providing homologous compounds to the ones included in the training
set. It is worth noting that the model described by Garrigues et al.53 might
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be relevant to assess binding of long molecules, shown to inhibit the mul-
tidrug transporter.4 Finally, all authors used only one single three-dimensional
structure of each compound, which will obviously have a huge impact on the
generated 3D pharmacophore. This aspect was highlighted by Cianchetta et
al.54 who noted the similarity in the features of dierent published models,
but noticed the divergence in their geometrical and spatial repartition within
the pharmacophores.
P-glycoprotein transports a wide variety of structurally unrelated com-
pounds, and has at least two binding regions (activating and inhibitory binding
regions).1, 30, 31 The traditional pharmacophoric approach based on a three
dimensional "lock and key\ model, which is the method applied in traditional
Structure Activity Relationship (SAR) studies where a protein will have one
single binding site and will bind one kind of substrate, might thus not be the
method giving the highest predictivity for the interaction between drugs and
P-glycoprotein.
Discriminant linear model The other common approach for predicting sub-
strates of P-glycoprotein is the discriminant linear model, a multivariate gen-
eralized regression method.46, 55 Several methods are derived from this model,
like the support vector machine approach (SVM),56 the principal component
analysis (PCA),56 partial least squares discriminant analysis (PLSD),45, 48, 54
or machine learning approach (neural network).45 These methods start with
numerous descriptors and try to nd a linear correlation between experimental
data and the descriptors. These descriptors are similar as those listed above,
however the spatial property is lost. The geometry of the molecules is thus
generally assessed by other descriptors like the number of rotatable bonds,
and the ability of membrane partitioning with LogP or similar descriptors; it
is also possible to transform the 3D information (from a single 3D structure
of the drugs) into 2D descriptors, for instance the length of the molecule, the
distance between particular regions, the globularity, etc.45, 48, 54, 56 The model
established by Gombar et al.46 is based on 254 descriptors, from which 27
were signicant, including hydrogen bond donor and acceptor, calculated mo-
lar refraction, and molecular E-state. Cianchetta et al.54 used the 94 Volsurf
descriptors, and the 940 Almond descriptors, in which the most signicant
descriptors were molecular weight, rugosity, polarisability, molecular volume,
hydrogen bonding ability, and hydrophobicity. Crivori et al.45 used the same
descriptor sets, but in this case the relevant descriptors were size, shape,

exibility, molecular surface, globularity, elongation, hydrophobic regions, and
hydrogen bonding ability. Cabrera et al.55 used only 9 descriptors, from which
6 were signicant: atomic charge, molar refraction, polar surface area, polar-
isability, partition coecient, and van der Waals radii. Li et al.48 also used a
small number of descriptors: steric eld, electrostatic eld, hydrogen bonding
ability, hydrophobic eld, and hydrophobicity. Finally, Xue et al.56 selected
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159 signicant descriptors from the 1000 obtained with Dragon.
The datasets used to establish the models were from various sources, and
vary also in number of compounds. Li et al. used the data of 20 steroids
which are substrates and/or inhibitors of P-glycoprotein, measured on SW600
Ad300 cells by drug accumulation and eux studies, without including any
non-substrate or non-inhibitor. For substrates, their training set contained
10 compounds, whereas the validation set 3 compounds; for inhibitors, 18
compounds were included in the training set, and only 2 compounds in the
validation set. They obtained for both models a cross-validated q2 of 0.720
and 0.520, respectively. Crivori et al. included 53 drugs (22 substrates, 31
non-substates) in their training set, measured in Caco-2 cells (transcellular
transport assay) and against calcein-AM (competition assay); the test set was
composed of 272 in-house compounds (115 substrates, 157 non-substrates).
The PLSD model on the training set gave a sensitivity of 86%, and a speci-
city of 90%. The model applied on the validation set gave a sensitivity of
61% and a specicity of 81%. Cianchetta et al. used the same assays, on
129 compounds (100 in-house substances), all of them being P-glycoprotein
substrates, dispatched into a training set of 109 compounds, and a test set
of 20 compounds. They obtained a coecient of correlation r2 of 0.72 and
0.83 using the Volsurf and the Almond descriptors, respectively. Xue et al.
claimed that they used 116 substrates (described as being transported or in-
ducing over-expression) and 85 non-substrates from the literature, without cit-
ing their sources. The training set contained 142 compounds (74 substrates,
68 non-substrates), the optimization set (used to calibrate the model) 34
drugs (22/12), whereas the validation set had 25 compounds (19/6). The
described model gave a sensitivity of 84% and a specicity of 67%, and a 5
time cross-validation a sensitivity of 81% and a specicity of 79%. Gombar et
al. used 95 compounds described by Seelig et al.,35 containing 32 substrates
and 63 non-substrates. The validation set contained 58 in-house compounds
(35/23), giving a sensitivity of 94% and a specicity of 78%. Finally, Cabrera
et al. used 163 compounds (91/72) for the training set, originating from var-
ious sources (transcellular transport, ATPase assay, competition assay, drugs
inducing over-expression), and 40 (22/18) compounds in the validation set.
The authors described a sensitivity of 81% and a specicity of 72% on their
validation set.
Like for pharmacophore models, the discriminant linear models have some
drawbacks inherent to the method applied. Most problems of the discrimi-
nant linear model approach might come from the intrinsic mechanism of drug
binding to P-glycoprotein. A drug, which has to be amphiphilic, will rst have
to partition into the lipid membrane, be 
ipped to the inner lea
et, and -
nally bind to the transporter. This two-step process might require a separate
structure-activity relationship analysis for membrane binding, as suggested by
Seelig et al.3 (for review, see Stouch and Gudmundsson61). Even for the
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ATPase assay, this binding is relevant since drugs will also have to partition
into the outer membrane lea
et of the inside-out vesicles, in order to reach
P-glycoprotein.
Rule-based approach A ruled-based model has been proposed by Didzi-
apetris et al.47 They used 11 descriptors (hydrogen acidity and basicity, hy-
drogen bonding ability, pKa, number of rotatable bonds, polar surface area,
number of aromatic rings, molecular weight, hydrophobicity, and characteristic
volume), from which only ve were signicant for P-glycoprotein substrates
prediction: hydrogen basicity, hydrogen bonding ability (acceptors and donors),
molecular weight, and pKa. Using these descriptors they dened simple rules to
discriminate between substrates and non-substrates of P-glycoprotein: com-
pounds with (N+O)  8, MW > 400 and acid Pka > 4 are likely to be
P-glycoprotein substrates, whereas compounds with (N+O)  4, MW < 400
and basic pKa < 8 are likely to be non-substrates. This approach resembles
the "rule of ve\ for drug-like molecules, as described by Lipinski.62, 63
The calibration set contained 220 compounds for which P-glycoprotein
anity was determined by transcellular transport experiment, with 101 sub-
strates and 119 non-substrates. On this dataset, the model was unable to
classify 89 compounds (40%). On the remaining 131 compounds (65/66),
the model lead to a sensitivity of 86%, and a specicity of 85%. The valida-
tion set contained the 220 compounds of the calibration set, as well as 780
compounds collected from around 600 original publications and review papers.
The model could not classify 453 compounds (45%). On the 547 (166/381)
remaining compounds, the model gave a sensitivity of 89%, and a specicity
of 90%.
Contrary to pharmacophore models, Didziapetris et al. did not nd a
particular importance of aromaticity for P-glycoprotein substrates. This can
be explained by the much larger size of their training set comparing to the
sets used to develop the pharmacophore models. The authors also highlight
the importance of amphiphilicity for P-glycoprotein substrates, and note that
3D pharmacophores might not be adequate to assess this parameter due to
the variety of the conformational space for each compound. They describe
drug P-glycoprotein interaction as "fuzzy specicity\ with no clearly expressed
binding sites, as previously suggested by Sharom (one single binding site that
can accommodate several ligand molecules),26 and Litman et al.30, 31 However
the fact that experimental data were "binarized\ (1 for substrates, 0 for non-
substrates) and the rigidity of the rules might lead to misprediction, especially
for compounds having borderline properties (like a molecular weight around
400).
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2.3 Development of a new model for drug binding to
P-glycoprotein based on a two-step mechanism
As described previously, a substrate of P-glycoprotein will rst have to parti-
tion into the outer lea
et of the lipid membrane of the cell, then to diuse to
the inner lea
et, where it will bind to the multidrug transporter.5 Thus the
binding constant of the substrate from the aqueous environment (w) to the
transporter (t), Klw , can be considered as the product of its partition coe-
cient from the aqueous environment to the lipid membrane (l), Klw , and its
binding constant from the lipid environment to the transporter, Ktl .4 Conse-
quently, the free energy of substrate binding from the aqueous environment to
the transporter, Gtw , will be the sum of the free energy of its binding from
the aqueous environment to the lipid membrane, Glw , and its binding from
the lipid environment to the transporter, Gtl .
This two-step process, membrane partition and protein binding, has so far
not been taken into account by other published in silico P-glycoprotein models,
as presented in the above section. Moreover, due to the confusion still reigning
between substrates, modulators or inhibitors of P-glycoprotein, the available
models might not always be relevant to predict intrinsic or apparent substrates
since they have been elaborated on experimental data coming from one type of
in vitro assay, or even mixing the results of several assays describing dierent
mechanisms. One should also keep in mind that numerous models try to nd
dierent features for substrates and inhibitors, which is irrelevant since most
inhibitors will be transported depending on the applied concentration.4
Intrinsic substrates are compounds recognized by P-glycoprotein, thus lead-
ing to a change in the basal ATP hydrolysis activity of the transporter. Those
drugs will be unambiguously detected by the ATPase activity assay. How-
ever they might not be detected by the transcellular transport assay or the
competition assay if they diuse too rapidly through the cell membrane.
Apparent substrates are intrinsic substrates large or charged enough to dif-
fuse slowly through the cell membrane and accumulate in the inner lea
et of
the lipid bilayer, so that the transporter will be able to eciently eux them
out of the cell since the local membrane concentration of the drug will be high.
Considering the particular binding sequence of a P-glycoprotein substrate, in
a rst step from the aqueous environment to the lipid membrane, and in a
second step from the lipid environment to the transporter, and taking into
account the dierences of experimental settings between the dierent in vitro
assays to assess P-glycoprotein substrates and inhibitors, we were able to de-
velop several models, named prediction rules, to describe the results of the
dierent experimental assays. As mentioned previously, the binding constant
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of the substrate from the aqueous environment to the transporter corresponds
to the product of its partition coecient from the aqueous environment to
the lipid membrane, and its binding constant from the lipid environment to
the transporter. It has been shown that the lipid-water partition coecient
can be approximated from the substrate's cross-sectional area, AD,10 and its
air-water partition coecient, Kaw , by the following equation:
Klw = Kaw _exp MAD=kT ; (2.1)
where M is the lateral packing density of the membrane.7 Additionally, the
free energy of substrate binding from the lipid membrane to the transporter was
shown to correlate with the sum of the free energies of hydrogen-bond forma-
tion between hydrogen-bond acceptor groups on the substrate,35 to hydrogen-
bond donor groups in the transmembrane helices of the transporter,25
Gtl =
∑
GHi; (2.2)
given the fact that these hydrogen bonds are arranged in a particular spatial
distance, called type I and type II units (see section 3.2.8 on page 67).4
Using the calculated cross-sectional area and the distribution coecient,
LogD (or the octanol-water partition coecient, LogP, and the pKa), of the
molecules, which correlate to the air-water partition coecient, Kaw , the
membrane-binding step could be assessed. Using the hydrogen-bonding ability
to P-glycoprotein (via type I and type II units), the transporter-binding step
could be assessed. Finally the prediction rules could be developed, combin-
ing these descriptors into a modular binding approach, to simulate the results
obtained with the dierent experimental in vitro assays.
Thus we developed one prediction rule for each in vitro assay, named the
ATPase activity assay, the competition assay, and the transcellular transport
assay. The prediction rules are based on reliable in vitro data, collected in the
publications of Schwab et al.,36 Litman et al.,30 and Mahar Doan et al.28 The
rst paper presents results of all three in vitro assays, whereas the second one
does not have results of the ATPase activity assay.
2.3.1 Prediction of the ATPase activity assay
As stated previously (on page 26), ATPase activity assay detects all intrin-
sic substrates, as well as inhibitors of P-glycoprotein, since they will modify
the basal ATP hydrolysis of the transporter. The prerequisite is to make a
concentration-dependant measure of the P-glycoprotein activity (and not a
single concentration measurement) to get all kinetic parameters, since dier-
ent drugs will have dierent concentrations of half-maximum P-glycoprotein
activation, K1. This explains inconsistent results observed in the publication
of Schwab et al.,36 where some drugs (terfenadine and miconazole) gave a
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positive result in the competition assay, whereas they did not enhance the
P-glycoprotein ATP hydrolysis activity.
The prediction rule for the ATPase activity assay has been established in a
straightforward way: since any drug interacting with P-glycoprotein will change
the basal ATP hydrolysis activity of the transporter,30, 31 only the ability of the
drug to bind to the transporter, and the membrane concentration of the drug,
thus the membrane binding step from the aqueous environment to the lipid
bilayer, will have some in
uence on the outcome of the in vitro assay. Thus
the prediction rule has only to assess the binding of the drug to the transporter
via hydrogen bond formation, given the fact that the drug will partition into
the lipid membrane. The prediction rule is the following:
If EU.TOTAL >= 1 And EU.TOTAL < 8 And (LogD(7.4) >= -0.5
And LogD(7.4) < 4.5)
Then Display("activation", 1)
ElseIf (EU.TOTAL >= 8 And LogD(7.4) >= 0) Or (EU.TOTAL >= 1
And EU.TOTAL <= 4.5 And LogD(7.4) >= 6.1)
Then Display("inhibition", 2)
Else Display("no activity", 3)
The distribution coecient, LogD, calculated at pH 7.4, assesses the hy-
drophobicity of the molecule (highly hydrophilic drugs will not partition into
the lipid bilayer, thus they will not be able to reach the transporter), whereas
the binding to the transporter is assessed with the type I and type II units
as described in the previous paragraph, whose total is implemented in the
EU.TOTAL variable (total of energy units, corresponding to the free energy of
drug binding from the lipid to the transporter, Gtl) (see section 3.2.8 on
page 67).35 Thus compounds having a Gtl of 0 will not change the activity
of ATP hydrolysis of P-glycoprotein, whereas inhibitors will be hydrophobic
compounds with a high Gtl , and intrinsic substrates hydrophobic compounds
with a low Gtl .
Table 2.1 presents the experimental and predicted results of the ATPase
activity assay on a set of 28 compounds collected from the publication of
Schwab et al.36 The limit between active and inactive compound has been set
by the authors at 1.2 nmol Pi/mg protein/min, which corresponds to the 98%
condence level of mean background activity.
The prediction rule was able to correctly predict 21 out of 28 drugs in this
dataset, which corresponds to a prediction accuracy of 75%. However several
mispredicted compounds can be easily explained. Since the measurements
of P-glycoprotein ATPase activity were made at one single concentration
(20 M), it is dicult to resolve intrinsic substrates from inhibitors; moreover,
some drugs might give no change in the basal ATP hydrolysis if the applied
concentration is too low or too high. Ivermectin has been shown to be a potent
P-glycoprotein inhibitor by preventing its ATPase activation by verapamil, at a
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Table 2.1: Comparison of experimental and predicted results of ATPase ac-
tivity assay. EUH corresponds to the variable EU.TOTAL.
Compound LogD7:4 EUH
In vitro resulta Predictionx[nmol/mg/min]
[D-Pen2,5]Enkephalin -2.28 3.5 4.0 no activity
Astemizole 4.79 1 18 activation
Cimetidine 0.32 1 2.8 activation
Clotrimazole 6.24 2 7.5 inhibition
Colchicine 1.3 5 0.1 activation
Cyclosporin A 2.92 11.5 9.8 inhibition
Dexamethasone 1.83 3.5 4.0 activation
Digoxin 1.26 9.5 0.3 inhibition
Erythromycin 2.25 10 4.0 inhibition
Etoposide 0.6 11 -0.2 inhibition
Hydrocortisone 1.61 2.25 0.7 activation
Itraconazole 5.62 5.5 18 no activation
Ivermectinb 4.04 11 -3.4 inhibition
Ketoconazole 4.29 5 27 activation
Mibefradil 3.43 3 8.9 activation
Miconazoleb 6.18 1.5 1.0 no activation
Midazolam 4.32 2.5 6.0 activation
Morphine -0.1 2.5 3.7 activation
Nelnavir 5.16 3 6.2 activation
Nicardipine 3.64 3.75 18 activation
Pimozide 4.28 2.5 11 activation
Quinidine 1.55 1.5 20 activation
Ranitidine -0.77 0 -2.4 no activation
Ritonavir 4.24 5.75 19 activation
Saquinavir 3.75 4 30 activation
Terfenadineb 5.45 1 0.4 no activation
Verapamil 2.66 3.75 21 activation
Vinblastine 3.26 9 33 inhibition
a The limit between no activation and activation has been set at
1.2 nmol/mg/min by the authors.
b These compounds have been tested within a range of 0.1-20 M.
x Italic values correspond to mispredicted compounds.
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concentration as low as 4 M.64 Colchicine has also been shown to be bound to
P-glycoprotein and modify verapamil eux by P-glycoprotein.31, 65 In the case
of etoposide, it has been shown to bind to P-glycoprotein and inhibit verapamil
accumulation, however the maximal inhibition occurs at 60 M,66 whereas the
applied concentration in the publication of Schwab et al. was only 20 M;36 at
this concentration no inhibition was found by Muller et al.66 In a similar man-
ner, Matsunaga et al. showed that 20 M of digoxin signicantly increased the
ATPase activity of P-glycoprotein.67 [D-Pen2,5]enkephalin showed an ATPase
activity of 4.0 nmol/mg/min, whereas it has been predicted as non-activating.
However this compound contains a carboxy group with a calculated pKa of 3.08
(calculated with the Advanced Chemistry Development (ACD/Labs) Software
V8.14 for Solaris). P-glycoprotein has been shown not to transport negatively
charged compounds, thus the result of this experiment is disputable.
Litman et al.30 measured the ATPase activity of 30 compounds, over a
broad range of concentrations (0.2 M-400 M). Using a modied form of the
Michaelis-Menten equation taking into account both the ascent and the decline
of the ATPase activity curve (corresponding to an activating binding site,
occupied at low drug concentration, and an inhibitory binding site, occupied
at high drug concentration), the authors tted the ATP hydrolysis activity
of P-glycoprotein. From the kinetic parameters, we calculated the ATPase
activity for each drug at 20 M, and used the prediction rule displayed below
to predict the activation-inhibition.
If pKa(acidic) > 5 And EU.TOTAL >= 1 And EU.TOTAL < 7 And
LogP > -0.5 And LogP < 4.5
Then Display("activation", 0)
ElseIf pKa(acidic) > 5 And ((EU.TOTAL >= 7 And LogP > 0) Or
(EU.TOTAL >= 1 And EU.TOTAL <= 4.5 And LogP > 6))
Then Display("inhibition", 0)
Else Display("no activity", 0)
Table 2.2 presents the experimental and the predicted values for the AT-
Pase activity assay for 30 compounds, collected from the publication of Litman
et al.,30 at a drug concentration of 20 M. Colchicine has been excluded from
the dataset due to solubility problem.
The prediction rule presented above was able to correctly predict the AT-
Pase activity of P-glycoprotein for 29 out of 30 drugs (96.7%), with 13 com-
pounds leading to inhibition, two compounds showing no activity, and 15 com-
pounds leading to ATPase activation. The mispredicted compound, valino-
mycin, showed a strong activation at low concentration (V1 = 2.3, K1 =
0.03 M) and a strong inhibition at high drug concentration (V2 = 0, K2 =
16.1 M). Thus the K2 of the ATPase activity at 20 M is close to 1, leading
to the experimental misprediction if 1 M is taken as concentration.
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Table 2.2: Comparison of experimental and predicted results of ATPase
activity assay. EUH corresponds to the variable EU.TOTAL.
Compound LogP EUH pKay ATPasez Predictionx
Amiodarone 7.8 1.66 8.45 / 43 0.83 inhibition
Amitriptyline 4.92 1 9.24 / 43 1.19 activation
Chlorpromazine 5.41 1.75 9.43 / 43 1.38 activation
Cyclosporin A 2.92 12.25 4.74 / 15.5 0.64 inhibition
Daunorubicin 1.83 9.25 8.64 / 7.15 0.83 inhibition
Diltiazem 2.79 2.75 8.91 / 43 1.48 activation
Dipyridamole 3.07 3.9 6.37 /13.54 1.83 activation
Epirubicin 1.27 9.7 8.64 / 7.12 0.93 inhibition
Fluphenazine 4.36 2.7 7.9 / 15.5 1.39 activation
Fusidine 4.97 1.55 - / 4.8 1.06 no activity
Gramicidin S 8 8.17 10.5 / 43 0.22 inhibition
Me
oquine 2.87 1.75 10.13/13.13 0.94 activation
Methotrexate -1.85 1.7 5.23 / 4.7 1 no activity
Pimozide 6.3 2.5 9.42 /12.11 0.7 inhibition
Progesterone 3.87 1.5 - / 50 1.8 activation
Promethazine 4.81 1.33 8.98 / 43 1.36 activation
Propafenone 3.37 1.7 9.31 /13.82 1.78 activation
Propranolol 3.48 1.25 9.14 /13.84 1.11 activation
PSC-833 1.64 13 4.74 / 50 0.31 inhibition
Quinidine 3.44 1.5 8.56 /13.05 1.46 activation
Reserpine 3.32 7 6.6 / 43 0.94 inhibition
Spironolactone 2.78 4.8 - / 43 1.7 activation
Tamoxifen 6.3 1.1 8.69 / 43 0.73 inhibition
Terfenadine 7.62 1 9.57 /13.31 0.75 inhibition
Tri
uoperazine 5.03 2.66 7.82 / 43 1.31 activation
Tri
upromazine 5.54 2.25 9.43 / 43 1.44 activation
Valinomycin 4.49 14 -0.77/11.32 1.03 inhibition
Verapamil 3.79 3.65 8.92 / 43 1.77 activation
Vinblastine 3.7 9 7.64 /11.36 0.96 inhibition
Vincristine 2.82 7.75 5 / 43 0.91 inhibition
y The rst value corresponds to the basic pKa, the second value to the
acidic pKa.z These compounds have been tested within a range of 0.2-400 M;
the value corresponds to the ATPase activity at 20 M.
x Italic values correspond to mispredicted compounds.
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2.3.2 Prediction of the competition assay
As discussed in section 2.1.3, the competition assay is based on the displace-
ment of the P-glycoprotein substrate calcein-AM, which becomes 
uorescent
and negatively charged (thus preventing its diusion out of the cell) once inside
the cytoplasm. A modulator is an intrinsic P-glycoprotein substrate, having a
higher binding anity toward the transporter than calcein-AM. To predict the
competition of a molecule against calcein-AM, we thus established a predic-
tion rule taking into account (i) the number of type I or type II units present
on the molecule (to be able to bind to the transporter), and the lipophilicity
of the molecule, to assess whether the molecule will enter the cell membrane.
Indeed, a molecule which is too hydrophilic will not be able to partition into
the lipid bilayer. The size of the molecule, i.e. its cross-sectional area, has not
to be taken into account, since the competition assay will detect all intrinsic
substrates.
We collected experimental data from the publication of Schwab et al.,36 in
which 28 compounds were tested in a concentration range of 0.05 to 50 M,
against a concentration of 0.25 M of calcein-AM. The positive control was
the P-glycoprotein substrate verapamil applied at a concentration of 50 M.
The prediction rule developed for this dataset of 28 compounds was the fol-
lowing:
If LogP > 3 And EU.TOTAL >= 0.5 And pKa(acidic) > 5
Then Display("competition", 0)
Else Display("no competition", 0)
Indeed, the molecule has to be hydrophobic enough (large octanol-water par-
tition coecient), and contain at least one type I or type II unit, in order to
bind to P-glycoprotein. Moreover, since P-glycoprotein does not transport
negatively charged compounds, we set a limit for acidic pKa to rule-out com-
pounds having for instance a carboxy group which will be negatively charged at
physiological pH. Table 2.3 presents the experimental and the predicted values
for the calcein-AM competition assay, for the dataset of 28 drugs tested by
Schwab et al.36
The prediction rule was able to correctly predict 25 out of 28 drugs (89.3%),
with one mispredicted inhibitor (saquinavir), and two mispredicted non-inhibitors
(erythromycin and midazolam). Interestingly, saquinavir was a border-line in-
hibitor, since it showed an IC50 higher than 50 M on cell lines overexpressing
either mouse mdr1a or mouse mdr1b P-glycoprotein. On the other hand, mi-
dazolam showed an IC50 lower than 50 M (which corresponds for the authors
to the limit between inhibitor and non-inhibitors) on cell lines overexpressing
mdr1b P-glycoprotein (IC50 = 33 M). In a similar manner, two border-lines
compounds, erythromycin and vinblastine, were classied as inhibitors: the
former showed an IC50 of 43 M on porcine P-glycoprotein overexpressing cell
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Table 2.3: Comparison of experimental and predicted results of
calcein-AM competition assay. EUH corresponds to the
variable EU.TOTAL.
Compound LogP EUH calcein-AMa Predictionx
[d-pen]enkephalin 2.01 3.5 >50 no competition
astemizole 6.43 2 1.3 competition
cimetidine 0.57 2 >50 no competition
clotrimazole 6.26 2 6.7 competition
colchicine 1.3 7 >50 no competition
cyclosporin a 4.12 13 0.8 competition
dexamethasone 1.83 3.25 >50 no competition
digoxin 0.5 14 >50 no competition
erythromycin 3.06 14.5 >50 competition
etoposide 0.6 13 >50 no competition
hydrocortisone 1.61 3.5 >50 no competition
itraconazole 5.66 7 2.1 competition
ivermectin 4.11 15.5 0.1 competition
ketoconazole 4.35 7 4.8 competition
mibefradil 6.27 4.5 1.8 competition
miconazole 6.25 2.5 3.5 competition
midazolam 4.33 2.75 >50 competition
morphine 0.89 3 >50 no competition
nelnavir 5.53 4 3.4 competition
nicardipine 3.82 7 2.3 competition
pimozide 6.3 2.5 2.9 competition
quinidine 3.44 2 5.6 competition
ranitidine 0.27 1.5 >50 no competition
ritonavir 6.27 6.5 12 competition
saquinavir 2.55 4 12 no competition
terfenadine 7.62 1 1.4 competition
verapamil 3.79 6 6.3 competition
vinblastine 3.7 9 >50 competition
a Calcein-AM corresponds to the concentration, in M, of the
drug inhibiting 50% of calcein-AM, compared to the inhibition
of 50 M verapamil.
x Italic values correspond to mispredicted compounds.
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lines, and the latter showed an IC50 higher than 50 M in mdr1a mouse P-
glycoprotein and human P-glycoprotein overexpressing cell lines. However they
were as well close the the separation between inhibitors and non-inhibitors.
We collected a second set of in vitro data from the publication of Mahar
Doan et al.28 They measured the calcein-AM inhibition of 93 drugs, applied at
a concentration of 100 M. Calcein-AM concentration was 0.25 M, whereas
the positive control was the P-glycoprotein substrate GF120918 (elacridar)
applied at a concentration of 1 M. The discrimination between inhibitors and
non-inhibitors has been set by the authors at a limit of 10% of maximum in-
hibition (inhibition observed with 1 M GF120918 against calcein-AM). Since
the experimental settings were dierent from those used by Schwab et al.,36
we had to dene a new prediction rule, to discriminate inhibitors from non-
inhibitors. The prediction rule was the following:
If (EU.TOTAL >= 0.5 And LogP >= 3.5) Or (EU.TOTAL >= 2.5
And LogP > 2.5) And pKa(acidic) > 5
Then Display("inhibition", 0)
Else Display("non inhibition", 0)
The prediction rule is however very similar to the rule established for the dataset
of Schwab et al.36 The dataset of Mahar Doan et al.28 contained four highly
negatively charged compounds which are not transported by P-glycoprotein
(acrivastine, cetirizine, indomethacin, and sulfasalazine). Table 2.4 presents
the experimental and the predicted values for the dataset of 93 compounds.
Table 2.4: Comparison of experimental and predicted results of calcein-AM
competition assay.
Compound LogP EUH1 calcein-AM2 Prediction3
Acrivastine 4.33 2 3.57 no inhibition
Alprenolol 3.1 2 15.4 inhibition
Amantadine 2.44 0 2.1 no inhibition
Amitriptyline 4.92 1 25.5 inhibition
Amprenavir 3.1 6 14.7 inhibition
Antipyrine 0.38 1.5 1.02 no inhibition
Astemizole 7.88 2 71.5 inhibition
Atenolol 0.16 2 0.07 no inhibition
Biperiden 4.25 0 4.97 no inhibition
1The value of EUH corresponds to the maximal number of type I and type II units found
in all conformations for each compound.
2The values correspond to the percentage of inhibitory potential of the drug at 100 M,
compared to the inhibitory activity of 1 M GF120918, a potent and specic P-glycoprotein
inhibitor. The limit between non-inhibition and inhibition has been set at 10% by the authors.
3Italic values correspond to mispredicted compounds.
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Table 2.4: (continued)
Compound LogP EUH calcein-AM Prediction
Bromocriptine 3.82 6.5 61.6 inhibition
Bufuralol 3.5 2 14.3 inhibition
Buspirone 2.63 4 24.1 inhibition
Carbamazepine 2.45 2.5 1.22 no inhibition
Cetirizine 4.66 2.5 3.32 no inhibition
Chlorpheniramine 3.38 2 2.36 inhibition
Chlorpromazine 5.41 2 46.9 inhibition
Chlorprothixene 5.18 1 57.5 inhibition
Cimetidine 2.05 2 0.16 no inhibition
Clemastine 5.95 2.5 28.4 inhibition
Clomipramine 5.19 2 48.2 inhibition
Clonidine 3.98 0 0.63 no inhibition
Cyclobenzaprine 4.78 1 23.1 inhibition
Desipramine 4.9 1 12.8 inhibition
Diltiazem 2.7 4.5 37.3 inhibition
Diphenhydramine 3.27 2.5 11.1 inhibition
Domperidone 3.9 3 10.4 inhibition
Doxapram 5.75 4 11.7 inhibition
Doxepin 4.03 2.5 15.3 inhibition
Doxylamine 3.27 2.5 5.37 inhibition
Eletriptan 5.08 3 2.6 inhibition
Famciclovir 2.46 6 3.12 no inhibition
Flumazenil 1 4.5 3.89 no inhibition
Fluoxetine 3.82 1.5 23.5 inhibition
Flurazepam 6.58 3.25 22.6 inhibition
Fluvoxamine 4.03 2.5 20.8 inhibition
Guanabenz 3.94 0 8.6 no inhibition
Guanfacine 2.2 0 5.05 no inhibition
Haloperidol 4.3 2.5 37.2 inhibition
Imipramine 4.8 2 5.37 inhibition
Indinavir 2.92 4.5 1.81 inhibition
Indomethacin 4.27 2.5 4.63 no inhibition
Ketamine 2.18 0 1.23 no inhibition
Labetalol 3.09 3 7.11 inhibition
Levomeprazine 4.68 3.5 25.6 inhibition
Lidocaine 2.44 0 1.7 no inhibition
Loperamide 6.29 4 76.3 inhibition
Lorcainide 4.85 2.5 16.4 inhibition
Mannitol -2.2 0 0.35 no inhibition
Maprotiline 4.49 1 36.7 inhibition
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Table 2.4: (continued)
Compound LogP EUH calcein-AM Prediction
Mephentermine 2.78 0 1.43 no inhibition
Meprobamate 0.7 4 2.24 no inhibition
Mequitazine 5.68 2 33.5 inhibition
Metergoline 4.79 1.5 84.4 inhibition
Methysergide 2.45 2 3.83 no inhibition
Metoprolol 1.88 2 5.08 no inhibition
Mexilitene 2.15 0 0.37 no inhibition
Midazolam 6.72 2.75 74.9 inhibition
Nalbuphine 1.31 2 0.07 no inhibition
Naloxone 2.09 3 0.73 no inhibition
Naltrexone 1.92 3 2.03 no inhibition
Nelnavir 5.91 4 30.6 inhibition
Neostigmine 1.77 1.5 1.91 no inhibition
Nitrazepam 2.46 1 3.66 no inhibition
Nordiazepam 2.93 1 5.17 no inhibition
Nortriptylene 4.32 1 13.7 inhibition
Noscapine 1.94 6.5 35.5 no inhibition
Oxprenolol 2.1 2 5.53 no inhibition
Perphenazine 4.2 2 65.4 inhibition
Pheniramine 2.89 2 1.49 no inhibition
Pirenzepine 2.4 3.5 2.16 no inhibition
Procyclidine 4.35 0 16.2 no inhibition
Progabide 3.06 3 14.1 inhibition
Promazine 4.55 2 16.3 inhibition
Promethazine 4.81 2 16.3 inhibition
Propranolol 3.48 2 6.22 inhibition
Protriptylene 4.09 1 15 inhibition
Risperidone 4.11 3.75 52.6 inhibition
Roxindole 5.02 1 32.7 inhibition
Saquinavir 3.58 4 35.5 inhibition
Scopolamine 0.62 4 0.54 no inhibition
Selegiline 2.9 0 3.02 no inhibition
Sulfasalazine 2.88 4 3.45 no inhibition
Sumatriptan 0.93 3 0.76 no inhibition
Tacrine 2.71 0 4.76 no inhibition
Terfenadine 7.08 1 100 inhibition
Trazodone 3.58 3.5 21.1 inhibition
Trimethoprim 0.91 5 1.35 no inhibition
Trimipramine 4.97 2 22.8 inhibition
Verapamil 3.79 6 56.4 inhibition
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Table 2.4: (continued)
Compound LogP EUH calcein-AM Prediction
Warfarin 2.6 4 1.43 no inhibition
Zimeldine 3.99 2 7.4 inhibition
Zolmitriptan 2.22 2 1.01 no inhibition
Zolpidem 3.4 1.5 17.3 inhibition
From the 93 compounds, with 45 central nervous system targeted drugs
and 48 peripherically targeted drugs, the prediction rule was able to correctly
discriminate 83 compounds (89.2%). From the 47 compounds showing an
inhibition lower than 10%, 6 were mispredicted (82.2% of correct prediction),
and from the 46 compounds showing an inhibition higher than 10%, 4 com-
pounds were mispredicted (91.3% of correct prediction). Only one inhibitor
was mispredicted due to its absence of type I or type II units, procyclidine
(Figure 2.5). Indeed, this compound shows no usual type I unit, however it
OH
N
Figure 2.5: Two-dimensional structure of procyclidine.
has been shown that phenyl groups and tertiary nitrogen can be involved in
type I or type II units,35 but the fact that a phenyl ring can be involved in a
type I or type II unit together with a tertiary amine has not been described
so far. However this is in accordance to a type II (1, 5) pattern as described
by Seelig.35 Another explanation might be that two molecules of procyclidine
bind together in the transmembrane channel of P-glycoprotein. If the presence
of a type I or type II unit between a phenyl group and a tertiary nitrogen, or the
presence of two molecules in the transporter at the same time is conrmed,
this would imply that procyclidine would be correctly predicted, since its LogP
is 4.35.
A closer look at the mispredicted compounds shows that generally all of
them are close to the limit dened in the prediction rule, except procyclidine
(as explain above). Several mispredicted non-inhibitors showed a positive re-
sult in the transcellular transport assay (indinavir, labetalol, eletriptan, diphen-
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hydramine). These incoherences between transcellular transport assay and
competition assay indicates that these drugs are apparent substrates of P-
glycoprotein, but most likely bind to P-glycoprotein more weakly than calcein-
AM, and are thus not able to eciently compete against it.
We also modelled the substrate of P-glycoprotein used by the authors as
positive control, GF120918; with a LogP of 4.98 and a maximal number of type
I and type II units of 5, this compound was correctly predicted as modulator
of calcein-AM towards P-glycoprotein (see page 23). As a comparison, the
modelling of calcein-AM showed a maximal number of type I and type II units
of 11, and a LogP of 3.49. This compound is thus also correctly predicted as
a P-glycoprotein substrate.
2.3.3 Prediction of the transcellular transport assay
The results of the transcellular transport assay might be the most dicult to
predict. As stated previously, an intrinsic substrate, meaning a compound that
will be transported by P-glycoprotein and thus give a change in the ATP hy-
drolysis by the transporter, might not be detected by the transcellular transport
assay. Indeed, this assay will only give positive results for apparent substrates,
which are intrinsic substrates diusing slowly enough to be eciently euxed
by P-glycoprotein, and thus accumulating in the apical region of the cells. For
the prediction of the transcellular transport assay, one has to consider several
parameters:
 The hydrophobicity of the molecule: if a compound is too hydrophilic,
it will not be able to partition into the lipid bilayer of the cells, and thus
will not reach the transporter. This parameter is assessed by means of
the octanol-water partition coecient, LogP.
 The charge of the molecule: only the uncharged fraction of a drug
will permeate through the lipid membrane of the cells; the ionization
constant of the molecules plays thus an important role in the diusion
through the cell membrane.
 The size of the molecule: if a compound diuses too rapidly through
the membrane, P-glycoprotein will not be able to eux it in an ecient
manner, thus the compound will not accumulate in the apical part of
the cells, giving a negative result in the transcellular transport assay.
In contrast, a compound which is "big\ enough to diuse slowly, and
is eciently euxed, will give a positive result for the transport assay.
However, if a molecule is too large, it will not be able to partition into
the lipid bilayer. In a rst step, we assessed the size of the molecule
with its molecular weight. Once the algorithm for the calculation of the
cross-sectional area was achieved, the size of the molecule was assessed
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in a second step with the calculated cross-sectional area, as described
elsewhere.10
 The interaction with P-glycoprotein: as described previously, the binding
anity of a molecule to the transporter is assessed using the number of
hydrogen-bond formation between them, using type I and type II units.35
We collected experimental data for transcellular transport assay for 13 drugs, in
the publication of Schwab et al.36 These drugs were also tested for the calcein-
AM competition assay, as well as ATPase assay. The authors used wild type
pig kidney cells (LLC-PK1), as well as transfected either with human (MDR1)
or mouse (mdr1a) P-glycoprotein gene, at a density of 1.4  105 cells/well
leading to a con
uent cells monolayer. The tightness of the monolayer was
assessed with inulin, a paracellular 
ux marker (as it cannot diuse through the
cell membrane). The specic activity of the test compounds was 3 Ci/mL,
corresponding to compound concentrations of less than 350 nM. The tested
drug was applied in the apical part of the cells, and samples were collected
from the basolateral part of the cells; in a second experiment, the drug was
applied in the basolateral part, and samples collected from the apical part.
The rst prediction rule developed for this dataset of 13 compounds was the
following:
If EU.TOTAL >= 0.5 and pKa(acidic) > 5 and (pKa(basic) >= 9 Or
MW >= 500 Or (LogP < 2 And LogP > 0.5))
Then Display("transport", 1)
Else Display("no transport", 3)
Table 2.5 presents the experimental and predicted results of the transcellular
transport assay on the set of 13 compounds collected from the publication of
Schwab et al.36 The limit between transported and not transported compounds
has been set by the authors at 1.5 for the ratio B!AA!B . The rst prediction
rule to estimate the transport of drug through P-glycoprotein overexpressing
cells, using the molecular weight as a parameter to assess the size of the
molecules, was able to correctly predict the transcellular transport of 11 out
of 12 drugs (91.7%). The only mispredicted compound, erythromycin, was
predicted as being accumulated on the apical side of the cells, whereas the
in vitro transcellular transport assay gave a negative result. However this
compound showed an activation of the ATPase activity of P-glycoprotein,
proving that it is an intrinsic substrate. Moreover, Schuetz et al. showed
that the rate of A! B 
ux of erythromycin was diminished in P-glycoprotein
overexpressing cells;68 their setup was identical as the one used by Schwab et
al.,36 plating 2106 cells/well, and applying the drug at a nal concentration
of 2 or 5 M (0.25 Ci/mL). The B!AA!B ratios are not given, however, they
can be estimated from the transcellular transport measurements. For wild
type, the transport ratio was 7:64:7 = 1:62 after 4 hours of experiment. For
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Table 2.5: Comparison of experimental and predicted results of the transcellular
transport assay. EUH corresponds to the variable EU.TOTAL.
Compound LogP EUH MW pKay B!AA!B Predictionx
[d-pen]enkephalin 2.01 3.5 645.79 7.9 / 3.08 0.8 no transport
benzylpenicillin 1.83 3 334.39 -1.32/ 2.62 1 no transport
cimetidine 0.57 2 252.34 6.73 / 16.5 0.5 no transport
colchicine 1.3 7 399.44 - /14.87 2.2 transport
cyclosporin a 4.12 13 1202.61 4.74 / 15.5 7.7 transport
dexamethasone 1.83 3.25 392.46 - /12.14 2.8 transport
digoxin 0.5 14 780.94 - / 13.5 4.4 transport
erythromycin 3.06 14.5 733.93 8.14 /13.08 1.2 transport
mibefradil 6.27 4.5 495.63 9.3 /12.55 2.1 transport
morphine 0.89 3 285.34 8.26 / 9.5 1.5 transport
saquinavir 2.55 4 670.84 7.35 / 15.5 3.4 transport
verapamil 3.79 6 454.6 8.5 / 43 5.7 transport
vinblastine 3.7 9 810.97 7.64 /11.36 1.7 transport
y The rst value corresponds to the basic pKa, the second value to the acidic pKa.x Italic values correspond to mispredicted compounds.
Figure 2.6: Three-dimensional structure of erythromycin, oriented at an
hydrophilic-hydrophobic interface (see Table 2.6).
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the P-glycoprotein overexpressing pig kidney cells, the transport ratio was
10:35
1:55 = 6:68 for human MDR1 gene, and
7:6
1:55 = 4:9 for mouse mdr1a gene.
The corrected value (corresponding to the experimental value in Table 2.5) was
thus 4.12 for the human P-glycoprotein. As as consequence, this compound
was detected as transported by Schuetz et al.
Once the algorithm for the calculation of the cross-sectional area has been
validated,10 we established a second prediction rule for estimation of the results
of the transcellular transport assay, which consider the cross-sectional area
instead of the molecular weight to assess the size of the molecules. The
prediction rule was the following:
If pKa(acidic) >= 5 And Ad[7.4] < 170 And EU.TOTAL >= 0.5 And
(Ad[7.5] > 75 Or pKa(basic) >= 9)
Then Display("transport", 1)
Else Display("no transport", 3)
Table 2.6 presents the results of the experimental transcellular transport assay,
as well as the results of the prediction using the second prediction rule. The
calculated cross-sectional area has been also included in the table.
Table 2.6: Comparison of experimental and predicted results of the transcellular
transport assay, using the second prediction rule. EUH corresponds to
the variable EU.TOTAL, AD to the calculated cross-sectional area.
Compound LogP EUH AD [A2] pKay B!AA!B Predictionx
[d-pen]enkephalin 2.01 3.5 100.72 7.9 / 3.08 0.8 no transport
benzylpenicillin 1.83 3 42.52 -1.32/ 2.62 1 no transport
cimetidine 0.57 2 42.01 6.73 / 16.5 0.5 no transport
colchicine 1.3 7 90.71 - /14.87 2.2 transport
cyclosporin a 4.12 13 155.44 4.74 / 15.5 7.7 transport
dexamethasone 1.83 3.25 76.28 - /12.14 2.8 transport
digoxin 0.5 14 86.56 - / 13.5 4.4 transport
erythromycin 3.06 14.5 95.44 8.14 /13.08 1.2 transport
mibefradil 6.27 4.5 79.43 9.3 /12.55 2.1 transport
morphine 0.89 3 48.01 8.26 / 9.5 1.5 no transport
saquinavir 2.55 4 140.22 7.35 / 15.5 3.4 transport
verapamil 3.79 6 81.9 8.5 / 43 5.7 transport
vinblastine 3.7 9 129.18 7.64 /11.36 1.7 transport
y The rst value corresponds to the basic pKa, the second to the acidic pKa.x Italic values correspond to mispredicted compounds.
The second prediction rule was able to correctly predict 11 out of 13
compounds (84.6%); one of the mispredicted compound was erythromycin (as
with the rst prediction rule), whereas the second mispredicted compound was
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morphine. This compound showed no modulation in the calcein-AM assay,36
and a B!AA!B ratio of 1.5 in the same publication (which corresponds to the limit
between transported and non-transported compounds), and a ratio lower than
1.5 (B!AA!B = 1:47 at 10 M morphine, and B!AA!B = 1:37 at 150 M morphine)
in the publication of Crowe (on Caco-2 cells).69 Morphine has a relatively small
cross-sectional area, thus this compound will diuse rapidly through the cell
membrane. It contains a total of 3 type I or type II units, it will thus interact
with P-glycoprotein. Morphine is a intrinsic substrate (giving a change in the
ATP hydrolysis by the transporter), and a weak apparent substrate due to its
small cross-sectional area and pretty low basic pKa. However the calculated
cross-sectional area represents a better descriptor for the passive diusion of
the molecules through the lipid bilayer, and to assess the accumulation of the
drugs in the inner lea
et of the membrane, which is an important parameter
for ecient eux of the drugs out of the cells by P-glycoprotein.
To assess the results of the in vitro data of a second dataset of tran-
scellular transport experiments, we adapted the second prediction rule to the
experimental settings of Mahar Doan et al.28 They measured the bidirectional
eux of the same dataset of 93 drugs presented previously (on page 40), us-
ing canine kidney cells (MDCK) overexpressing human MDR1 P-glycoprotein
gene. The cells were seeded at a density of 3105 cells/well and the drugs
applied at a concentration of 10 M. Paracellular diusion was assessed using
mannitol, a highly hydrophilic compound (LogPexp = -2.47), and the positive
control for P-glycoprotein transport was amprenavir. A drug was dened as
transported when the B!AA!B ratio was higher than 1.5. All transported drugs
were then tested in the presence of 2 M of GF120918 (cf. page 40), and
the transport ratio decreased in all cases to ' 1. The prediction rule was the
following:
If LogD(7.4) < 0.49 And EU.TOTAL >= 0.5 And Ad >= 42
Then Display("if entry", "0, 0, 0, 118, 156, 234")
ElseIf ((EU.TOTAL >= 0.75 And Ad > 75) Or (EU.TOTAL >= 2 And Ad > 68)
Or (EU.TOTAL >= 3 And Ad > 43)) And Ad < 142 And LogD(7.4) >= 0.5
Then Display("transport", 3)
Else Display("no transport", 1)
Table 2.7 contains the results of the experimental data of the transport
assay (corresponding to the quotient between the B!AA!B ratio in the presence
of the tested drug, and the B!AA!B ratio in the presence of the tested drug and
2 M GF120918, a potent inhibitor of P-glycoprotein), and the prediction
of the in vitro assay using the third prediction rule dened above. The limit
between transport and no transport has been set by the authors at 1.5 for the
ratio B!AA!B .
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Table 2.7: Comparison of experimental and predicted results of the transcel-
lular transport assay.
Compound LogP EUH AD [A2] pKa1 B!AA!B Prediction2
Acrivastine 4.33 2 59.41 9.01/1.99 4.26 if entry
Alprenolol 3.1 2 39.98 9.17/13.88 1.06 no transport
Amantadine 2.44 0 38 10.75/- 1.25 no transport
Amitriptyline 4.92 1 53.75 9.24/- 0.93 no transport
Amprenavir 3.1 6 72.75 1.76/11.54 22.66 transport
Antipyrine 0.38 1.5 36.58 0.7/- 1.09 no transport
Astemizole 7.88 2 77.13 9.03/- 1.66 transport
Atenolol 0.16 2 75.82 9.17/13.88 1 if entry
Biperiden 4.25 0 59.14 9.8/- 1.07 no transport
Bromocriptine 3.82 6.5 106 6.72/9.6 1.21 transport
Bufuralol 3.5 2 48.28 8.97/13.67 0.83 no transport
Buspirone 2.63 4 36.14 6.43/- 1.04 no transport
Carbamazepine 2.45 2.5 62.15 13.94/- 0.87 if entry
Cetirizine 4.66 2.5 61.84 6.43/3.27 7.52 if entry
Chlorpheniramine 3.38 2 53.67 9.33/- 0.99 no transport
Chlorpromazine 5.41 2 48.44 9.43/- 1.03 no transport
Chlorprothixene 5.18 1 54.5 9.15/- 0.83 no transport
Cimetidine 2.05 2 41.99 6.73/- 3.82 if entry
Clemastine 5.95 2.5 57.48 10.23/- 1.39 no transport
Clomipramine 5.19 2 52.92 9.43/- 1.29 no transport
Clonidine 3.98 0 37.7 9.16/- 0.94 no transport
Cyclobenzaprine 4.78 1 53.76 9.21/- 0.88 no transport
Desipramine 4.9 1 47.71 10.4/- 1.1 no transport
Diltiazem 2.7 4.5 68.34 8.94/15 1.74 transport
Diphenhydramine 3.27 2.5 54.59 1.14/43 1.11 no transport
Domperidone 3.9 3 79.84 8.76/- 32.5 transport
Doxapram 5.75 4 67.53 9.01/11.11 1.41 transport
Doxepin 4.03 2.5 50.7 8.47/- 0.88 no transport
Doxylamine 3.27 2.5 51.39 9.19/15 0.88 no transport
Eletriptan 5.08 3 51.88 8.69/- 41.01 transport
Famciclovir 2.46 6 43.59 10.35/- 2.33 transport
Flumazenil 1 4.5 40.73 4.58/43 1.05 no transport
Fluoxetine 3.82 1.5 57.55 10.05/43 1.27 no transport
Flurazepam 6.58 3.25 55.28 9.79/15 1.06 transport
1The rst value corresponds to the basic pKa, the second to the acidic pKa.
2"transport\ corresponds to a transported compound; "no transport\ corresponds to
a compound which is not transported or whose passive diusion is too fast to allow apical
accumulation; "if entry\ corresponds to a compound which might be eciently transported if
it manages to enter the cell membrane. Italic values correspond to mispredicted compounds.
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Table 2.7: (continued)
Compound LogP EUH AD [A2] pKa B!AA!B Prediction
Fluvoxamine 4.03 2.5 44.77 9.39/43 1.02 no transport
Guanabenz 3.94 0 31.62 9.66/- 1.11 no transport
Guanfacine 2.2 0 37.7 7.34/11.07 1.02 no transport
Haloperidol 4.3 2.5 56.7 8.25/13.85 1.11 no transport
Imipramine 4.8 2 47.86 9.49/- 1.01 no transport
Indinavir 2.92 4.5 106.25 5.19/14.4 9.76 transport
Indomethacin 4.27 2.5 44.25 -9.2/3.96 0.88 no transport
Ketamine 2.18 0 49.8 6.59/- 1 no transport
Labetalol 3.09 3 45.07 9.2/8.21 8.43 transport
Levomeprazine 4.68 3.5 50.03 9.34/43 1.22 transport
Lidocaine 2.44 0 42.63 8.53/- 0.98 no transport
Loperamide 6.29 4 96.2 8.05/13.85 9.2 transport
Lorcainide 4.85 2.5 57.45 9.54/- 1.45 no transport
Mannitol -2.2 0 41.24 -/13.14 0.75 no transport
Maprotiline 4.49 1 48.13 10.63/- 0.9 no transport
Mephentermine 2.78 0 33.96 10.38/- 0.76 no transport
Meprobamate 0.7 4 39.38 -1.09/13.09 1.02 no transport
Mequitazine 5.68 2 62.89 10.3/- 2.2 transport
Metergoline 4.79 1.5 74.45 9.54/12.45 1.02 no transport
Methysergide 2.45 2 54.73 7.48/14.46 4.46 no transport
Metoprolol 1.88 2 40.85 9.17/13.89 1.26 no transport
Mexilitene 2.15 0 34.55 8.58/43 0.74 no transport
Midazolam 6.72 2.75 65.79 5.65/- 0.96 transport
Nalbuphine 1.31 2 60.45 7.35/9.39 2.15 transport
Naloxone 2.09 3 54.36 6.73/9.16 1.48 transport
Naltrexone 1.92 3 57.09 7.53/9.16 1.01 transport
Nelnavir 5.91 4 115.52 7.53/9.58 13.94 transport
Neostigmine 1.77 1.5 60.61 -3.12/- 2.3 if entry
Nitrazepam 2.46 1 56.72 3.19/11.35 1.23 if entry
Nordiazepam 2.93 1 55.22 3.4/11.72 0.92 no transport
Nortriptylene 4.32 1 52 10.08/- 1.32 no transport
Noscapine 0.56 6.5 78.21 6.32/43 1.06 transport
Oxprenolol 2.1 2 43.28 9.17/13.89 1.56 if entry
Perphenazine 4.2 2 52.54 6.85/14.96 1.08 no transport
Pheniramine 2.89 2 53.28 9.35/- 1.09 no transport
Pirenzepine 2.4 3.5 57.79 7.72/11.29 2.16 transport
Procyclidine 4.35 0 57.62 10.48/14.2 0.93 no transport
Progabide 3.06 3 50.28 10.31/16.48 0.93 if entry
Promazine 4.55 2 44.49 9.43/- 0.98 no transport
Promethazine 4.81 2 50.76 9.25/- 0.83 no transport
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Table 2.7: (continued)
Compound LogP EUH AD [A2] pKa B!AA!B Prediction
Propranolol 3.48 2 36.85 9.14/13.84 1.21 no transport
Protriptylene 4.09 1 51.92 10.61/- 2.35 no transport
Risperidone 4.11 3.75 54.37 7.89/43 1.66 transport
Roxindole 5.02 1 62.07 8.64/10.15 1.15 no transport
Saquinavir 3.58 4 140.63 7.61/11.05 53.16 transport
Scopolamine 0.62 4 38.69 8.01/14.11 1.09 no transport
Selegiline 2.9 0 32.53 7.53/- 0.62 no transport
Sulfasalazine 2.88 4 43.45 1.86/2.88 0.76 if entry
Sumatriptan 0.93 3 54 9.49/11.31 1.12 if entry
Tacrine 2.71 0 36.87 9.64/- 1.18 no transport
Terfenadine 7.08 1 95.12 9.57/13.32 2.38 transport
Trazodone 3.58 3.5 40.48 6.73/- 1.12 no transport
Trimethoprim 0.91 5 48.19 7.34/- 1.76 if entry
Trimipramine 4.97 2 56.12 9.37/- 0.79 no transport
Verapamil 3.79 6 81.95 8.92/- 1.75 transport
Warfarin 2.6 4 70.22 -/9.08 0.9 transport
Zimeldine 3.99 2 50.38 8.07/- 0.97 no transport
Zolmitriptan 2.22 2 51.56 9.52/12.57 2 if entry
Zolpidem 3.4 1.5 51.07 6.91/- 1.37 no transport
The prediction rule was able to correctly predict the result of the transcel-
lular transport assay of 82 out of 93 drugs (88.2%), with two false negatives,
and nine false positives. Having a closer look to the mispredicted compounds
led to the observation that from the 9 false positives, two had a B!AA!B ratio
between 1.4 and 1.5 (naloxone and doxapram), and ve had a positive re-
sult for the calcein-AM competition assay (midazolam, 
urazepam, noscapine,
bromocriptine, levomeprazine). One of the two false negatives, methysergide,
had a negative result for the calcein-AM competition assay, suggesting that
the transport assay was a false positive observation.
2.3.4 Prediction of potential substrates from the National Cancer
Institute
The Developmental Therapeutics Program (DTP) of the National Cancer In-
stitute (NCI/NIH) has screened tens of thousands of compounds against a
panel of 60 human tumor cell lines representing nine tissue sites. The com-
pounds are generally tested at dierent concentrations (usually at ve 10-fold
dilutions, up to 100 M) for the ability to inhibit the growth of these cell
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lines. The dose-response data is used to calculate several concentration pa-
rameters, in particular the GI50, which corresponds to the concentration of the
test drug causing 50% growth inhibition. Furthermore thousands of molecular
targets including protein or gene expression levels have been measured in the
NCI panel of human tumor cell lines. We downloaded the expression prole of
P-glycoprotein obtained with dierent techniques (RT-PCR, Aymetrix mi-
croarrays) and normalized the data: the average expression level of all cell
lines was subtracted from the expression level of each individual cell line. Fig-
ure 2.7(a) depicts the P-glycoprotein gene expression level obtained by RT-
PCR. The analysis of the expression level obtained with other techniques (PCR,
Aymetrix microarrays) all lead to comparable data. It appears that only ve
cell lines have a high P-glycoprotein expression level: HCT15 and SW-620
(colon), CAKI-1 and UO-31 (renal), and NCI/ADR-RESD (breast). In a sec-
ond step, we compared the activity prole of 44'652 compounds taken from the
DTP, and selected the 6'547 drugs having a global growth inhibitory power on
the dierent cancer cell lines. This allowed the reduction of the initial dataset
of 85.5% to a subset of only active compounds. In a third step, the activity
prole of the 6'547 selected drugs, each drug being previously tested against
each cancer cell line of the panel, was compared to the P-glycoprotein expres-
sion level on the same cell lines. As expected, some drugs showed a reduced
activity on the ve cell lines over-expressing P-glycoprotein (Figure 2.7(b),
whereas other drugs showed no particular reduction of activity on these ve
cell lines (Figure 2.7(c)). We selected the rst 37 compounds showing the
highest decrease of eciency on the cell lines over-expressing P-glycoprotein
(highest correlation between P-glycoprotein expression prole and activity pro-
le), called putative substrates, and the last 43 drugs showing no decrease of
eciency on these cell lines (lowest correlation between P-glycoprotein expres-
sion prole and activity prole), called putative non-substrates.
The cross-sectional areas of the 80 compounds were calculated as de-
scribed elsewhere,10 and the total number of type I and type II units was
obtained as described above. Octanol-water distribution coecients at pH
7.4 (LogP and pKa) were obtained with Marvin Sketch. As described above,
to be an apparent substrate, a drug has (i) to have at least one type I or type
II unit to interact with P-glycoprotein, (ii) be hydrophobic enough to partition
into the lipid bilayer, (iii) to be cationic or neutral, and (iv) be large enough to
diuse slowly through the membrane, and be thus eciently euxed by the
multidrug transporter. Hence we plotted in a three-dimensional diagram the
distribution coecient (LogD), the number of type I and type UU units (EUH),
as well as the calculated cross-sectional area (AD). We expected to obtain
a discrimination between putative substrates (at least one type I or type II
unit, hydrophobic and large molecules), and putative non-substrates (eventu-
ally small, no type I or type II units, and negatively charged, thus low LogD7:4).
Figure 2.8 shows the three-dimensional plot of LogD, EUH, and AD; it demon-
2.3. NEW MODEL BASED ON A TWO-STEP BINDING MECHANISM 53
CCRF-CEM
HL-60(TB)
K-562
MOLT-4
RPMI-8226
SR
A549/ATCC
HOP-62
NCI-H226
NCI-H23
NCI-H460
COLO 205
HCC-2998
HCT-116
HCT-15
HT29
KM12
SW-620
SF-268
SF-295
SF-539
SNB-75
U251
LOX IMVI
MALME-3M
M14
SK-MEL-2
SK-MEL-5
UACC-257
IGROV1
OVCAR-3
OVCAR-4
OVCAR-5
OVCAR-8
SK-OV-3
A498
ACHN
CAKI-1
RXF 393
TK-10
UO-31
PC-3
DU-145
MCF7
NCI/ADR-RES
MDA-MB-231/ATCC
HS 578T
MDA-MB-435
BT-549
T-47D
0 100 200 300 400 500 600 700
 
Normalized MDR1 expression level (arbitrary units)
(a)
-4 -3 -2 -1 0 1
Log(GI
50
) (Normalized values)
(b)
-4 -3 -2 -1 0 1
Log(GI
50
) (Normalized values)
(c)
Figure 2.7: (a) normalized P-glycoprotein expression level on 50 cell lines
investigated in the Developmental Therapeutics Program; (b)
activity prole of NSC 80469, a putative substrate of P-
glycoprotein; (c) activity prole of NSC 600223, a putative non-
substrate of P-glycoprotein.
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Table 2.8: 37 putative substrates of P-glycoprotein.
Compound LogD pKay EUH AD [A2] Prediction
NSC 125973 4.2 -2.44/12.53 12 135.08 substrate
NSC 139105 4.42 8.21 / - 1.99 53.5 non substrate
NSC 289922 5.99 - / - 1 73.07 non substrate
NSC 328426 2.8 - /12.66 15.83 97.83 substrate
NSC 337766 3.74 6.49 / - 0 65.52 non substrate
NSC 342443 2.67 - / 12.6 11.33 91.72 substrate
NSC 352670 0.73 - / - 3.39 77.28 non substrate
NSC 368891 4.35 6.66 / - 0.64 53.07 non substrate
NSC 600223 -2.75 -2.52/ 3.99 13.73 129.91 non substrate
NSC 646946 1.09 - / - 1 143.74 substrate
NSC 656177 4.07 -2.44/11.88 12.5 143.67 substrate
NSC 661748 10.92 - / 8.48 1.33 169.26 substrate
NSC 664401 3.95 -2.44/11.93 11.75 125.63 substrate
NSC 664403 4.26 -3.7 /12.07 12.5 133.36 substrate
NSC 664404 3.82 -3.69/12.07 12.67 140.37 substrate
NSC 666606 2.28 -4.43/11.07 13.08 124.62 substrate
NSC 667645 2.74 7.72 /17.93 0 61.63 non substrate
NSC 668404 3.38 -3.37/11.75 14.5 156.1 substrate
NSC 671864 3.23 -4.34/ 11.9 13 139.84 substrate
NSC 671865 4.82 -4.34/ 11.9 14.75 145.33 substrate
NSC 671866 4.46 4.69 /12.53 12.5 145.34 substrate
NSC 671867 3.47 -4.9 / 9.62 12.83 168.45 substrate
NSC 671871 2.27 -2.81/11.91 12.75 118.82 substrate
NSC 671872 4.15 -2.44/11.92 11.12 115.07 substrate
NSC 673185 3.15 -4.41/10.75 13.5 170.5 substrate
NSC 673186 3.38 -2.44/11.92 14 133.82 substrate
NSC 673187 3.15 -2.44/11.92 12.5 121.87 substrate
NSC 673188 4.34 -2.44/11.92 14 132.94 substrate
NSC 673191 5.08 -2.44/11.92 13 142.7 substrate
NSC 673192 3.41 3.24 /11.95 12.75 115.5 substrate
NSC 673193 4.46 3.48 /11.95 10.5 138.03 substrate
NSC 675252 2.42 8.49 /15.67 0.53 85.22 non substrate
NSC 675256 4.46 8.21 /11.34 1 38.13 non substrate
NSC 701744 2.38 3.5 /10.88 4.5 150.11 substrate
NSC 80465 -2.11 - / - 1 60.33 non substrate
NSC 80467 -1.65 - / - 2.37 58.11 non substrate
NSC 80469 -0.31 - / - 1.23 44.83 non substrate
y The rst value corresponds to the basic pKa, the second value to the
acidic pKa.
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Table 2.9: 43 putative non-substrates of P-glycoprotein.
Compound LogD pKay EUH AD [A2] Prediction
NSC 45383 -4.16 4.03 / 0.95 6.5 81.65 non substrate
NSC 52947 -0.83 9.17 / 9.94 4.5 72.76 non substrate
NSC 94739 2.44 7.65 / 9.27 1.5 57.57 non substrate
NSC 123976 2.88 - /12.75 5.25 105.02 non substrate
NSC 126728 1.84 - /12.69 6 88.3 non substrate
NSC 138780 0.85 - /13.42 7 69.23 non substrate
NSC 163062 0.27 - /12.94 4 48.01 non substrate
NSC 177499 1.7 -0.13/ 9.48 3.5 46.66 non substrate
NSC 200737 2.02 - /12.68 7.5 83.93 non substrate
NSC 251698 3.5 - /13.49 4.75 111.34 non substrate
NSC 295505 -0.57 8.63 /12.75 0 54.51 non substrate
NSC 326408 2.39 0.3 /11.91 4.75 97.95 non substrate
NSC 352890 -1.15 4.54 /12.83 1 48.56 non substrate
NSC 407808 0.28 - /12.65 7 110.26 non substrate
NSC 603724 -0.09 - /11.59 8 82.85 non substrate
NSC 626168 1.36 -5.62/ 9.74 6.5 99.73 non substrate
NSC 626169 1.36 -5.62/ 9.74 7.25 106.26 non substrate
NSC 626170 1.64 -5.62/ 9.74 6 114.29 non substrate
NSC 626369 0.85 - /12.87 1.5 58.1 non substrate
NSC 645804 -0.94 8.98 /12.75 0.25 54.2 non substrate
NSC 648772 3.11 0.58 /12.15 3.5 84.18 non substrate
NSC 648910 1.42 - /10.07 6 55.08 non substrate
NSC 650393 3.2 8.14 /12.83 2.25 78.65 non substrate
NSC 650394 3.36 6.35 /12.83 3.5 78.66 non substrate
NSC 650395 2.65 7.74 / 9.6 4.25 72.03 non substrate
NSC 650396 3.51 6.56 / 9.5 4.5 75.49 non substrate
NSC 668421 5.41 5.58 /13.32 1.25 79.71 non substrate
NSC 673805 0.25 9.18 /12.74 0.5 45.87 non substrate
NSC 676836 2.55 - /11.15 7.5 74.38 non substrate
NSC 677588 2.12 -0.69/ 9.17 4 50.9 non substrate
NSC 681237 2.3 8.68 /12.59 0 61.28 non substrate
NSC 681239 1.53 -0.7 /11.25 2 59.01 non substrate
NSC 683094 4.27 -2.78/12.11 0.5 68.49 non substrate
NSC 683098 2.98 1.1 /12.13 1 61.1 non substrate
NSC 687939 2.73 - / 11.9 5.5 92.55 non substrate
NSC 690267 1.34 -3.2 /12.22 3.75 86.96 non substrate
NSC 693541 3.13 -1.4 /12.19 1.5 83.35 non substrate
NSC 693542 2.6 3.7 /12.19 1.5 53.59 non substrate
NSC 696128 2.63 3.19 /11.45 3.75 58.57 non substrate
NSC 698103 3.11 -0.78/ 8.76 4 58.84 non substrate
NSC 698104 4.11 -1.36/22.65 1.5 67.48 non substrate
NSC 699482 1.8 8.42 /12.17 3 49.02 non substrate
NSC 700011 1.78 8.45 /11.35 2.25 61.86 non substrate
y The rst value corresponds to the basic pKa, the second value to the
acidic pKa.
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Figure 2.8: Three-dimensional diagram for the discrimination between puta-
tive substrates () and putative non-substrates (l).
strates the dierence in the activity prole of the two populations of drugs (the
one having a decreased activity on the cell lines over-expressing P-glycoprotein,
and the second one showing no particular decrease in the activity), can be seen
on the 3D diagram. Indeed, as expected, putative substrates have at least one
type I or type II unit, and are large, whereas the putative non-substrates are
localized in the portion of the diagram with low cross-sectional area and low
number of type I or type II units. They also show slightly lower LogD; some
of these drugs are highly negatively charged. However 10 putative substrates
are in the same range as the putative non-substrates; we suppose that these
compounds might be euxed by other multidrug transporters, like the MRP1.
For instance NSC 600223 contains a carboxy group, and thus cannot be trans-
ported by the P-glycoprotein.
2.4 Conclusion
Several methods have been developed to predict substrates and non-substrates
of the multidrug transporter P-glycoprotein. The binding of a drug to the
transporter occurs (i) with a partition from the aqueous phase to the lipid
membrane, and (ii) with the binding from the lipid membrane to the trans-
porter, we developed specic prediction rules to take into account this two-step
binding mechanism. The two steps have to be predicted individually, this is pos-
sible if lipid-water, Klw , or the air-water partition coecient, Kaw , is known.4
The lipid-water partition coecient, Klw , of a specic membrane can either
be measured or it can be derived from the air-water partition coecient, Kaw ,
according to Eq. (2.1), Taking into account the cross-sectional area, AD, of
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the molecule and the packing density, m, of the membrane.4 The binding
constant from the lipid membrane to the transporter, Ktl , can be estimated
by counting the number of hydrogen bond acceptor patterns (see Eq. (2.2)).
Since each in vitro assay monitors a specic phenomenon (where the dierence
between intrinsic and apparent substrate can be assessed), one prediction rule
has been established to predict the result of each assay.
The prediction rules have been tested on several datasets, leading to high
prediction accuracies. Moreover, the understanding of the binding mechanism
allowed to resolve the apparent inconsistencies observed by several authors
between dierent in vitro assays, and can be used to develop new prediction
rules to assess the results of new experimental settings.
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Chapter 3
Computational tool for the
predictions
3.1 Introduction
The eect of P-glycoprotein on drug's eux out of targeted cells has gained
more and more importance, especially for the development of a new drug.
Several in silico models have been established with the aim to predict if a
compound will be carried out by P-glycoprotein.
Since we developed several models to assess substrates of P-glycoprotein
(one model for each in vitro assay), and since these models are based on new
descriptors, we had to develop some algorithms to handle them; we decided
to this purpose to establish a whole working interface to handle compounds,
multiple conformations, some usual descriptors and our original ones, as well
as our rule-based models for the prediction of the passive diusion and the
active eux of drugs by multidrug transporters, in particular P-glycoprotein
(Figure 3.1).
3.2 Presentation of the software
3.2.1 Aim and roots of the software
The software is designed to handle within a graphical interface, several les,
compounds, multiple conformations, and to be able to calculate for each com-
pound in a rst step all parameters required for the prediction of the drug's
passive diusion and active eux, and in a second step to calculate the pre-
diction itself.
The software has been programmed using Microsoft Visual Studio .NET
2002 ; thus it works under Microsoft Windows. All the libraries implemented
into the software have been written during the PhD, except:
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Figure 3.1: Main user interface of the software. The left panel is the com-
pound panel, the top panel is the visualization panel, and the
bottom panel is the results panel.
 Jmol applet v10.2 (jmol.sourceforge.net), used for the three-dimensional
visualization of the molecule in the visualization panel of the software.
 OpenBabel library (openbabel.sourceforge.net), used to transform MOL
les into SMILES strings.
 ModEncryption library (www.freevbcode.com/ShowCode.asp?ID=2919),
used to encrypt/decrypt informations and prediction rules that are not
intended to be readable by the user.
Moreover the software uses some external plugins to calculate the LogP using
dierent algorithms, however the XlogP algorithm has been also implemented
within the software.70
3.2.2 Input
For an optimal compatibility with other softwares and to avoid unnecessary
conversion steps, we decided to use for the input of structures the Structure
Data Format (SDF); this format is the most widely used public standard to
handle structural and data information on chemicals. SDF les are simple
ASCII text les containing any number of records, each record consisting in two
blocks, one structural block (which contains a list of atoms and a connection
table for atoms binding) and one information block (consisting of zero or
more data elds). The SDF format was originally developed and published by
Molecular Design Limited (MDL).
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The structural block can exist on its own in individual les, having the .MOL
extension. Each MOL le contains only one structure and cannot contain any
additional information (data elds). The software can handle MOL les as
well, and these missing data elds can be added afterward from the software
itself. A parser designed to read SDF les as well as MOL les has been
programmed and implemented into the software.
3.2.3 Project
The software handles SDF les, MOL les, data elds, as well as calculations
and prediction results in project les. These les carry the .PGP extension.
A project le keeps track to zero or more input les (SDF or MOL), contains
the description of the transporters, the variables, the prediction rules, it also
contains all results of the calculations that have been carried out for each
compound, and some additional display information (for instance the size of
the display window, or the way data elds are displayed and regrouped).
Each new project (empty project, or new project based on a SDF le or a
MOL le) will be initially fed with the information contained in a template le.
This le is by default localized in the same folder as the running application,
and is called default.pgc (PgPredix Conguration File). Each modication in
the transporters denition, the prediction rules, the variables and the way data
elds are organized in the visualization panel can be saved in the template le;
these settings will be used for each new project.
The conguration of an opened project can be saved in a .PGC le; this
can be useful for the portability of the software, or to save the current cong-
uration (as a backup) before making some modications on prediction rules or
transporters denition. Inversely, the conguration of an opened project can
be overwritten by importing the conguration of another PGC le. The whole
conguration or only parts of the conguration (for instance only parameters
of the variables, or the one of the transporters) might be imported.
Since the PGP project le does not embed the structures, but only main-
tains a link to the various SDF or MOL les that have been added to the
project, these structure les should always be kept together with the PGP
project le. However at any time SDF les or MOL les can be added to
the opened project, and structure les already attached to a project might be
removed from the project. This will automatically remove from the compound
list all compounds belonging to the structure le (SDF or MOL le) that
has been removed from the project. Moreover single records (compounds)
might be excluded from the project; this might be useful to perform some
calculations on only a subset of conformations, for instance. The excluded
compounds might be recovered at any time.
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3.2.4 Output
Since the software represents a complete working interface and has the pos-
sibility to handle and display structures, perform simple mathematical opera-
tions, or sort the results, one can use it without any other additional softwares.
The PGP project le will keep all the information needed for proper operation.
However one might want to use the generated results in other softwares.
 The results can be exported in a tab-delimited le, which has the .XLS
extension. This le will be directly compatible with Excel, or any other
spreadsheet analysis software.
 The results can also be exported directly in the source SDF les: the
information block of the input les will be updated with the new data
elds corresponding to the prediction rules name or variable name and
the related information. All input les can also be merged into a single
SDF le; this can be useful to have to handle only two les at a time
(one SDF le and one PGP project le), instead of a whole list of, for
instance, MOL les coupled to one project le. If this merging process is
executed, the newly generated SDF le will be included into the current
PGP project le, and all other structure les (SDF of MOL les) will be
automatically removed from the project.
 Each individual structure can also be exported as MOL le, thus con-
taining only the structure information (atoms and connections between
atoms) and no additional information. The structures can be exported
one at a time or all of them. Moreover, the amphiphilicity axis, mean-
ing the axis representing the way the molecule will be oriented at an
hydrophilic-hydrophobic gradient (Figure 3.2), can be embedded in the
MOL le. Since the MOL les can only handle "real\ atoms and no addi-
tional information, the amphiphilicity had to be embedded as two "real\
atoms connected together. We chose the represent the hydrophilic cen-
ter of mass with a chloride atom (Cl), and the hydrophobic center of
mass with a magnesium atom (Mg). The reason of choosing these two
atoms is that (i) they have nearly identical van der Waals radii (1.75 A
for Cl, 1.73 A for Mg), which is useful for representations as seen on
Figure 2.6, and (ii) the Cl-Mg covalent bond will never occur in reality,
this allows to unequivocally nd the amphiphilicity axis embedded in the
MOL le.
3.2.5 Data elds
As described previously, each record in a SDF le contains one structural block,
and one information block. The information might contain one or more data
elds, each data eld consisting in one eld name and one value. When a
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Figure 3.2: Visualization panel showing a folded conformation of verapamil,
with the amphiphilicity axis (purple) and the cross-sectional area
of the molecule (orange cage)
SDF le is included in a project, the software will read for each record the
information block and collect all eld names and their attached values. These
information will be displayed in the software, in the tree panel as well as in the
display panel.
Figure 3.3: User interface to manage the data elds of the compounds.
The data elds of each compound can be edited within the software (Fig-
ure 3.3). The user can add a new data eld (consisting of one eld name and
one value), edit or delete an existing eld. The user can also add a new data
eld to all compounds loaded in a project, and edit or delete an existing data
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eld only if all records (compounds) contain the same value for the selected
eld.
One should emphasize the fact that these modications on data elds
(new, modied or deleted elds) will not be saved in the project, since these
informations are not maintained in the PGP project le, unless the user exports
these informations in the source SDF le (as described in the section 3.2.4).
In the display panel, the data elds can be grouped into groups. Each
group will have a name and a list of attached data elds, which are called
items (Figure 3.4). The groups will be displayed like folders and items like
subfolders. All items that are attached to a group will not appear at the root
level on the display panel. However the user might create a group named root,
which will contain items that are present in a group but will also appear at the
root level.
Figure 3.4: User interface to manage the display groups.
All data elds are displayed in the tree panel. However the user might want
to have only some useful information displayed in the display panel. Thus one
can hide some items; these items will still be available for calculation but they
simply will not appear on the display panel. All items that are not included
in any group and that are not hidden will be shown at the root level on the
display panel.
3.2.6 Variables
The previously described data elds are not available directly in the calculations
(prediction rules). One have to link them to a variable. Each variable might
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be referring to one or several data elds, and the data elds will be classied
by order of priority. The aim of variables is the following: one might have
several data elds describing the same parameter, several of these elds might
be present for one single record (compound), or several records in one project
might contain data elds having dierent eld names but describing the same
parameter. Instead of having to dene complicated prediction rules handling
these dierent eld names, or having to dene several prediction rules to handle
each eld name, the user will simply have to use the variable in the prediction
rule, and the software will search for the availability of data within the listed
data elds, following the priority order (Figure 3.5).
Figure 3.5: User interface to manage the variables and their dependencies.
Let us consider a simple example. The octanol-water partition coecient,
LogP, might be obtained from several sources, experimental or computational
ones. Thus one might dene a variable named LogP, which will refer to several
data elds, by order of priority, LOGP_EXP (for experimental value), CLOGP,
KOWWIN, PUBCHEM_CACTVS_XLOGP (which is the eld for LogP from National
Institutes of Health's PubChem substances). Thus when calling the variable
LogP, the software will rst search in the record data elds for LOGP_EXP, then
if no experimental data is available it will search for the CLOGP data eld and
so on. If no listed data eld is available, the variable will return an error (and
as a consequence, the prediction rule referring to this variable will also return
an error).
An important variable is Cmpd_Name. When reading a new SDF le, the
software will search in the information block of each record (compound) for
the eld names listed under Cmpd_Name. If one of these data elds is found,
the corresponding value will be used as compound name, which is the unique
identier of each record. If no compound name is found, the software will
attribute an arbitrary unique identier, which will be Compound [#], where
# is an incrementing number. If a compound name is found but this name
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was already attributed to another record as unique identier, this record will
have as unique identier the compound name followed by [#], where # is an
incrementing number.
One might dene as data elds for the variable Cmpd Name the following
names: CAS_RN (American Chemical Society identifying number), NSC (Cancer
Chemotherapy National Service Center identifying number), PUBCHEM_COMPOUND_CID
(PubChem identifying number).
3.2.7 Constants
The variables described previously are designed to handle the data elds of
each individual compounds. However one might want to have global variables
which can be modied, but which have the same value for all compounds
included in a project. This particular kind of variables are called constants.
Five constants are embedded in the software, the Avogadro's number (Na),
the Boltzmann constant (kB), the Pi value (Pi), and two constants that can
be modied in the options window within the software: the temperature (con-
guration.Temperature) and the pH (conguration.pH). Other constants can
be created/updated/deleted and saved in the default template le. The con-
stants, like variables, are available in the prediction rules.
3.2.8 Calculations
Several algorithms and plugins have been implemented in the software. They
allow the calculation of several parameters that might be used afterward in
prediction rules. The following section will list each calculation item, and the
corresponding result(s). Indeed one calculation item might generate one or
several data elds. Moreover, each generated data eld will also be automat-
ically added to a variable having the same name as the eld name; this allows
the user to directly apply the software's generated data in prediction rules.
MW+Formula will calculate, for each record (compound), its exact molec-
ular weight (by eventually adding missing hydrogens), and the empirical
formula. The generated elds will be MW for the molecular weight and
FORMULA for the empirical formula.
SMILES will "calculate\ the SMILES (Simplied Molecular Input Line Entry
System) compound formula, using the openBabel plugin. The generated
eld will be SMILES.
Maximal length will calculate the distance between each pair of atoms of a
structure, an the output will be the largest distance found. The gener-
ated eld will be LMAX.
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pKa is used to search for ionizable atom(s), and attribute them pKa values. It
will also search for carboxy groups, as well as quaternary ammonium ions.
The compound charge is also returned (based on source le information
and not on the pH and pKa). The user might feed the software with
pKa values, and these values must have the following syntax: the eld
names PKA1_TYPE and PKA2_TYPE must have the values acidic or basic,
and the eld names PKA1_VALUE and PKA2_VALUE must have as values
numerical entries. The software will search for basic and acidic ionizable
atoms, and attribute them the fed pKa values. These fed values might
be present in the information block of records in the source SDF les,
or added afterward as described previously.
The generated elds will be CHARGE for the global charge of the molecule,
COOH for the number of carboxy groups, PKA1.VALUE for the value of the
rst pKa, PKA1.TYPE for the type of the rst pKa (either acidic or basic),
PKA2.VALUE for the value of the second pKa, PKA2.TYPE for the type of
the second pKa (either acidic or basic).
The pKa module has been developed based on the method described by
Sayle.71
LogP with XLogP will calculate the LogP as described by Wang et al.70 The
XLogP algorithm has been implemented in the software. The generated
eld will be XLOGP.
LogP with KowWin will calculate the LogP using the Syracuse Research Cor-
poration (SRC) online KowWin plugin. The generated elds will be
KOWWIN for the calculated LogP, and LOGP_EXP for the experimental
LogP, if the value was available in the SRC online database.
LogP with ALogPS will calculate the LogP using the VCC Lab ALogPS plu-
gin. The generated eld will be ALOGPS.
Polar Surface Area will calculate the topological polar surface area, accord-
ing to Ertl et al.72 The described algorithm has been implemented in
the software. The generated eld will be PSA.
EU(H) will calculate the hydrogen-bonding ability of the molecule to the se-
lected transporter (see below). The generated elds will be EU.TOTAL for
the total number of hydrogen-bond formation, EU.TYPE0 for the number
of single atoms able to form hydrogen-bonds, EU.TYPE1 for the number
of type I units, and EU.TYPE2 for the number of type II units.
Cross-sectional area will calculate the cross-sectional area of the molecule,
oriented at an hydrophilic-hydrophobic gradient. This algorithm will rst
run the pKa calculation since the charges and their localization have to
be known. The generated elds will be AMPHIL_MOM which has been a
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tryout for the prediction of the amphiphilic moment of the molecule,
AD or AD[#] which is the calculated cross-sectional area, in A2, where
# in the current dened pH, LEN_AMPHI is the distance between the
hydrophilic and the hydrophobic centers of mass, in A, LEN_MOL is the
total length of the molecule oriented at the amphiphilic interface, in A,
and VOID_VOLUME is the void volume generated by a molecule inserted
into a lipid membrane, in A3.
The algorithm developed and implemented in the software has been described
elsewhere.10
3.2.9 Transporters
We presented in section 3.2.8 the possibility to calculate the hydrogen-bonding
ability of the molecules to a transporter. By default, the software comes with
one already congured transporter, P-glycoprotein. However one might want
to dene a new transporter; the following section will describe the available
settings, this should also help in understanding how the software assesses the
interaction of a molecule to the transporter, and the meaning of the previously
cited elds EU.TOTAL, EU.TYPE0, EU.TYPE1 and EU.TYPE2.
Figure 3.6: User interface for the conguration of the transporters.
One single PGP project le can handle several transporters; the template
le as well. However for the calculations of EU(H), one can calculate the
interactions of the molecules to one transporter at a time since the user has
to choose the current "active transporter\.
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It has been suggested that a substrate of P-glycoprotein will interact to
the transporter via hydrogen bonds formation; these bonds will form only if the
molecule shares some specic hydrogen bond acceptor patterns, which can be
of two types:
Type I units are two hydrogen bond acceptors, spatially distant of 2.5  0.5
A, and
Type II units are either two hydrogen bond acceptor groups, spatially distant
of 4.6  0.6 A, or three hydrogen bon acceptors groups with a distance
of 4.6 0.6 A between the rst and the third group, with an intermediate
hydrogen bond acceptor group.
These hydrogen bond acceptor groups must be electronegative atoms (O,
N, S, F, Cl) with an unshared electron pair, or unsaturated systems with a
-electron orbital (like a phenyl ring). Oxygens involved in a specic pattern
might be a carbonyl group (>C O), an alkoxy group ( OR) or one (but not
two) hydroxy group ( OH). Nitrogens involved in a specic pattern might be
an imine ( N ), a pyrrole (N1CCCC1), a pyridine (n1ccccc1), or a tertiary
amine ( NR2).
It has also been shown that the free orbitals of the two or three hydrogen
bond acceptors must be oriented in the same direction, within a range of 0 to
123.
A new transporter can be parametered as follows (Figure 3.6):
Transporter name is the name attributed to the transporter.
Action spectrum can be any of these three parameters, neutral compounds,
negatively charged compounds and positively charged compounds. This
setting will be available in the prediction rules (see further).
Patterns width represents the width of narrow (type I) patterns and wide
(type II) patterns. For P-glycoprotein, the type I unit has a width of
2.5  0.5 A, whereas the type II unit has a width of 4.6  0.6 A.
When searching for interaction patterns between the molecule and the
transporter, the software will exclude all groups of two or three hydrogen
bond acceptor groups that are outside of these ranges.
Patterns angle corresponds to the maximal angle between the free orbitals of
the two hydrogen bond acceptors of one pattern. The acceptable range
is 0 to 180; the latter value corresponds to antiparallel free orbitals.
Type I pattern: as described previously, type I units are formed by two hy-
drogen bond acceptor groups, separated by a specic spatial distance
and a specic angle between free orbitals. The user might select two
hydrogen bond acceptor groups to dene a new type I unit; moreover,
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each pattern will have a specic weight, corresponding to the contribu-
tion to the total free energy of binding of the drug to the transporter
(Gtl). This weight can be any numerical value. See below for the list
of available hydrogen bond acceptor groups. The sum of these weights
of all type I units carried by a molecule gives the EU.TYPE1 eld in the
EU(H) calculation.
Type II pattern: we also described that the type II units are formed by two or
three hydrogen bond acceptor groups. The user has to specify if the type
II unit is formed by two or three groups, and select the corresponding
groups in the list of available hydrogen bond acceptor groups (see below
for the complete list). As for type I units, type II units have a specic
weight for the Gtl . The sum of these weights of all type II units carried
by a molecule gives the EU.TYPE2 eld in the EU(H) calculation.
Single atom (aka Type 0 pattern): the software has the possibility to count
single atoms able to form hydrogen bonds with the transporter. For
single atoms, the user has to choose one hydrogen bond acceptor group
(see below for the complete list), and specify one weight for the free
energy of binding to the transporter (Gtl). The sum of the weights
of all single atoms forming hydrogen bonds of one molecule gives the
EU.TYPE0 eld in the EU(H) calculation.
The last calculation output of the EU(H) section is the eld EU.TOTAL.
This eld is the sum of all free energy contributions of Type I Units, Type II
Units and Single atoms.
The available hydrogen bond acceptor groups are the following (the ? sym-
bol represents any non-hydrogen atom, and the considered atom is depicted
in bold):
 O C
 O S
 O N
 O P
 ? O ?
 ? OH
 N OH
 P OH
 ? N<??
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 ? N
 ? N O
 ? N<OO
 ? NH ?
 ? NH
 ? NH2
 ? S ?
 ? SH
 Aromatic cycle
 ? C C ?
 ? F
 O C OH
 HO C O
3.2.10 Prediction rules
The prediction rules represent the core of the software. This is were the user
can really interact with the software. A prediction rule is a "command\ that
will collect information in variables and constants, do simple mathematical
operations, compare variables or dierent results together, and nally either
display a result (for instance the result of a comparison), or export a structure
to a specic folder. The results of the prediction rules will be displayed in the
results panel of the user interface. The prediction rules are evaluated using a
parser implemented in the software, which will convert the rules into Reverse
Polish Notation, to allow a faster processing of the rules on large datasets.
The following section will describe the objects the user can work with, then
the values and the operators, and nally the statements and the methods
(Figure 3.7).
Objects
The objects of the prediction rules are the elements the user can work with.
They belong to two groups, the variables and constants, and the rules. The
variables and constants have been described in section 3.2.6 and section 3.2.7,
they give access to any information stored in the input SDF les, or informa-
tion fed afterward from the software itself. As stated previously, several eld
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Figure 3.7: User interface for the edition of the prediction rules.
names can be stored within one single variable, for an easier handling of several
data elds describing the same parameter.
The rules are the results generated by other (and previously evaluated) predic-
tion rules. The aim is to avoid long and complicated rules, but the user has
to be warned that a prediction rule referring to the result of another predic-
tion rule will generate an error if the latter has not been evaluated yet. Thus
the prediction rules should be ordered to avoid any unexpected halt in the
evaluation process.
Values and Operators
Prediction rules can deal with three types of values: numerical values, logical
values, and character strings.
Numerical values can be any number, integer or not; scientic notations
constitute valid numerical values as well.
Logical values should be recognized in prediction rules, however in case of
problem the user should try to use string-embedded logical values (that
means, instead of using True or False, the user should use "True" or
"False").
Character strings are text enclosed in double quotation marks.
The operators belong to three groups: arithmetic operators, logical oper-
ators, and comparison operators.
Arithmetic operators take numerical values (either literals or variables) as
their operands and return a single numerical value. The standard arith-
metic operators are addition (+), substraction ( ), multiplication (),
and division (=). These operators work in the standard way. One should
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note that the usual arithmetic rules apply, hence multiplication and divi-
sion will have priority over addition and substraction; one can use paren-
thesis to change the priority order. One fth arithmetic operator is
the string concatenation operator (&). It is used to join two character
strings.
Logical operators: three logical operators are available: the bitwise And oper-
ator returns True if both operands are identicals; the bitwise Or operator
returns True if at least one of the two operands is True. The bitwise
Xor operator returns True if one but not both operands are True.
Comparison operators: six comparison operators are available. The equal
operator (==) returns True if the operands are equal. The not equal
operator (<>) returns True if both operands are dierent. The greater
than operator (>) returns True if the rst operand is greater than the
second one, and the greater than or equal to operator (>=) returns
True il the rst operand is greater or equal to the second operand. The
smaller than operator (<) returns True if the rst operand is smaller
than the second one, and the smaller than or equal to operator (<=)
returns True if the rst operand is smaller or equal to the second one.
Statements and methods
Only one type of conditional statements is available. These statements are:
If...Then...
Elseif...Then...
Else...
Only the rst two statements are required, whereas Elseif...Then and Else
statements are optional. One can use as many Elseif...Then statements
are needed, but one can use only one Else statement.
There are many methods available in the software. They belong to two
groups: the methods of the rst group allow manipulation of variables or rules
values, whereas the methods of the second group are designed to output the
results. The two output methods can be used only alone or after a Then or
a Else statement. The manipulation methods cannot be used after a Then
or a Else statement. The following section will enumerate alphabetically all
available methods, starting with the two output methods.
Output methods:
Display(x, y): displays the result (x) without background (y=0) or with a
"Good\ (y=1), "Medium\ (y=2), or "Bad\ (y=3) background. The
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symbol y can also be a string containing six comma-delimited number
corresponding to the RGB value of the text and the RGB value of the
background of the cell. Ex: Display("test", "0, 0, 0, 118, 156, 234")
will display the text test with a black font on a blue background.
Export Mol(x, y): exports the current molecule into the specied folder (x)
by adding (y=1) or not (y=0) the amphiphilicity axis (see section 3.2.4
for the denition of the amphiphilicity axis).
Manipulation methods:
Abs(x): absolute value of x.
Angle(x, y): gives the angle between the orbitals of atom x and atom y.
Average(x): gives the average value of a variable (x) within a whole dataset.1
Distance(x, y): gives the distance between atom #x and atom #y (atoms
number can be displayed by right-clicking on a structure and selecting
Text ! Atom number), in angstrom.
Exp(x): exponential value of x.
Ln(x): neperian logarithm of x.
Log(x): base 10 Log of x.
LogD(x): log of the distribution coecient at pH x. This function uses the
LogP variable.
Export Mol(x, y): exports a structure in the x folder with (y=1) or without
(y=0) amphiphilicity vector embedded in the mol le.
Max(x): gives the maximal value of a variable (x) within a whole dataset.1
Example of usage:
If Ad[7.4] == Max(Ad[7.4]) Then
Display("Largest structure")
Min(x): gives the minimal value of a variable (x) within a whole dataset.1
Optional(x): it will skip the variable x if the corresponding eld(s) is/are ab-
sent from the database.
1These three methods (Average, Max, and Min) do not work on the whole dataset, but
on each group of compounds, that means compounds sharing the same compound name
(with the incrementing number in brackets, as unique identier) will be evaluated together.
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pKa(x): gives the acidic or basic dissociation constant (pKa) of the com-
pound, with x="acidic\ or x="basic\. This function requires the result
of the pKa calculation.
Power(x, y): raises the number x at the power y.
Required(x): it will skip the whole section (from If or ElseIf to the next
ElseIf or Else or the end of the rule) if the variable x is absent from
the database.
Round(x, y): rounds the number x with y decimals.
SpeciesNeg(x): amount of negatively charged species at a given pH (x). This
method requires the result of the pKa calculation. The returned value
is comprised between 0 (no negatively charged species) and 1 (100% of
negatively charged species).
SpeciesPos(x): amount of positively charged species at a given pH (x). This
method requires the result of the pKa calculation. The returned value
is comprised between 0 (no positively charged species) and 1 (100% of
positively charged species).
Sqrt(x): square root of x. Same as Power(x, 0.5).
Zwitterion(x): calculates the amount of zwitterionic species at pH x. The
output is a number comprised between 0 and 1. Since this function
requires two pKas, one can use it with the Optional( ) argument,
skipping the function if only one pKa is provided.
3.2.11 Tuning the calculation of the cross-sectional area
Several parameters of the software can be modied by the user. Some of
them concern the interface, some others will in
uence the calculation of the
cross-sectional area (Figure 3.8). Here we will discuss only the settings having
a consequence on the calculation results.
Missing hydrogens. As described elsewhere,10 there is a linear relationship
between cross-sectional area calculated by considering the hydrogens, or by re-
moving them from the structure. If no hydrogen are found in the structure, the
software will automatically correct the calculated cross-sectional area to take
into account the missing hydrogens. However, one can increase the processing
speed by removing the hydrogens from the structure for the calculation of the
cross-sectional area (in fact the hydrogens are not removed but they are not
considered), and applying the correction for the missing atoms. This feature
might be useful when calculating the cross-sectional area of many structures.
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Figure 3.8: Conguration window for the tuning of the cross-sectional area
calculation
Water probe. The surface of the projection of all atoms into the plan is
smoothed by a water probe which has by default a radius of 1.4 A. The user
might want to change the size of the water probe; a radius of 0 A will give the
exact surface of the contour of the projection, whereas a larger radius might
be more relevant to simulate in vitro data.
pH. Since the charge has an strong in
uence on the orientation of the
molecule at a hydrophilic-hydrophobic interface, the software calculates the
repartition of charges within the molecule and attributes the weights for the
calculation of the hydrophilic center of mass according to these charges. Thus
the pH will dramatically in
uence the charge repartition, and the orientation
of the molecule. Hence the user can change the pH at which the charges
are calculated; this will aect the orientation of the molecule, and thus the
calculated cross-sectional area.
Hydrophilic contributions. To take into account the eect of the charge on
the orientation of the molecules, an arbitrary weight of 100 has been attributed
to a fully charged tertiary amine or a carboxy group. However the user might
want to change these weights, for instance to give a higher or a lower in
uence
of the charge on the orientation of the molecule, and thus on the calculated
cross-sectional area.
3.2.12 Scripting language
It is often pretty useful to have a three-dimensional representation of the
structures the user is working with, and to see directly all the information and
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the results on the user interface. However when working on large databases or
on many les, it might be useful to use the scripting language of the software,
since the graphical interface is much slower than pure processing. Hence the
software embed a scripting language that gives the user access to all functions
he might use in the software.
Description of the scripting language
The script les must have the .PGS extension (which stands for PgPredix
Scripting File). Scripts are plain ascii texts, and each command must be on a
new line. Empty lines are allowed, and comment lines must start with the //
tag. Scripting commands are not case sensitives, but variables and rules are
case sensitive. Character strings can be in simple or double quotes, but these
are not required. The following section will describe each scripting command
alphabetically.
Scripting commands
add eld(string compound; string eld name; string eld value) Adds
a new data eld to the specied compound, or to all compounds (using the
wildcard symbol, ) (data elds were described in section 3.2.5).
add mol(string le name) Adds a substance (MOL le) or a group of sub-
stances (SDF le) to an opened project.
add rule(string rule name; string rule denition; fstring rule descrip-
tiong) Adds a new prediction rule or edits an existing prediction rule (pre-
diction rules were described in section 3.2.10). The rule_description eld
is optional.
add vareld(string variable name; string eld name) Adds a new eld
name into the specied variable; the variable is created if it does not yet exists.
If the variable exists, the eld name is added at the bottom of the list (lowest
priority in the processing). The variables have been discussed thoroughly in
section 3.2.6.
calc(string function; string compound) Calculates the chosen function for
the specied compound or all compounds (using the wildcard symbol, ). The
calculations have been described in section 3.2.8; the variables and data elds
generated are those specied in this section.
List of available functions:
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 "ad\: calculates the cross-sectional area. The settings for the calcula-
tion (as described in section 3.2.11) can be parameterized using the set
command.
 "alogps\: calculates the LogP using the ALogPS plugin.
 "eu\: nds the hydrogen bond donnors/acceptors patterns.
 "kowwin\: gets the experimental LogP (if available) and the calculated
LogP using the Kowwin algorithm; this requires an Internet connection.
 "lmax\: calculates the maximal length of the compound.
 "mw\: calculates the molecular weight and the summation formula of
the compound.
 "smiles\: gets the SMILES string of the compound.
 "species\: calculates the acidic and basic pKa's.
 "tpsa\: calculates the polar surface area, using the TPSA algorithm
implemented in the software.
 "xlogp\: calculates the LogP, using the XLogP algorithm implemented
in the software.
close project() Closes the current project.
del rule(string rule name) Deletes the specied prediction rule.
del vareld(string variable name; string eld name) Deletes the speci-
ed data eld of the selected variable.
del var(string variable name) Deletes the variable and all its data elds.
export mol(string compound; string le name; integer 
ag) Exports the
specied compound (using it unique identier, as described in section 3.2.6) in
a MOL le (le name); if 
ag=0, the amphiphilicity axis will not be embedded,
if 
ag=1 the axis will be embedded. If 
ag=2, the axis will be embedded and
the les cage.py and vector.py will be created in the c:ntempn folder (for use
with PyMol). The denition of the amphiphilicity axis has been described in
section 3.2.4.
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export sdf(string compound; string le name; integer include rules) Ex-
ports structure(s) of one compound or all compounds (use the wildcard symbol,
) to one SDF le (le name), including (include rules=1) or not (include
rules=0) the results of the prediction rules.
export xls(string le name) Exports all the results (obtained with the run
rule function) to a tab-delimited le (which name is specied in le name).
new project(string le name) Opens a PGP project le, or creates a new
project based on a MOL or a SDF le.
open project(string le name) Opens an existing PGP project le.
run rule(string rule name; string compound) Runs the chosen rule or all
rules (using the wildcard symbol, ) for the specied compound or all com-
pounds (using the wildcard symbol, ).
save project(string le name) Saves the project in the specied PGP project
le.
save settings() Saves the settings changed with the set function. If settings
are not saved, they won't be available during the next session.
set(string setting, string value) Sets the setting to the specied value. List
of customizable settings:
 "ph\: sets the pH for the calculation of the cross-sectional area.
 "ph tag\: denes if a tag is added to the eld name generated by the
calculation of the cross-sectional area; if ph tag is set to true, the eld
name will be AD[#] with # the current pH, otherwise it will be AD.
 "digits\: sets the minimal number of digits for compound duplicates.
 "hydrogen\: value must be "true\ to remove the hydrogens and ap-
ply a correction in the calculation of the cross-sectional area, otherwise
"false\.
 "increase vdw\: set to "true\ to increase the size of the Van der Waals
radii of charged atoms, for the calculation of the cross-sectional area;
set to "false\ otherwise. The increase will be by a factor of jchargej+1.
 "probe\: sets the radius of the water probe, for the calculation of the
cross-sectional area (in A).
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 "rule def\: if rule def="true\, the rules denitions will be included in the
tab-delimited le (obtained with the "export xls\ function), otherwise
the rules denitions will not be included.
 "temperature\: set the temperature.
swap rule(string rule1, string rule2) Exchanges the rule1 with the rule2;
this will permute the columns in the output le (obtained with the export xls
function). This might be also useful for rules referring to the result of another
rule; in this case this rule has to be placed after the other one.
Scripting example
The following section will show an example of a script le. It will open a source
SDF le containing multiple conformations of the same compound (benzylpeni-
cillin), add several prediction rules, feed the source with experimental pKas,
calculate the cross-sectional area at pH 7.4 and export the structure of the
smallest calculated cross-sectional area, calculate the cross-sectional area at
pH 8 and exporting all results in a tab-delimited le.
//
//Benzylpenicillin
//
new_project("D:\Substances\Benzylpenicillin_all.sdf")
add_rule("Ad_Display74"; "Display(Ad[7.4], 0)")
add_rule("Ad_Display8"; "Display(Ad[8], 0)")
add_rule("Energy_display"; "Display(Energy, 0)")
swap_rule("Ad_Display74"; "Energy_display")
add_rule("Export_Smallest"; "If AD[7.4] == Min(Ad[7.4]) Then
Export_Mol("D:\Substances\smallest\", 0)")
add_field(*; "PKA1_VALUE"; "2.62")
add_field(*; "PKA1_TYPE"; "acidic")
add_field(*; "PKA2_VALUE"; "-1.32")
add_field(*; "PKA2_TYPE";"basic")
set("ph"; "7.4")
set("ph_tag"; "true")
calc("ad"; *)
add_rule("EU_Avg"; "Display(Average(EU.TOTAL), 0)")
calc("eu"; *)
set("ph"; 8)
calc("ad"; *)
run_rule(*; *)
del_rule("Export_Smallest")
export_xls("D:\Substances\Benzylpenicillin_all.xls")
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close_project()
3.3 Conclusion
The software represents a versatile and useful tool to handle many compound
structures, calculate usual descriptors as well as the original descriptors devel-
oped in order to assess the particularity of two-step binding of drugs to the
multidrug transporter P-glycoprotein, rst the partitioning into the lipid bilayer
(where the cross-sectional area represents a highly predictive parameter), and
then the binding to the transporter via specic hydrogen bond patterns (type
I and type II units). The working interface oers a convenient way to handle
structures and related information, and gives the user the opportunity to visu-
alize the three dimensional structure of each compound, as well as important
parameters, like the type I and type II units, or the way the compound will
be oriented at a hydrophilic-hydrophobic interface. Moreover, the scripting
language oers the possibility to realize larger calculations, and to automatize
some repetitive tasks on several structure les. Finally, the high 
exibility of
the software, on input, variables, transporter denition, and prediction rules,
allows a wide variety of applications, for instance the elaboration of a whole
set of hydrogen bonding denition and prediction rules to assess the binding of
a drug to another transporter, like the multidrug resistance transporter MRP1.
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Halogenation of Drugs Enhances Membrane
Binding and Permeation
Grÿgori Gerebtzoff,[a] Xiaochun Li-Blatter,[a] Holger Fischer,[b] Adrian Frentzel,[c]
and Anna Seelig*[a]
Introduction
Most drugs permeate biological membranes by passive diffu-
sion. The extent of permeation depends, on one hand, on the
properties of the membrane and, on the other, on those of the
diffusing molecule. Membranes are highly organized, aniso-
tropic systems that are nevertheless fluid enough to allow con-
siderable translational, rotational, and flexing movements of
the constituent lipid and protein molecules. Under physiologi-
cal conditions, the lipid-bilayer membrane is in a liquid crystal-
line state and behaves like optically uniaxial crystals with the
optical axis perpendicular to the surface of the membrane.[1]
This is in contrast to membrane-mimicking systems such as oc-
tanol or hexadecane, which are isotropic organic solvents. By
using solid-state NMR techniques, a quantitative analysis of the
molecular ordering and dynamics of a lipid bilayer has become
possible with a segment-to-segment resolution. The packing
density of the hydrocarbon chains is well described in terms of
a statistical order profile. Membrane packing and ordering in-
crease with the cholesterol content and decrease with increas-
ing temperature or increasing fatty acyl chain unsaturation (for
a review see ref. [2]).
The lateral packing density of a lipid bilayer can, alternative-
ly, be assessed in comparison to the packing density of a lipid
monolayer (for a review see ref. [3]). The packing density of
planar bilayers consisting of the most abundant natural lipid,
1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine, POPC, was
determined as pM=32 mNm
1 at ambient temperature.[4] That
of unilamellar lipid vesicles is somewhat lower and varies be-
tween pM=25±32 mNm
1 depending on the size of the vesi-
cle,[5] while that of cholesterol-containing membranes such as
erythrocyte membranes is higher (pM=32±35 mNm
1).[6] The
membrane packing density influences binding[7,8] and permea-
tion[9] of drugs in an exponential manner.
The properties of the drug with the strongest impact on
membrane binding are hydrophobicity (which is suitably re-
flected by the air±water partition coefficient) and the cross-
sectional area.[9,10] Whereas partitioning into an isotropic or-
ganic solvent increases with the molecular volume,[11] partition-
ing into an anisotropic lipid bilayer decreases exponentially
with increasing cross-sectional area of the molecule.[7,8,9] Drugs
are generally weak bases or weak acids that are present in a
charged as well as an uncharged form under physiological
conditions. Charged and uncharged molecules can insert into
the lipid±water interface; however, only a fraction of un-
charged drugs can permeate a lipid membrane.
Strategies to enhance passive diffusion often consist of re-
placing a hydrogen residue by a chlorine or a trifluoromethyl
residue. Despite the relatively high numbers of halogenated
drugs on the market, little information is available on the
quantitative effects of halogenation on drug binding to mem-
branes and drug diffusion through membranes. We therefore
quantify the influence of such replacements on the lipid±water
partition coefficient, Klw, and the permeability coefficient, P. We
chose chlorinated and fluorinated phenothiazine analogues
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Halogenation of drugs is commonly used to enhance membrane
binding and permeation. We quantify the effect of replacing a
hydrogen residue by a chlorine or a trifluoromethyl residue in po-
sition C-2 of promazine, perazine, and perphenazine analogues.
Moreover, we investigate the influence of the position (C-6 and
C-7) of residue CF3 in benzopyranols. The twelve drugs are charac-
terized by surface activity measurements, which yield the cross-
sectional area, the air±water partition coefficient, and the critical
micelle concentration. By using the first two parameters (AD and
Kaw) and the appropriate membrane packing density, the lipid±
water partition coefficients, are calculated in excellent agreement
with the lipid±water partition coefficients measured by means of
isothermal titration calorimetry for small unilamellar vesicles of
1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine. Replacement
of a hydrogen residue by a chlorine and a trifluoromethyl residue
enhances the free energy of partitioning into the lipid membrane,
on average by DGlw1.3 or 4.5 kJmol1, respectively, and the
permeability coefficient by a factor of ~2 or ~9, respectively. De-
spite exhibiting practically identical hydrophobicities, the two
benzopyranol analogues differ in their permeability coefficients
by almost an order of magnitude; this is due to their different
cross-sectional areas at the air±water and lipid±water interfaces.
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(analogues of promazine, perazine, and perphenazine) to in-
vestigate the influence of the type of halogenation, and 6- and
7-trifluoromethyl benzopyranol to investigate the influence of
the position of aCF3 group.[12]
We characterized the drugs in terms of their cross-sectional
area, AD, their air±water partition coefficient, Kaw, and their criti-
cal micelle concentration, CMCD, which are all obtained by
means of surface-activity measurements (SAMs).[9, 13] Using the
first two parameters, AD and Kaw, we calculated Klw for mem-
branes of different packing densities, pM. This approach is vali-
dated by comparing the lipid±water partition coefficients pre-
dicted on the basis of surface-activity measurements with
those determined by means of isothermal titration calorimetry,
ITC.[10]
The permeability coefficient, P, is then calculated by taking
into account the lipid±water partition coefficient derived from
surface-activity measurements, the ionization constant, and the
pKa of the compound as outlined previously.
[14]
Experimental Section
Compounds : Promazine¥HCl, triflupromazine¥HCl, trifluoperazi-
ne¥2HCl, and fluphenazine¥HCl were obtained from Sigma±Aldrich,
Steinheim, Germany. cis-Flupenthixol¥2HCl, chlorpromazine¥HCl,
chlorperphenazine¥HCl, 6-trifluoromethyl benzopyranol (6-trifluoro-
methyl-3,4-dihydro-4-(1,6-dihydro-1-methyl-6-oxo-3-pyridazinyl-
oxy)-2,2-dimethyl-2H-1-benzopyran-3-ol) and 7-trifluoromethyl
benzopyranol (7-trifluoromethyl-3,4-dihydro-4-(1,6-dihydro-1-
methyl-6-oxo-3-pyridazinyloxy)-2,2-dimethyl-2H-1-benzopyran-3-ol)
were kind gifts from Merck, Darmstadt, Germany. Perazine¥dima-
leate and chlorperazine¥HCl were kindly provided by Jacek WÛjci-
kowski, Institute of Pharmacology, Polish Academy of Science,
KrakÛw, Poland, and by F. Hoffmann±La Roche Ltd. , Basel, Switzer-
land, respectively.
Buffers : For SAMs and ITC, Tris/HCl buffer (50 mm), containing
NaCl (114 mm) was used. SAMs were performed at ambient tem-
perature (T=241 8C), and ITC was measured at 37 8C. Buffers
were adjusted to pH 7.4 at the temperatures used for the respec-
tive measurements. For SAMs, stock solutions of drugs were pre-
pared at concentrations of 104±102m either in nanopure water
with a resistance of 17±18mWm1 or in methanol. For ITC drugs
were dissolved in buffer solution.
For SAMs we either used a Teflon trough designed by Fromherz
(Mayer Feintechnik, Gˆttingen Germany)[15] with a filling volume of
one compartment of 20 mL or a home-built Teflon trough (filling
volume 3 mL). To maintain a constant humidity, the troughs were
covered by a Plexiglas hood. The surface pressure, p=g0g, where
g0 is the surface tension of the pure buffer and g the surface ten-
sion of the drug solution, was monitored with filter paper (What-
man No. 1) connected to a Wilhelmy balance. For drugs dissolved
in methanol, the measured surface pressure was corrected for the
intrinsic surface pressure of methanol.[13] The total methanol con-
centration in the final drug solution was 10% (v/v). For the home-
built trough, in which evaporation is not compensated for by an
added volume as in the Fromherz trough, the surface pressure was
corrected for the effects of evaporation and buoyancy.
The thermodynamics of drug adsorption at the air±water interface
is described by the Gibbs adsorption isotherm:
dp ¼ RTGdlnC ð1Þ
Here C is the concentration of the amphiphile in the Teflon trough,
RT is the thermal energy per mole, and G is the surface excess con-
centration defined as the inverse of the product of the Avogadro
number, NA, and the area requirement of the surface active mole-
cule at the interface, AS :
G ¼ ðNAASÞ1 ð2Þ
The surface excess concentration, G, increases with C up to a limit-
ing value G¥. As long as G is constant, a plot of p versus logC
yields a straight line. The area requirement of the compound, AS,
was evaluated from the quasilinear part, dp/d lnC, of the Gibbs ad-
sorption isotherm:
G1 ¼ ð1=RTÞdp=d ln C ð3Þ
For data analysis, we developed a program that selects the quasi-
linear part of the p/logC plot in an automatic and reproducible
manner.
To evaluate the air±water partition coefficient, the Szyszkowski
equation was used:
p ¼ RTG1 ln ðKawCþ1Þ ð4Þ
This is an integral version of Equation (3) combined with a Lang-
muir adsorption isotherm. Combining Equations (2) and (4) allows
evaluation of Kaw by calculating the slope of the linear regression
line through data points corresponding to the quasilinear part of
the p versus logC plot by using AS, determined as described
above:
KawC ¼ epASNA=RT1 ð5Þ
C is the equilibrium concentration of the drug, Ceq, in bulk solution,
which is defined as the total concentration, Ctot, minus the concen-
tration of the drug adsorbed to the air±water interface, Cb :
Ceq ¼ CtotCb ð6Þ
Cb is the product of G and the surface area of the solution, A, per
total volume, V (Cb=GAV
1). Cb is negligibly small as long as Kaw is
small (<106m1) and is therefore generally neglected (Ceq~Ctot).[9]
In the present evaluation procedure, however, we correct for Cb;
this slightly influences the parameters of hydrophobic compounds,
such as trans-flupenthixol.
Lipid±water partition coefficients determined from surface-
activity measurements : Knowledge of the Kaw and the AD of a
drug allows estimation of Klw according to Equation (7):
[9]
Klw ¼ KawepMAD=kT ð7Þ
Here kT is the thermal energy, and pM is the lipid packing density
of the membrane. Klw [m
1] is defined as the quotient of mole frac-
tion of drugs bound to the membrane, Xb, and the concentration
of the drug in aqueous solution, Ceq [molL
1]:
Klw ¼ Xb=Ceq ð8Þ
Klw can be transformed to the dimensionless partition coefficient,
glw, defined as the quotient of the drug concentration in the mem-
brane and the drug concentration in the aqueous phase, both
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given in [molL1]:
glw ¼ Cm=Ceq ¼ C1:Klw ð9Þ
Cl is the molar concentration of lipid (Cl=1.05 molL
1) if the densi-
ty of lipids is assumed to be 1=0.8 kgL1 and the molecular
weight is MW=760.1 Da (POPC).
Free energies : The free energy of self-association or micelle forma-
tion, DGmic, the free energy of partitioning into the air±water inter-
face, DGaw, and the free energy of partitioning into the lipid±water
interface, DGlw, are obtained as follows:
DGmic ¼ RT ln ðCMCD=CwÞ ð10Þ
DGaw ¼ RT ln ðCwKawÞ ð11Þ
DGlw ¼ RT ln ðCwKlwÞ ð12Þ
where Cw is the molar concentration of water (Cw=55.5 molL
1 at
241 8C and Cw=55.3 molL1 at 37 8C).
Permeability coefficient : As outlined previously,[14,16] P can be esti-
mated on the basis of surface activity measurements. For a non-
electrolyte P is proportional to the product of glw and the diffusion
coefficient, D :
P ¼ glwD=Dx ð13Þ
where Dx is the thickness of the membrane. The diffusion coeffi-
cient is defined as:
D ¼ kT=ð6phrÞ ð14Þ
where kT is the thermal energy, h is the membrane viscosity, and r
is the molecular radius, which is derived from AD. For the following
calculations, the membrane viscosity is assumed to be h=1 poise
and the membrane thickness, Dx=50 ä.
The fraction of the nonionized form of a basic drug, fA, that is pres-
ent at a particular pH can be calculated as:
fA ¼
½A

½AHþ
 þ ½A
 ¼ ð1þ 10
pKapHÞ1 ð15Þ
where [A] and [HA+] are the concentration of the uncharged and
the ionized form of the drug, respectively. For the calculation of
the permeability coefficients, we use the standard pKa values cor-
rected for temperature. The partition coefficient for the permeating
species of a basic drug, g*lw, is thus:
g*lw ¼ g:fA ð16Þ
and the permeability coefficient is :
P ¼ g*lwD=Dx ð17Þ
Isothermal titration calorimetry : Drug partitioning into small uni-
lamellar vesicles (SUVs) was measured by means of high-sensitivity
ITC with a Microcal VP-ITC calorimeter (Microcal, Northampton,
MA). A suspension of small unilamellar vesicles formed from
1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) (Cl=30±
35 mm) was injected in 3±10 mL aliquots into the drug solution in
the calorimeter cell (Vcell=1.4037 mL) by using a Hamilton syringe
coupled with a stepping motor. For all drugs, injections gave rise
to exothermic heats of reaction, produced by the partitioning of
the drug into the membrane (for further details see refs. [10] and
[17]).
For uncharged drugs, binding to the membrane is best described
by a simple partition equilibrium:
Klw ¼ Xb=Ceq ð18Þ
For the charged cationic drugs used in the present investigation,
this simple approach [Eq. (18)] is not adequate and yields concen-
tration-dependent partition coefficients. This is due to the fact that
partitioning of the drug into the electrically neutral lipid±water
interface leads to a positive surface charge density, s, (defined as
total surface charge, QT per total membrane surface area, AT) and,
in turn, to a positive surface potential, Y. As a consequence, the
lipid±water partition coefficient decreases with increasing concen-
tration.[18] A concentration-independent binding constant, Klw0, can
either be obtained by plotting Xb/Ceq against Ceq and extrapolating
to Ceq=0, as shown previously for the binding of cationic peptides
to POPC vesicles, or by applying the Gouy±Chapman theory.[18]
Results
The compounds investigated are displayed in Table 1A and B.
The phenothiazine analogues, series A±C, as well as the benzo-
pyranol analogues, series D, carry an uncharged or hydropho-
bic residue, R1, and a cationic or hydrophilic residue, R2, and
are thus amphiphilic compounds. Series A±C represent proma-
zine, perazine, and perphenazine analogues carrying a hydro-
gen atom, a chlorine atom, or a trifluoromethyl group as resi-
due R1. Compounds in series D exhibit identical sum formulas
but differ with respect to the position of the nonpolar CF3
group (R1a and R1b).
Surface activity measurements, SAMs
Injection of an amphiphilic drug into a monolayer trough filled
with buffer is followed by partitioning of the drug between
the aqueous phase and the air±water interface. Molecules in
the air±water interface orient such that the hydrophilic residue,
R2, remains immersed in the aqueous phase and the hydro-
phobic residue, R1, reaches into the air. The surface activity as
a function of concentration (p/logC plot or Gibbs adsorption
isotherm) was measured for all compounds at pH 7.4 and
pH 8.0. The lower pH corresponds to the condition in aqueous
bulk solution, and the higher pH reflects that close to an elec-
trically neutral lipid membrane to which cationic drugs are
bound and which therefore exhibits a positive surface poten-
tial, Y.[5, 19, 20]
Cross-sectional areas, air±water partition coefficients, and
critical micelle concentrations
Figure 1 shows the p/logC plots of the promazine and pera-
zine analogues, series A and B, respectively. The slope of the
quasilinear part of the Gibbs adsorption isotherm (solid line)
yields the surface excess concentration, G¥ [Eq. (3), below], and
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in turn the surface area requirement, As, of the drug molecule
at the air±water interface [Eq. (2), below]. The intersection of
the linear slope and the solid line drawn through the points of
constant surface pressure at high concentrations is defined as
the critical micelle concentration of the drug, CMCD. Due to a
comparatively low amphiphilicity (see Discussion) and a con-
comitant high tendency to aggregate at higher pH values,
chlorpromazine could only be measured up to pH 7.8.
Figure 2A shows the p/logC plots of triflupromazine as a
function of the pH. At high pH the compounds are only parti-
ally charged and therefore partition into the air±water interface
even at low concentrations (C<106m). The lower the pH of
the solution, the lower is the air±water partition coefficient,
Kaw, the flatter the slope of the p/logC plot and the larger the
area requirement of the molecule at the air±water interface, As.
The pH dependence of the surface area requirement, As, (&)
and the critical micelle concentration, CMCD (~) for triflupro-
mazine are summarized in Figure 2B. At low pH values where
the drug is fully protonated, the area requirement at the inter-
face, As, is large due to charge-repulsion effects,
[9] but decreas-
es with increasing pH. For promazine (not shown) and triflu-
promazine (Figure 2B), the minimum area would, in principle,
be reached close to pH 8.5. However, these drugs tend to form
small micelles or aggregates, even below the apparent CMCD
at pH>7.5. This can lead to a decrease in the slope of the
Gibbs adsorption isotherm and, in turn, to a small apparent in-
crease in area as seen in Figure 2B. Therefore, for the highly
charged compounds promazine and triflupromazine, we used
the extrapolated minimal values at pH 8.5 for the following
calculations.
For most cationic drugs, however, the surface area require-
ment, AS, measured at pH 8.0 corresponds well to the mini-
mum area and thus reflects the cross-sectional area, AD, of a
drug as shown previously.[9] Table 2 summarizes As, assumed to
correspond to AD, the corresponding Kaw, and CMCD.
Figure 2C shows the free energy of self association, DGmic
(^) [Eq. (12)] in comparison to the free energy of partitioning
into the air±water interface, DGaw (&) [Equation (10)] for triflu-
promazine. The difference between DGaw and DGmic was de-
fined as the amphiphilicity, DDGam, of the compound:
[9]
Table 1. Analogues investigated.
Series Name R1 R2
A promazine H
chlorpromazine Cl
triflupromazine CF3
B perazine H
chlorperazine Cl
trifluoperazine CF3
C chlorperphenazine Cl
fluphenazine CF3
cis-flupenthixol CF3
trans-flupenthixol CF3
Series Name R1a R1b R2
D 6-(trifluoromethyl)benzopyranol CF3 H
7-(trifluoromethyl)benzopyranol H CF3 Figure 1. p/logC plots of promazine (series A) and perazine (series B) ana-
logues. Solid symbols indicate the quasilinear part of the Gibbs adsorption
isotherm. The corresponding slope is shown as a solid line. A) Promazine
(squares), chlorpromazine (circles), and triflupromazine (triangles). The p/logC
plots of promazine and triflupromazine consist of two independent measure-
ments. B) Perazine (lozenges), chlorperazine (pentagons), and trifluoperazine
(triangles). Measurements were performed at pH 8.0 (50 mm Tris/HCl containing
114 mm NaCl).
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DGawDGmic ¼ DDGam ð19Þ
As seen in Figure 2C, the amphiphilicity of triflupromazine is
largest at low pH.
Figure 3A displays the p/logC plots of 6- and 7-trifluoro-
methyl benzopyranol at pH 8.0. The two compounds differ dis-
tinctly with respect to the slopes of the quasilinear part of the
Gibbs adsorption isotherms and thus with respect to the cross-
sectional areas, AD, as seen in Table 2. Moreover, they differ
with respect to their amphiphilicity, 7-trifluoromethyl benzo-
pyranol (DDGam=7.73 kJmol1) is more amphiphilic than 6-
trifluoromethyl benzopyranol (DDGam=6.94 kJmol1). This
can be rationalized by calculating the sum of the vectors of
amphiphilicity. These were calculated for a set of multiple con-
formers from which the conformer with the highest amphiphil-
ic moment was selected.[21] Figure 3B displays the calculated
vectors of amphiphilicity,[21] which are DDGam=7.41 and
5.54 kJmol1, respectively; this is in reasonable agreement
with the measured amphiphilicities.[9] Here the amphiphilicities
are given for T=24 8C.
Lipid±water partition coefficient
Knowledge of Kaw and AD allows calculation of Klw for mem-
branes with a specific pM according to Equation (7). For the
present calculations we used pM=27 and 35 mNm
1, for SUVs
formed from POPC at 37 8C[5,10] or cholesterol-containing natu-
ral membranes, respectively.[6] Calculated lipid±water partition
coefficients are summarized in Table 2. For comparison, Klw's of
the phenothiazine analogues were also measured by means of
ITC. As an example, the titration of a fluphenazine solution by
SUVs formed from POPC is displayed in Figure 4A. The titration
of all phenothiazines gave rise to exothermic titration patterns.
With increasing lipid concentration, the free-drug concentra-
tion in the measuring cell and the heat flow decreased con-
comitantly. Figure 4B shows the heats of reaction, hi, obtained
by integration of the heat-flow peaks. The molar binding en-
thalpy DH0exp was determined directly from the cumulative heat
release.[10,17]
Permeability coefficients
The permeability coefficients, P, were calculated according to
Equation (17) for membranes with lateral packing densities of
p=27 and 35 mNm1 by using the pKa values of the drugs at
37 8C.[23] The data are summarized in Table 2.
Discussion
In the following, we discuss the effects of drug halogenation
on a drug's ability to permeate membranes. We place special
emphasis on analyzing the difference between replacing a hy-
drogen residue by a chlorine or a trifluoromethyl residue in
phenothiazine analogues (Table 1 series A±C). Moreover, we
analyze the influence of the position of a CF3 residue in ben-
zopyranol analogues (series D). To this purpose, we character-
ized twelve different drugs by means of SAMs. Measurements
of the surface pressure as a function of concentration (Gibbs
adsorption isotherms) yield i) the cross-sectional area, AD, of
the molecule when it is oriented in the amphiphilic gradient of
the air±water interface or the lipid±water interface, ii) Kaw,
which mainly reflects the hydrophobicity of the compound,
and iii) CMCD, which reflects the tendency of the compound to
Figure 2. Surface-activity measurements of triflupromazine as a function of pH.
A) p/logC plots at pH 4.5 (stars), pH 6.0 (triangles), pH 7.4 (circles), pH 8.0
(pentagons), pH 8.5 (hexagons), and pH 9.0 (squares). B) Cross-sectional area
(squares), and critical micelle concentration (triangles). C) Free energy of parti-
tioning into the air±water interface, DGaw (squares), and free energy of micelle
formation, DGmic (diamonds). The solid and dashed lines in B and C are sigmoi-
dal fits to the data.
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self associate in solution. Klw and P are calculated on the basis
of the data obtained from SAMs as outlined previously.[10,14]
The effect of halogenation is discussed on three levels : the
first level deals with drugs in solution and at the air±water in-
terface, which are characterized by the ionization constant,
pKa, the critical micelle concentration, and the air±water parti-
tion coefficient. The second level deals with the thermodynam-
ics of interfacial membrane partitioning, and the third level
with the kinetics of membrane permeation.
Drugs in solution and at the air±water interface
Ionization constants of the drugs in aqueous solution (standard
values) are given in Table 2. For the promazine analogues, the
pKa values decrease with increasing electronegativity of residue
R1 in the order H>Cl>CF3; this is in agreement with previous
observations.[22] For the perazine and perphenazine analogues
this effect is less pronounced.
Apparent ionization constants depend on many factors such
as temperature,[23] the dielectric constant, e, of the environ-
ment, and the association state of the drug.[24] The pKa values
of a drug at the air±water interface and in a drug micelle differ
from that of a drug in solution since neighboring charged
groups influence each other.[24] The ionization constant of a
drug at the air±water interface under conditions in which only
half of the air±water interface is occupied (G=G¥/2) is ob-
tained from the pH dependence of DGaw (Figure 2C). The ioni-
zation constant under conditions in which the air±water inter-
face is fully occupied (G=G¥) is obtained from the pH depen-
dence of surface area requirement, AS (Figure 2B). For triflupro-
mazine the respective values are pKa (G¥/2)=8.5 and pKa (G¥)=6.7.
From these two values it is possible to estimate the pKa value
of the monomer in solution as outlined previously.[24] An inter-
mediate value is obtained for the pH dependence of critical
micelle concentration, CMCD (Figure 2B and C) (pKa (CMC)=8.2).
This is consistent with small, highly curved vesicles for which
the splay of the head groups is larger than in a tightly packed
Figure 3. A) Gibbs adsorption isotherms (p/logC plots) of 6-trifluoromethyl ben-
zopyranol (squares) and 7-trifluoromethyl benzopyranol (circles) measured at
pH 8.0 (50 mm Tris/HCl containing 114 mm NaCl). B) Calculation of the vector
of amphiphilicity for 6- (right) and 7-trifluoromethyl benzopyranol (left) with
the program CAFCA.[21] The vector addition starts from the most hydrophilic
residue (the oxygen atom of the pyridazin-3-one moiety was taken as an initial
point) and points towards the most hydrophobic region of the molecule. The
direction of the vector indicates the most probable orientation of the molecule
in the amphiphilic gradient of the air±water interface. Conformer selection was
performed according to the procedure described previously.[21] Briefly, vectors of
amphiphilicity were calculated for a set of multiple conformers from which the
conformer with the highest amphiphilic moment was selected.
Figure 4. Isothermal titration calorimetry of fluphenazine. The fluphenazine sol-
ution (101.88 mm) was contained in the measuring cell of a calorimeter and
SUVs (10.1 mm) were injected (4 mL at each injection). Measurements were per-
formed in buffer solution (50 mm Tris, 114 mm NaCl) at pH 7.4 and a tempera-
ture of 37 8C. Top: Titration curve. Bottom: Heats of reaction, hi. The solid line is
the theoretical binding isotherm calculated according to the Gouy±Chapman
theory.
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planar drug layer at the air±water interface but smaller than
that at a half-occupied air±water interface (G¥/2).
Shifts of ionization constants to lower values are also ob-
served if drugs insert into the lipid±water interface.
The cross-sectional areas of the phenothiazine analogues in
series A±C vary between AD=40 and 58 ä
2. Only the flupen-
thixols exhibit slightly larger
cross-sectional areas; this might
be due to the rigidity of the
double bond in residue R2. Re-
placement of a H atom by a Cl
atom does not, on average, lead
to a significant increase in AD, in
contrast to a replacement by a
CF3 group, which leads to a
measurable increase. The AD
ratios for the different analogues
vary between r=1.0 and r=1.4
and are given in Table 3.
Measurement of the two ana-
logues of series D, 6- and 7-tri-
fluoromethyl benzopyranol,
revealed an AD ratio r=1.6
(Table 3). The change in the
cross-sectional area upon changing the position of the CF3
group is thus due to a change in the orientation of the vector
of amphiphilicity drawn from the most hydrophilic residue R2,
immersed in aqueous solution (e~80), to the most distant hy-
drophobic residue R1, reaching into the air (e~1), as illustrated
in Figure 3B.[21] Since the dielectric constant of air is similar to
that of lipids (e~2), it can be assumed that the molecular ori-
entation at the two interfaces is identical.
The air±water partition coefficient increases for compounds
in series A±C in the order: H<Cl<CF3 and reflects the increase
in hydrophobicity of residues R1. Replacement of H by Cl or
CF3 leads, on average, to an increase in Kaw of a factor of ap-
proximately r=2 or r=14, respectively, or to an increase in the
negative free energy of partitioning into the air±water inter-
face of 1.5 or 6.6 kJmol1, respectively. The effect of hal-
ogenation is somewhat more pronounced in perazine than in
promazine analogues. This may be due to the fact that the
effect of charge still dominates in the latter analogues. The
air±water partition coefficients of the two benzopyranol ana-
logues in series D are practically identical.
The free energy of self-association or micelle formation, DGmic,
is significantly enhanced by the replacement of a H by a Cl or
a CF3 residue. Surprisingly, at first, the difference between the
two halogen residues is small.
Table 2. Data obtained from surface-activity measurements and isothermal titration calorimetry.
Series Compound MW
(base)
pKa pKa
378C
AD
[a] Kaw CMCD DDGam Klwcalc
[mm1]
Klw ITC D î10
8 P [cms1] P [cms1]
[gmol1] [ä2] [mm1] [mm] [kJmol1] (27 mNm1) [mm1] [cm2s1] (27 mNm1) (35 mNm1)
A Promazine 284.42 9.42[27] 9.1 42.0 15 2.86 9.69 1.20 1.55[10] 5.38 11 5
Chlorpromazine 318.86 9.2[28] 8.9 40.0 20 0.22 3.78 1.61 2.34[10] 6.36 26 12
Triflupromazine 352.42 9.07[29] 8.7 50.0 129 0.16 7.88 5.52 5.10[10] 5.34 102 40
B Perazine 339.5 8.01[30] 7.7 42.0 30 0.83 8.32 2.14 2.20 5.53 184 84
Chlorperazine 373.94 8.1[31] 7.8 41.1 61 0.21 6.60 4.53 4.53 6.28 367 170
Trifluoperazine 407.5 8.08[32] 7.8 57.4 609 0.08 10.11 15.71 17.60[10] 5.29 1088 368
C Chlorperphenazine 403.97 7.9[29] 7.6 50.3 105 0.11 6.35 4.42 4.50 5.67 377 147
Fluphenazine 437.52 8.1[31] 7.8 55.4 520 0.10 10.22 15.78 14.00 5.41 1038 390
cis-flupenthixol 434.52 7.8[33] 7.5 63.0 1081 0.05 10.47 20.31 20.00[10] 5.07 1633 503
trans-flupenthixol 434.52 7.8[33] 7.5 66.0 4504 0.032 12.8 70.02 24.00 4.95 5503 1602
D 6-trifluoromethyl ben-
zopyranol
370.11 2.61 2.4 85.4 138 0.12 7.24 0.63 4.35 58 12
7-trifluoromethyl ben-
zopyranol
370.11 2.61 2.4 53.9 121 0.19 8.07 4.04 5.48 465 1670
[a] For the highly charged molecules promazine and triflupromazine the minimum area, AD, was extrapolated to pH 8.5. Data given represent average values from
several measurements. Maximum error range is5%. AD is the cross-sectional area, CMCD, the critical micelle concentration, and Kaw, the air±water partition coeffi-
cient [Equation (5)] . Klw is the lipid±water partition coefficient which was either calculated according to Equation (7), Klwcalc, or measured by means of isothermal ti-
tration calorimetry, Klw ITC. D is the diffusion coefficient [Equation (14)] , and P, the permeability coefficient [Equation (17)] . SAM and ITC were performed at 241 8C
and 37 8C, respectively. For simplicity all DG values were calculated at 37 8C.
Table 3. Ratios, r, of cross-sectional areas, air±water partition coefficients, critical micelle concentrations, lipid±
water partition coefficients (calculated from SAMs), and permeability coefficients for analogues with and without
halogen residues.
Residue R1 Series rAD rKaw rKlw rP rP
(27 mNm1) (35 mNm1)
Cl/H A 1 1.34 1.3 2.40 2.50
B 1 2.0 2.13 1.99 2.02
CF3/H A 1.25 8.62 4.48 9.56 8.24
B 1.38 20.13 7.08 5.91 4.38
CF3/Cl A 1.25 6.45 2.85 3.98 3.30
B 1.4 10.04 2.53 2.97 2.17
C 1.1 4.93 3.25 2.92 2.65
CF3 trans/cis C 1.05 4.17 3.45 3.37 3.19
6-CF3/7-CF3 D 1.59 1.15 0.45 0.12 0.07
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The amphiphilicity, DDGam, which is the difference between
the free energy of partitioning into the air±water interface,
DGaw, and the free energy of micelle formation, DGmic,
[9] in-
creases with increasing charge of the compound at constant
hydrophobicity or with increasing hydrophobicity at constant
charge (Table 4). For the drugs under study DDGam increases in
the order: Cl<H<CF3. The comparatively low critical micelle
concentrations and amphiphilicities of the chlorinated ana-
logues in series A, B and C is most probably due to the rela-
tively strong reduction in pKa values combined with a negligi-
bly small increase in hydrophobicity upon chlorination, and ex-
plains the comparatively high tendency of these analogues to
aggregate in solution.
Interfacial membrane partitioning
The lipid±water partition coefficients were calculated according
to Equation (7) by using the Kaw and AD of the compound
measured under conditions of minimal electrostatic repulsion
for membranes with a packing density, pM=27 and 35 mNm
1,
corresponding to that of small unilamellar vesicles formed
from POPC at physiological temperature and that of cholester-
ol-containing membranes, respectively. As seen in Table 2, the
lipid±water partition coefficients calculated for a membrane
packing density of pM=27 mNm
1 are in excellent agreement
with those measured for small unilamellar POPC vesicles by
means of ITC.[10] The lipid±water partition coefficients for the
promazine analogues have also been measured by means of
spectrophotometric techniques and are also in good agree-
ment (if transformed to the same units).[26]
The lipid±water partition coefficients of the compounds in
series A±C increase in the order of residue R1: H>Cl>CF3. The
exchange of a H to Cl or CF3 leads on average to an increase
in the negative free energy of membrane partitioning of
DGlw=1.5 or 4.5 kJmol1, respectively. The dominant factor
is the increase in hydrophobicity. For compounds in series D
that exhibit similar hydrophobicities, the lipid±water partition
coefficients are dominated by the different cross-sectional
areas, AD (Table 3).
Membrane permeation
On a third level, the kinetics of passive diffusion through the
lipid membrane are calculated on the basis of simple Stokesian
diffusion by using the parameters obtained from surface-activity
measurements and taking into account the pKa value of the
drugs. For a replacement of H by a Cl or a CF3 residue, the per-
meability coefficient, P, increases on average by a factor of ap-
proximately r=2 or r=9, respectively. The increase is again
somewhat larger for promazine than for perazine analogues.
Despite the differences between promazines and perazines,
the increase in P upon replacement of Cl by CF3 is rather con-
stant for all three types of analogues (promazines, perazines,
and perphenazines) and amounts to about r=3.5 (Table 3). It
is interesting to note that the two isomers, cis- and trans-
flupenthixol, differ distinctly in their Kaw and Klw as well as in P.
Due to the relatively small cross-sectional areas of the above
analogues, the packing density dependence of P is relatively
small for the phenothiazine analogues. This is different for 7-
and 6-trifluoromethyl benzopyranol, for which the ratios in
permeability coefficients are r=0.12 at the lower packing den-
sity investigated and only r=0.07 at the higher.
Conclusion
A characterization of drugs by SAMs allows a detailed analysis
of the effect of halogenation. The air±water and the lipid±
water partition coefficients of promazine, perazine, and per-
phenazine analogues increase in the order, R1: H<Cl<CF3 due
to the increase in hydrophobicity, despite a small increase in
cross-sectional area. The permeability coefficient increases in
the same order due to the increase in the lipid±water partition
coefficient and the decrease in the pKa values. For the small
phenothiazine analogues, the packing density dependence of
the permeability coefficient is rather small. The amphiphilicity
of the halogenated analogues increases in the order R1: Cl<
H<CH3; this explains the higher tendency of the chlorinated
analogues to aggregate. As shown for benzopyranols, the posi-
tion of a trifluoromethyl residue can change the amphiphilicity,
the cross-sectional area, and, as a consequence, the permeabil-
ity coefficient of a molecule.
Biological situation
The pH close to the surface of a living cell is generally acidic
despite the fact that the extracellular lipid leaflet is electrically
neutral. If one takes into account an acidic pH and the corre-
spondingly low air±water partition coefficient (cf. Figure 2A)
permeability coefficients can be orders of magnitude lower
than those given in Table 2.
Even compounds with low permeability coefficients can in
principle cross a membrane, provided the time to reach equilib-
rium is given. In natural environments however, equilibration
time is limited by metabolic processes–for example, the
action of cytochrome P450 and ATP-driven efflux transporters,
such as P-glycoprotein, which bind molecules within the lipid
membrane and export them out of the cell. If the export rate
Table 4. Difference in free energies of air±water partitioning, micelle forma-
tion or self-association, and membrane partitioning of analogues with and
without halogen residues calculated from SAMs.
Residue R1 Series DGaw DGmic DGlw
[kJmol1] [kJmol1] [kJmol1]
Cl/H A 0.75 6.66 0.75
B 1.79 3.51 1.94
CF3/H A 5.55 7.36 3.93
B 7.74 5.95 5.14
CF3/Cl A 4.81 0.70 3.18
B 5.95 2.44 3.20
C 4.11 0.24 3.28
CF3 trans/cis C 3.68 1.35 3.19
7-CF3/6-CF3 D 0.35 1.18 4.79
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of a drug is faster than the rate of passive diffusion into the
cell (influx), the drug will barely reach the cytosol. However, if
passive influx is distinctly faster than active efflux, the drug will
reach the cytosol even if it is a substrate for an efflux trans-
porter.[14] The simple permeability predictions on the basis of
SAMs provide an estimate of rates of passive influx of drugs
and allow for comparison with the rates of efflux processes.[14]
The present approach opens new possibilities for a detailed
understanding of membrane permeation in biological systems.
Keywords: chlorine ¥ fluorine ¥ ionization constants ¥ kinetics ¥
thermodynamics
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Enhancement of drug 
absorption by noncharged 
detergents through membrane 
and P-glycoprotein binding
Anna Seelig† & Grégori Gerebtzoff
†Biozentrum, Biophysical Chemistry, University of Basel, Klingelbergstrasse 70, CH-4057 Basel, 
Switzerland
Noncharged detergents are used as excipients in drug formulations. Until
recently, they were considered as inert compounds, enhancing drug absorp-
tion essentially by improving drug solubility. However, many detergents
insert into lipid membranes, although to different extents, and change the
lateral packing density of membranes at high concentrations. Moreover, they
bind to the efflux transporter P-glycoprotein (P-gp) and most likely to related
transporters and metabolising enzymes with overlapping substrate specifici-
ties. If their affinity to P-gp is higher than that of the coadministered drug
they act as modulators or inhibitors of P-gp and enhance drug absorption.
Inhibition of P-gp and related proteins can, however, cause severe side
effects. This paper first reviews the membrane binding propensity of differ-
ent noncharged detergents (including poloxamers) and discusses their ability
to bind to P-gp. Second, literature data on drug uptake enhancement by
noncharged detergents, obtained in vivo and in vitro, are analysed at the
molecular level. The present analysis provides the tools for an approximate
and simple prior estimate of the membrane and P-gp binding ability of
noncharged detergents based on a modular binding approach.
Keywords: active efflux, detergents, membrane packing density, modulators, 
passive influx, P-glycoprotein, solubilisers, substrates
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1.  Introduction
The first observation of the chemosensitising effect of detergents dates probably
back to 1972 when Riehm and Biedler [1] noted that Tween 80 enhanced the effect
of actinomycin D and daunomycin in drug-resistant cells. In the early 1990s several
groups [2-9] reported that nonionic detergents, commonly used as excipients in drug
formulations, modulated the activity of P-glycoprotein (P-gp, multi-drug resistance
protein MDR1, ABCB1), an ATP-binding cassette (ABC) efflux transporter of
broad substrate specificity (for review see [10,11]). P-gp is highly expressed in different
tissues with protective functions such as the blood–brain barrier (BBB) [12], liver,
pancreas, kidney, colon and the intestinal barrier (IB) [13]. This tissue distribution
indicates that P-gp prevents the accumulation of xenobiotics and metabolites in the
brain and plays a significant role in their excretion into urine, bile and the intestinal
lumen (for review see [14]). High levels of P-gp are also observed in certain cancer
cells. In a given tissue the expression level of efflux transporters can vary depending
on genetic predisposition, age, diet and medication [15] (and references therein). 
P-gp is the best-investigated representative of a large family of 49 ABC transport-
ers identified so far [16], which all play a significant role in ADME [17]. Many ABC
transporters show overlapping substrate specificities. A detailed analysis has been
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Figure 1. Cartoon showing the apical location of P-glycoprotein in the intestinal barrier, where it pumps its substrates into
the intestinal lumen removing them from the body, or in the blood–brain barrier, where it pumps its substrates into the
blood, removing them from the brain. Substrate binding to P-glycoprotein takes place in the cytosolic membrane leaflet. Substrate
affinity to the transporter from the aqueous phase (expressed as free energy of transporter–water binding, ∆G0tw; arrow 3) is the sum of
the substrate affinity to the lipid membrane (expressed as free energy of lipid–water partitioning, ∆G0lw; arrow 1) and the drug affinity to
the transporter in the lipid membrane (expressed as free energy of transporter–lipid binding, ∆G0tl; arrow 2).
Apical
Basolateral
1
2
1
3
3
performed for P-gp and the multi-drug resistance-associated
protein, MRP1 [18], but much remains to be clarified in this
field. P-gp transports cationic or electrically neutral com-
pounds, whereas MRP1 transports electrically neutral or neg-
atively charged compounds. Substrates common to both
transporters are electrically neutral compounds that carry spe-
cific hydrogen bond acceptor patterns. As shown in this
review, many neutral detergents have such structural elements
and, therefore, react most likely with both transporters and
possibly even with other ABC transporters. Overlapping sub-
strate specificity has also been observed for P-gp and the
metabolising enzyme CYP [19].
P-gp binds its substrates in the cytosolic lipid leaflet of the
plasma membrane and flips them to the outer leaflet or
exports them to the extracellular medium at the expense of
ATP hydrolysis [20]. To reach the P-gp binding region
exogenous substrates first partition into the membrane and
then cross the lipid bilayer, whereas endogenous substrates
directly insert into the cytosolic membrane leaflet as illus-
trated in Figure 1. Substrate binding to P-gp from the aqueous
phase can be divided in two consecutive steps: a lipid–water
partitioning step and a transporter–lipid binding step. The
free energy of transporter–water binding, ∆G0tw (reflecting the
binding affinity of the substrate to the transporter from the
aqueous phase) can, therefore, be expressed as sum of the free
energy of lipid–water partitioning, ∆G0lw (reflecting the bind-
ing affinity of the substrate for the lipid membrane), and the
free energy of transporter–lipid binding, ∆G0tl (reflecting the
affinity of the substrate to the transporter after insertion into
the lipid membrane) [21].
P-gp inhibition by detergents has been widely discussed,
and was assumed to result either from a direct detergent–P-gp
interaction [2,4,7,22] or from membrane fluidisation leading to
an indirect protein destabilisation [5,6,23]. It should be noted
that not only detergents (see Section 3.2), but also many drugs
that are substrates for P-gp, such as verapamil [24] or dibucaine
[21,25], disorder membranes. To fully understand the effect of
membrane fluidisation on P-gp, further experiments are
required. Rege et al. have shown that the detergents Tween 80
and Cremophor EL, which fluidise lipid bilayers, as well as
Vitamin E D-α-tocopheryl poly(ethylene glycol) 1000 succi-
nate (TPGS), which rigidifies lipid bilayers, inhibit multiple
efflux transporters, and concluded that membrane fluidisation
may not be a general mechanism to reduce transporter activity
[26]. Recently, it was observed that detergents exhibiting the
characteristics of P-gp substrates or modulators [15] activate
P-gp in a concentration-dependent manner in contrast to
detergents such as CHAPS, which are nonsubstrates [27]. This
further supports a direct interaction with P-gp.
Numerous in vitro and in vivo investigations on the enhance-
ment of drug absorption by noncharged detergents have been
published (see references cited in Table 3). The experiments
were performed with different combinations of drugs and
detergents either in vivo or in vitro using different cellular sys-
tems. At first sight, the resulting data seem complex; however, a
detailed analysis shows a consistent and rational picture of
detergent–membrane and detergent–P-gp interactions.
This review analyses the available data on absorption
enhancement of drugs by noncharged detergents to unmask
the relevant molecular processes. For this purpose: i) the non-
charged detergents, comprising membrane-anchoring deter-
gents and poloxamers; ii) the membranes used as model
systems; and iii) the transporter P-gp are characterised. This
review also addresses: i) whether the selected detergents insert
into the lipid membrane and ii) whether they subsequently
bind to P-gp. The analysis reveals that most of the selected
membrane-anchoring detergents (Table 1) are modulators of
P-gp and are able to enhance the absorption of the coadminis-
tered drug, provided their affinity to P-gp is higher than that
of the coadministered drug. Under these conditions the deter-
gents inhibit (or modulate) the P-gp efflux pump, thus allow-
ing the drugs to cross the membrane by passive diffusion.
Specific poloxamers, which do not insert into biological
membranes, may enhance absorption by mere solubilisation
Seelig & Gerebtzoff
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Table 1. Noncharged detergents as potential P-glycoprotein substrates
No. Structure Name
1
2
3
4
5
6
7
8
9
POPC 
(26853-31-6)
1,2-Dicaprylin 
(7384-98-7)
Tricaprylin Miglyol 808 
(538-23-8)
PEG oleate 
(9004-96-0)
Cremophor EL 
(9004-97-1) 
(9006-38-6)
Solutol HS-15 
(61909-81-7)
Vitamin E 
(59-02-9)
Vitamin E acetate 
(7695-91-2)
Vitamin E TPGS 
(9002-96-4)
Ellipses indicate type I units, grey background indicates nonpolar and white background polar environment, respectively.
POPC: 1-Palmitoyl-2-oleoyl-sn-3-glycerophosphocholine; TPGS: D-α-Tocopheryl poly(ethylene glycol) 1000 succinate.
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10
11
12
13
14
15
16
17
18
Tween 80 
(9005-65-6)
Octyl-β-D-glucoside 
(29836-26-8)
(26027-38-3)
n = 1: Triton X-100 
(9002-93-1) 
n = 2: Nonidet P-40 
(9036-19-5)
n = 1: 9002-92-0 
n = 3: 2315-62-0 
n = 8: 35056-97-4
Pentaethylene glycol 
(25322-68-3)
Polyoxyethylene glycerol ether 
(31694-55-0)
Pluronic L61
CRL-1605 (a = 40, b = 20)
Table 1. Noncharged detergents as potential P-glycoprotein substrates (continued)
No. Structure Name
Ellipses indicate type I units, grey background indicates nonpolar and white background polar environment, respectively.
POPC: 1-Palmitoyl-2-oleoyl-sn-3-glycerophosphocholine; TPGS: D-α-Tocopheryl poly(ethylene glycol) 1000 succinate.
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of the compounds or, in combination with highly cationic
drugs, by endocytosis. The analysis further shows that the
severe side effects that have been observed with several deter-
gents at high concentrations can also be traced back to a direct
interaction of detergents with P-gp, related ABC transporters
and CYP.
2.  Noncharged detergents
Table 1 displays the most abundant lipid in mammalian cell
membranes, 1-palmitoyl-2-oleoyl-sn-3-glycerophospho-
choline (POPC; compound 1), together with some of the
most frequently used noncharged detergents. The deter-
gents are divided in two sets: a first one, comprising com-
pounds 2 – 14; and a second one, comprising compounds
15 – 18. The compounds in the first set exhibit a hydropho-
bic tail, which is responsible for membrane anchoring
(shown on grey background), and a hydrophilic headgroup
(shown on white background). The latter generally consist
either of ester (lactone) or ether groups or combinations of
the two. The numerous oxygen atoms can act as hydrogen
bond acceptors and are probably responsible for hydrogen
bonding interactions with P-gp, as in Section 4.
The second set of compounds comprises polyethylene gly-
cols (PEGs) and polyoxyethylene–polyoxypropylene block
copolymers, the so-called poloxamers or Pluronics®, which
lack a typical membrane anchor. Poloxamers are formed from
alternating sequences of polyoxyethylene (EO)a and polyoxy-
propylene (PO)b, in which the length of the different blocks
(indicated by the subscripts a and b) can vary considerably.
They usually consist of a central hydrophobic polyoxy-
propylene (PO)a block and two flanking hydrophilic polyoxy-
ethylene (EO)b blocks. Typical examples are the Pluronics
L61 (EO2-PO30-EO2), L81 (EO3-PO43-EO3), P85
(EO26-PO40-EO26) (or poloxamer 235) and F68
(EO76-PO30-EO76) (or poloxamer 188). Poloxamers with a
hydrophilic centre and hydrophobic flanking regions such as
CRL-1605 (PO40-EO20-PO40) are also available (for further
examples of Pluronics see [28]).
3.  The biological membranes and membrane 
model systems
Lipid molecules, when brought into contact with water,
spontaneously organise themselves into a bilayer leaflet, with
the polar lipid headgroups remaining in the aqueous environ-
ment and the fatty acid tails forming the inner hydrophobic
core. The fluid (liquid crystalline) bilayer is the main organi-
sational element in biological membranes and behaves like
optically uniaxial crystals with the optical axis perpendicular
to the surface of the membrane. The anisotropic character of
membranes is not reflected by isotropic organic solvents such
as octanol, which are often used as membrane model systems. 
Using solid-state NMR techniques a quantitative analysis
of the molecular ordering and dynamics of a lipid bilayer is
possible with a segment-to-segment resolution. Well-defined
conformations are observed for the glycerol backbone and,
to some extent, also for the polar headgroups. The packing
of the fatty acyl chains can be described in terms of statis-
tical order profiles. For a given membrane the average order
of the fatty acyl chains is comparatively high close to the
headgroup region and decreases towards the centre of the
membrane. The shape of the order profiles are similar for
different membranes; however, the absolute values differ and
depend on the lipid composition. An increase in membrane
order is observed on insertion of cholesterol or replacement
of phosphatidylcholine headgroups by the smaller phos-
phatidylethanolamine headgroups. A disordering is observed
on incorporation of double bonds into the fatty acyl chains
or an increase in temperature. However, the incorporation of
transmembrane proteins barely influences the order profiles
of lipid bilayers  [29,30].
A lipid monolayer exhibits the same anisotropic organisa-
tion as a lipid bilayer, provided the lipids are compressed to
the same lateral packing density. The monolayer–bilayer
equivalence pressure, reflecting the lateral packing density of a
particular lipid bilayer, πM, was assessed for several biological
membranes and membrane model systems (see Table 2). The
highest lateral packing densities were observed for mixed
bilayers containing cholesterol and high levels of
Escherichia coli lipids, which are rich in phosphatidyl-
ethanolamines (πM = 40.5 – 46.5 mN/m at 37°C). Plasma
membranes of mammalian cell lines, such as Chinese hamster
ovary cells, CR1R12, murine embryo fibroblasts,
NIH-MDR1-G185, and porcine kidney cells, LLC-MDR1,
cover an intermediate range of lateral packing densities, πM =
30 – 35 mN/m at 37°C [21]. Because MDR1 transfection
seems not to alter the lipid composition [31], it can be assumed
that the corresponding wild-type cells (NIH3T3 and LLC)
exhibit similar lateral packing densities.
For the human BBB, the lateral packing density was esti-
mated as πM ≈ 35 mN/m. Using Equation 1 (see Section 1)
and taking into account the limiting molecular cross-sectional
area, AD = 80 Å2 for the BBB [32] and AD = 100 Å2 for the IB
[33], the lateral packing density of the human IB was
calculated as πM ≈ 28 mN/m.
The lateral packing density of planar lipid membranes
formed from POPC was determined as πM = 32 ± 1 mN/m at
ambient temperature [34], and that of large (100 nm), and
small (30 nm), unilamellar vesicles formed from POPC at
37°C was determined as πM = 28 ± 1 mN/m and πM = 25 ±
1 mN/m, respectively (Blatter and Seelig, unpublished
results). The decrease in packing density observed with
increasing vesicle curvature is due to the increasing splay of
the lipid headgroups in the outer membrane leaflet. The lat-
eral packing density of black lipid membranes depends on the
content of short chain alkanes and is generally significantly
lower than that of pure lipid bilayers (πM < 25 mN/m).
In summary, biological membranes are highly organised,
anisotropic systems exhibiting different lateral packing densities
Enhancement of drug absorption by noncharged detergents through membrane and P-glycoprotein binding
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of the lipid constituents. The lateral packing densities of bio-
logical membranes are often higher than those of the commonly
used membrane model systems. Despite their anisotropic organ-
isation biological membranes are fluid enough to allow consider-
able translational, rotational and flexing movements of the
constituent lipid and protein molecules.
3.1  Determination of lipid–water 
partition coefficients
To illustrate the influence of the lateral membrane packing
density for membrane partitioning, a method is discussed
based on surface activity measurements. Measurements of
the surface pressure, π, as a function of concentration
(Gibbs adsorption isotherm) allows to quantitatively meas-
ure the tendency of a drug to move to the air–water inter-
face. Because air has a similar dielectric constant as the
hydrocarbon region of the lipid membrane, the air–water
interface provides an ideal model for drug orientation at the
lipid–water interface. The analysis of the Gibbs adsorption
isotherm yields three characteristic parameters: i) the
air–water partition coefficient, Kaw; ii) the surface area of the
molecule at the air–water interface, AD; and iii) the critical
micelle concentration, CMC.
Whereas partitioning into the air–water interface at low
concentrations is essentially determined by the
amphiphilicity of the molecule, penetration of a drug
between the hydrocarbon chains in a lipid bilayer requires
additional energy, which is small for small molecules, but
can become prohibitively high for molecules with large
cross sections. To form a hole in a monolayer or bilayer, a
penetrating substance with a cross-sectional area, AD, has to
perform work, ∆W, against the lateral packing density, πM,
of the lipids [35]:
The lipid–water partition coefficient, Klw, is thus given by:
where K0 is a proportionality constant. Because the surface
pressure of the drug monolayer at the concentration 1/Kaw is
negligibly small, it was assumed that K0 can be replaced by
Kaw (note: approximately constant lateral packing density as
assumed in Equation 1 is valid for low detergent concentra-
tions only). This assumption was confirmed by measuring
both Klw and Kaw for a series of compounds [32,36]. With the
parameters, Kaw and AD, obtained from one single measure-
ment of the Gibbs adsorption isotherm, the lipid–water parti-
tion coefficients, Klw, for membranes of different lateral
packing densities, πM, can be calculated.
The influence of the membrane packing density, πM, on
the lipid–water partition coefficient, Klw, is illustrated in the
following examples. Decreasing the packing density from πM≈ 35 mN/m (BBB) to πM ≈ 28 mN/m (IB) for a compound
with a cross-sectional area, AD = 100 Å2 (AD = 50 Å2), leads to
an increase in the lipid–water partition coefficient, Klw, by a
Table 2. The packing density of biological membranes and lipid bilayers.
Lipid bilayer membrane Temperature T
[°C]
Packing density πM
[mN/m]
Ref.
Bilayers containing Escherichia coli lipids 37  46 ± 5 [21]
CR1R12 (Chinese hamster ovary cells) 37 ~ 35 [21]
Blood–brain barrier 37 ~ 35 [32]
Erythrocyte membrane Ambient  31 – 35 [94]
LLC-MDR1 (porcine kidney cells) 37 ~ 33 [21]
POPC (planar lipid bilayers) Ambient  32 ± 1 [34]
NIH-MDR1-G185 ≈ NIH3T3 
(murine embryo fibroblasts)
37 ~ 30 [21]
DMPC bilayers Ambient ~ 30 [95]
Intestinal barrier 37 ~ 28 [33]
POPC (large unilamellar vesicles) 37  28 ± 1 [96]
POPC (small unilamellar vesicles) 37  25 ± 1
Black lipid membranes/PAMPA Ambient  < 25
DMPC: Dimyristoylphosphatidylcholine; PAMPA: Parallel Artificial Membrane Permeation Assay; POPC: 1-Palmitoyl-2-oleoyl-sn-3-glycerophosphocholine.
∆W ADπM=
(1)
Klw K0 e
πMAD kT⁄⋅= -
(2)
Seelig & Gerebtzoff
Expert Opin. Drug Metab. Toxicol. (2006) 2(5) 739
factor of 5.4 (3.3). Decreasing the cross-sectional area from
AD = 100 Å2 to AD = 50 Å2 for a membrane with a lateral
packing density, πM = 35 mN/m (πM = 28 mN/m), leads to an
increase of the lipid–water partition coefficient by a factor of
∼ 70 (∼ 20).
In contrast to the partitioning into lipid membranes, parti-
tioning into isotropic solvents such as hexane or octanol has
been shown to increase with the molecular volume of the com-
pound [37]. Predicting the lipid–water partition coefficient
without taking into account the different lateral packing densi-
ties of membranes can be misleading for molecules with large
cross-sectional areas. Unfortunately, the air–water partition
coefficient, Kaw, is not available for all detergents shown in
Table 1. The lipid–water partition coefficients, Klw, and the
free energies of lipid–water partitioning, ∆G0lw, given in
Table 3 were, therefore, estimated on the basis of the CMC [38].
A detergent molecule in an aqueous phase containing lipid
vesicles has two possibilities, either to associate with other
monomers or to partition into the lipid membrane. The free
energy of the two processes, that is, the free energy of micelle
formation, ∆G0CMC, and the free energy of lipid–water parti-
tioning, ∆G0lw, are similar. The free energy of lipid–water
partitioning, ∆G0lw, can thus be estimated as follows:
where CW = 55.5 mol/l is the molar concentration of water.
The free energy of lipid–water partitioning, ∆G0lw, derived
from CMCs according to Equation 3 is included in Table 3.
For comparison, the calculated octanol–water partition coeffi-
cient LogP values (KowWin) are also given. For small com-
pounds and ‘soft’ membranes (πM = 25 – 28 mN/m) a
reasonable linear correlation is observed between LogP and
∆G0lw values derived from CMC and the ∆G0lw values
obtained from air–water partition coefficients, Kaw (not
shown). However, for compounds with larger cross-sectional
areas and densely packed membranes, the ∆G0lw values
obtained from air–water partition coefficients, Kaw, are
generally less negative.
3.1.1  Lipid–water partitioning of 
membrane-anchoring detergents
The lipid–water partition coefficients of several detergents
have been measured for POPC vesicles (diameter of 100 nm,
large unilamellar vesicles, πM ≈ 28 mN/m) using isothermal
titration calorimetry. Depending on the nature of the polar
and hydrophobic groups the lipid–water partition coefficients
for POPC vesicles were shown to vary considerably from Klw =
105/M for the oligo(ethylene oxide) alkyl ether, C12 EO3, to
only Klw = 25/M for octylmaltoside [38]. For the present
investigation the lipid–water partition coefficients estimated
on the basis of CMC values are summarised in Table 3.
3.1.2  Lipid–water partitioning of polyethyleneglycols 
and polyoxyethylene–polyoxypropylene block 
copolymers
PEGs exhibit low LogP values and are generally used to keep
compounds in solution or to prevent, rather than enhance,
cell adhesion or membrane partitioning. Poloxamers, which
are closely related, are also rather hydrophilic compounds,
exhibiting low LogP and high CMC values, as seen in Table 3.
Experimentally, membrane insertion of poloxamers was
investigated by modelling the outer leaflet of a lipid membrane
with a lipid monolayer. To study the role of the lateral lipid
packing density for insertion, lipid monolayers were spread on
a buffer surface at a given lateral packing density (or surface
pressure) and the poloxamers were injected underneath the
lipid monolayer. Wu et al. [39] observed insertion of poloxamer
P188 into dipalmitoylphosphatidylcholine (DPPC) or
dipalmitoylphosphatidyglycerol (DPPG) monolayers at very
low surface pressures of π < 5 mN/m. On compression of the
monolayers to surface pressures of π > 35 mN/m poloxamers
were squeezed out. Results for the two phospholipids were
similar, thus indicating that P188 insertion is not influenced
by headgroup electrostatics.
Related experiments were performed by Maskarinec et al. [40].
They injected poloxamer P188 into the subphase of densely
packed DPPC or DPPG monolayers (π = 30 mN/m) and
slowly released the surface pressure until insertion was observed
that occurred at surface pressures of π ≤ 22 mN/m. Both exper-
iments were performed at 30°C. Because the lateral packing
density of a monolayer, equivalent to that of a biologically rele-
vant bilayer, is generally πM ≥ 28 mN/m (Table 2), the lack of
insertion above a lateral packing density of π = 22 mN/m
suggests that poloxamer P188 does not insert into intact bio-
logical membranes. Poloxamer P188 was, however, reported to
selectively adsorb to damaged portions of electroporated
membranes and to promote healing of these membranes [41],
which is consistent with the above observation. In a further
investigation the ‘squeeze-out pressure’ in DPPC monolayers
was determined as π = 25 mN/m for Pluronic F68 (P188) and
π = 29 mN/m for Pluronic P85 [42].
Krylova and Pohl [43] reported insertion of Pluronic L61
(EO2-PO30-EO2) into planar black lipid membranes and large
unilamellar vesicles formed from diphytanoylphosphatidyl-
choline (DPhPC). At high concentrations L61 acted as
mobile carrier and formed ion channels. Black lipid mem-
branes generally exhibit rather low lateral packing densities
(πM < 25 mN/m) and vesicles formed from DPhPC, which
carry branched fatty acyl chains, may also exhibit relatively
low packing densities of πM < 28 mN/m.
Demina et al. [44] investigated the influence of different poly-
mers on the doxorubicin flip-flop rate in sonified egg lecithin
vesicles, which exhibit lipid packing densities of πM ≤ 25 mN/m.
They observed that increasing the length of the hydrophobic
∆G0lw RT CMC Cw⁄( )ln≈
(3)
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propylene oxide (PO) blocks increased the flip-flop activity,
whereas polymers with simple fatty acyl chain anchors such as
the Brij series had no effect. This suggests that flip-flop increases
with the defect induced in the loosely packed outer bilayer leaflet
by partially inserting polymers. Membrane disordering by
poloxamers was also observed in bovine brain microvessel
endothelial cells (BBMECs), whereby the highest effect was
obtained with Pluronic P85 [44,45].
In summary, detergents with hydrophobic anchors insert
into membranes exhibiting a wide range of lipid–water parti-
tion coefficients. However, poloxamers are unlikely to enter
intact living cells by passive diffusion if the lateral packing
density of the plasma membrane is πM ≥ 29 mN/m.
Lipid–water partition coefficients, Klw, of poloxamers are,
therefore, most likely negligibly small for tightly packed
membranes. The IB, with an estimated lateral packing density
of πM ≈ 28 mN/m, may be in a range where certain
poloxamers (e.g., P85) start to penetrate.
3.2  The influence of detergents on the lateral packing 
density of membranes
Short-chain, lipid-anchoring detergents such as oligo(ethylene
oxide) alkyl ether (e.g., C12EO8) [46], n-alkanols [47],
octyl-β-D-glucopyranoside [48] and Triton X-100 [49] generally
reduce the order parameter, S, of the lipid chains, the bending
modulus, κ, or the lipid lateral packing density, πM, at high
concentrations and physiological temperature. PEG-300 led
to a disordering of the membrane headgroup region in both
Caco-2 cells and Madin–Darby canine kidney cells
transfected with the human MDR1 gene (Madin–Darby
Canine Kidney [MDCK]-MDR1 cells). Vitamin E
incorporation (20 mol%) into DPPC membranes lead in
Figure 2. Homology model of P-glycoprotein [53]. It was built using as templates the crystal structure coordinates of the Vibrio
cholera lipid A transporter, MsbA, for the transmembrane domains and those of the Salmonella typhimurium histidine permease, HisP,
and the human TAP1 for the nucleotide-binding domains. Helices are shown in turquoise, and β-sheets in magenta. Hydrogen bond
donor groups of P-glycoprotein in the transmembrane sequences and in the extramembranous regions are indicated in blue and red,
respectively. The membrane is schematically indicated in yellow. POPC (1) and the membrane-anchoring detergents (numbers correspond
to those in Table 1), 1,2-dicaprylin (2), Cremophor EL (5), Vitamin E TPGS (9), Tween 80 (10) and Triton X-100 (13), are inserted in the
cytosolic membrane leaflet from where they can diffuse to the P-glycoprotein-binding region, whereas Pluronic L61 (17) is shown on the
extracellular side of the membrane as membrane insertion is unlikely. The detergents and lipids are represented as sticks, the van der
Waals surface are indicated as shadow and the hydrogen acceptors (oxygens) are in red.
1 1
17
5 2
9
10
13
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contrast to an increase in the acyl chain ordering by 17% [50].
Membrane ordering/disordering effects are generally observed
at much higher concentrations than used to inhibit P-gp [51].
The micromechanical properties of poloxamer/egg
phosphatidylcholine vesicles have been investigated using
atomic force microscopy. To obtain membrane-spanning
poloxamers, the lipid and the poloxamers were cosolubilised in
organic solvent. Water was added only after solvent evapora-
tion. The mixed vesicles were much more rigid than the pure
lipid vesicles and showed a several-fold higher bending modu-
lus, κ  [52]. This is in contrast to the membrane-disordering
effects observed by Demina et al. [44], which are most likely due
to partial insertion of poloxamers in loosely packed bilayers.
In summary, the detergent concentrations required for
absorption enhancement are generally much lower than the
concentrations used for measurements of membrane-order-
ing/disordering effects. It can, therefore, be concluded that
the membrane-ordering/disordering effects of the detergents
required for P-gp inhibition are relatively small.
4.  P-glycoprotein
Figure 2 displays a recent homology model of P-gp by Omote
and Al-Shawi [53]. The model reveals the two nucleotide-bind-
ing domains located at the cytosolic side of the membrane
and the two transmembrane domains each comprising a bun-
dle of six transmembrane helices, which together form one
functional entity. An analysis of the amino acids in the trans-
membrane helices revealed a high density of residues with
hydrogen bond donor side chains arranged in an amphipathic
manner [18]. Because P-gp and related ABC transporters of
hydrophobic compounds bind their substrates not from the
aqueous phase, but from the cytosolic membrane leaflet, the
lipid bilayer plays a synergistic role in substrate binding. It
accumulates the substrates due to their high lipid–water parti-
tion coefficient and, moreover, orients them such that the
polar parts reside in the lipid headgroup region and the more
hydrophobic parts in the hydrophobic core region. This is
illustrated in Figure 2, in which the membrane-anchoring
detergents are shown inserted into the cytosolic side of the
membrane. Pluronic L61, which does not insert into densely
packed membranes, is shown on the extracellular side. Due to
its low dielectric constant, ε, the lipid environment prioritises
electrostatic and hydrogen bonding interactions [21,54].
Screening the three-dimensional structures of a large
number of drugs revealed that the minimal common binding
element consisting of two or three hydrogen bond acceptor
groups in a specific spatial distance (so-called type I or II
units, shown in Figure 3) [54-58]. Because the transmembrane
sequences of P-gp are rich in hydrogen bond donor groups,
they may recognise the hydrogen bond acceptor groups of the
substrates through hydrogen bond formation in the lipid
membrane environment [53,59].
Examples for type I units include ester groups (Figure 3,
column 1, line 2), which are abundant in detergents as seen
in Table 1. It has recently been shown that polyoxyethylene
sequences, which exhibit no preformed type I units, are also
recognised by P-gp [27], thus suggesting that type I units can
be induced by rotation of carbon bonds following binding to
the transporter (Figure 3, column 1, line 3). Most detergents
exhibit preformed, rigid and/or inducible type I units as indi-
cated in Table 1. It is interesting to note that Vitamin E,
which is not an intrinsic P-gp substrate in its natural form, is
transformed to a substrate by pegylation. POPC is not a
Figure 3. Hydrogen bond acceptor patterns that are present in all P-glycoprotein substrates. Patterns formed from two
hydrogen bond acceptor pairs with a spatial separation of 2.5 ± 0.5 Å are called type I units and hydrogen bond acceptor pairs with a
spatial separation of 4.6 ± 0.5 Å are called type II. The latter consists of two or three hydrogen bond acceptor [55,57].
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substrate in its zwitterionic form; however, it may be a
substrate in its protonated, cationic form [60].
In summary, substrates have first to partition into the lipid
membrane in order to bind to P-gp. For the direct interaction
between substrates in the lipid environment and P-gp
hydrogen bonding interactions seem to be important. The
broad substrate specificity of P-gp is compatible with a
modular binding concept, in which the binding modules are
type I and II units. The membrane-mediated binding of
substrates to P-gp thus differs distinctly from the
water-mediated interactions.
4.1  Identifying substrates, modulators and inhibitors 
of P-glycoprotein
P-gp has a basal activity in the absence of externally added
intrinsic substrates, which is either due to uncoupled cycling [61]
or to the transport of endogenous substrates [62,63]. Addition of
intrinsic substrates generally induces a change (increase or
decrease) in the P-gp activity. Figure 4 displays the P-gp activity
as a function of Triton X-100 concentration (Log scale) (Blatter
and Seelig, unpublished results). For comparison, the P-gp
activity as a function of verapamil concentration is also dis-
played. Verapamil is a known P-gp substrate [24]. The activation
profiles show the characteristic bell-shaped dependence
observed previously for different drugs in living
MDR1-transfected cells [21], in plasma membrane vesicles of
transfected cells [64], and in reconstituted proteoliposomes [61].
The same type of activation profiles as shown in Figure 4 was
also obtained for Triton X-100 and other detergents such as
Tween 80 and C12EO8 in living MDR1-transfected cells [27].
The solid lines in Figure 4 are fits to the modified
Michaelis–Menten equation (Equation 4) proposed by
Litman et al. [64]. The model assumes an activating binding
region (occupied at low substrate concentrations) and an
inhibitory binding region (occupied at high substrate
concentrations) [21]:
where Vsw is the rate of phosphate release as a function of
substrate concentration in aqueous solution, Csw, and Vbas is
the basal activity in the absence of drug; V1, is the maximum
transporter activity and V2 is the minimum activity at infinite
substrate concentration. At the concentration Csw = K1,
half-maximum binding at the activating binding region and at
the concentration Csw = K2, half-maximum binding at the
inhibitory binding region, is reached.
The intrinsic drug transport rate is directly proportional
to the turnover number of P-gp. For example, the verapamil
(10 µM)-induced turnover was determined as 4.7 ± 0.8
ATP hydrolysed/P-gp/s [65,66]. Whether the transport cycle
of P-gp requires one [67] or two [68] ATP molecules per drug
transported is still a matter of debate. Intrinsic substrates
are thus defined as compounds that are transported at the
rate of ATP hydrolysis (or half the rate of ATP hydrolysis).
It has been shown that the rate of ATP hydrolysis and con-
comitantly the rate of transport decreases exponentially
with the binding affinity of the drug to the transporter,
whereby the binding affinity to the transporter (in the lipid
membrane) seems to be essentially due to hydrogen bond
formation [15,53].
At high concentrations each substrate can in principle act
as a modulator or inhibitor of P-gp, as seen in Figure 4. How-
ever, toxicity often prohibits the use of high concentrations. If
two different intrinsic substrates are added simultaneously to
P-gp-containing membranes, the substrate with the higher
binding affinity to P-gp (or higher free energy of trans-
porter–water binding, ∆G0tw) acts as a modulator [15,57]. As
shown below, detergents with a high free energy of drug bind-
ing from water to the transporter (or free energy of trans-
porter–water binding ∆G0tw) are modulators or inhibitors and
enhance drug absorption.
In summary, intrinsic substrates for P-gp can be identified
in silico as compounds that: i) are cationic or noncharged;
ii) are able to reach the inner cytosolic leaflet of the cytoplas-
mic membrane; and iii) carry hydrogen bond acceptor groups
arranged in type I and/or II units. Experimentally, intrinsic
substrates, modulators and inhibitors can be identified unam-
biguously by ATPase activation measurements. Intrinsic
substrates, modulators and, in most cases, inhibitors are
Figure 4. Triton X-100 activates P-gp. P-gp ATPase activation as
a function of the concentration of Triton X-100 (Li-Blatter and
Seelig, unpublished results) and verapamil [24] measured in
inside-out plasma membrane vesicle from mouse embryo
fibroblasts, NIH-MDR1-G185, measured at pH 7.4 at 37°C. The
data are fitted to a modified Michaelis–Menten equation
(Equation 4) [21,64].
P-gp: P-glycoprotein.
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transported. The rate of the intrinsic transport (which is not
the rate of apparent transport as shown in Section 4.2) is pro-
portional to the rate of ATP hydrolysis. The rate of intrinsic
transport decreases with increasing affinity of the compound
to the transporter.
4.2  Identifying apparent substrates
Experimentally, apparent substrates are generally deter-
mined by means of transport measurements across con-
fluent cell monolayers that express high levels of P-gp [69]. If
P-gp is located in the apical membrane (Figure 1) the appar-
ent transport across the confluent cell layer is composed of
the active transport by P-gp into the apical medium in
combination with passive influx into the cell and the
passive bidirectional diffusion across the basolateral mem-
brane. Under the assumption that the passive diffusion
across the basolateral membrane is identical in both
directions, the apparent efflux can be estimated using
Equation 5 [15]. It shows that the net flux, J, of compounds
depends on the sum of the active efflux, -V, by P-gp and the
passive influx, φ (both given in molecules transported
s-1cell-1):
Passive influx, φ, is proportional to the lipid–water parti-
tion coefficient, Klw, which in turn strongly depends on the
cross-sectional area, AD, of the molecule and the lateral pack-
ing density, πM, of the lipid bilayer (see Equation 2). Apparent
transport can thus be estimated as the sum of active efflux
(determined by ATPase measurements) and passive influx
(calculated on the basis of data obtained from surface activity
measurements) according to Equation 5 [15].
Intrinsic substrates with a large cross-sectional area and/or a
high charge that diffuse slowly are detected as apparent sub-
strates and do not reach the cytosol, whereas intrinsic sub-
strates that diffuse rapidly appear as ‘nonsubstrates’. Whether
a compound is an apparent substrate depends, however, not
exclusively on the characteristics of the compound, but also
on those of the lipid membrane. Typical intrinsic substrates
(e.g., verapamil with AD ≈ 80 Å2) can, therefore, be apparent
substrates in cell lines with a high lateral packing density and
apparent ‘nonsubstrates’ in cell lines with a lower lateral
packing density, πM.
Most detergents have cross-sectional areas, AD < 80 Å2, and,
therefore, are rather intrinsic than apparent substrates [15].
Because detergents can change the lateral packing density of
the lipid membrane at high concentrations they can also
modulate the passive influx, φ, of drugs. However, as
discussed in Section 3.2, the effect of detergents on the
membrane packing density is generally relatively low at the
concentrations used for P-gp inhibition.
In summary, apparent substrates are intrinsic substrates
with a low rate of passive influx due either to a large
cross-sectional area and/or a high charge. Because most deter-
gents diffuse rapidly they are generally intrinsic, but not
apparent substrates. At high concentrations they may enhance
passive influx of a coadministered drug by loosening the
membrane packing density and enhancing its influx rate (and
by thus transforming an apparent substrate to an apparent
‘nonsubstrate’). At the concentrations required for P-gp
inhibition these effects are, however, relatively small.
4.3  Estimation of the substrate binding affinity 
to P-glycoprotein
As illustrated in Figure 1, the intramembrane binding site of
P-gp implies that the free energy of drug binding from water
to the transporter (or the free energy of transporter–water
binding, ∆G0tw) of the substrate is the sum of the free energy
of lipid–water partitioning (∆G0lw), and the free energy of
binding from the lipid membrane to the transporter (or the
free energy of transporter–lipid binding ∆G0tl):
The free energy of transporter–water binding can be
expressed as:
where RT is the thermal energy per mole, Klw is the
lipid–water partition coefficient, Ktl is the transporter–lipid
binding constant and Cw = 55.5 mol/l is the molar concentra-
tion of water. The free energy of lipid–water partitioning,
∆G0lw, of 15 structurally different drugs has previously been
determined from surface activity measurements, using the
membrane packing density of 30 mN/m, for MDR1-trans-
fected mouse embryo fibroblasts (see Table 2), as ∆G0lw = -23 to
-34 kJ/mol. The free energy of transporter–water binding of the
drugs was derived from the concentration of half-maximum
P-gp activation as ∆G0tw = -30 to -54 kJ/mol. The free energy
of lipid–transporter binding, ∆G0tl, which is experimentally not
directly accessible, was determined as the difference of the latter
J φ V–=
(5)
∆G0tw ∆G0lw ∆G0tl+=
(6)
∆G0tw RT CwKlw[ ]ln Ktlln+( )–≅
(7)
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two free energies as ∆G0tl = -6 to -27 kJ/mol [21]. The free
energy of lipid–water partitioning, ∆G0lw, is thus generally
more negative (reflecting a higher affinity to the transporter)
than the free energy of binding of the drug from the lipid mem-
brane to the transporter, ∆G0tl. At half-maximum P-gp activa-
tion, the concentration of drugs bound to the membrane, Cb
[mmol/l lipid], is generally one to three orders of magnitude
higher than the corresponding aqueous concentration. The rel-
atively weak substrate–transporter interactions are thus com-
pensated by the high membrane concentrations of the drugs.
For a given drug (e.g., verapamil) the membrane concentration
for half-maximum activation (mmol/l lipid) is a constant,
although the aqueous concentration for half-maximum activa-
tion (mmol/l water) varies by up to two orders of magnitude,
increasing with increasing membrane packing density [21].
The free energy of transporter–lipid binding of the sub-
strate, ∆G0tl, was proposed to be the sum of the free energies,∆G0Hi, of the individual potential hydrogen bonds formed
between substrate and transporter [15,55]:
This hypothesis was tested by dividing the experimentally
determined ∆G0tl values by the number of hydrogen bond
acceptor groups per substrate yielding the apparent free
energy per hydrogen bond, ∆G0Hi. For a compound with only
one type I unit ∆G0Hi = -7.8 kJ/mol. With increasing number
of patterns the free energy of hydrogen bond formation
decreased and reached a limiting value of ∆G0Hi ∼ -2.5 kJ/mol
for compounds with more than four hydrogen bond acceptor
patterns (eight hydrogen bonds) [21].
4.4  Membrane-anchoring detergents as modulators 
of P-glycoprotein: estimation of binding affinity
For the present investigation the free energy of trans-
porter–water binding, ∆G0tw, was estimated according to
Equation 6 as the sum of the free energy of lipid–water parti-
tioning, ∆G0lw, and the free energy of transporter–lipid bind-
ing, ∆G0tl, where the former was estimated from the CMC
according to Equation 3, and the latter was calculated
according to Equation 8 as the sum of the free energies per
hydrogen bond formation using the limiting value of ∆G0Hi =
-2.5 kJ/mol [21]. For the estimation of ∆G0tl all hydrogen bond
acceptors in stable as well as in inducible type I units were
counted, except for poloxamers. For the latter, the value of
hydrogen bond acceptors was limited to 10, as a sequence of
10 PO units would span a lipid bilayer. Compounds with
similarly high numbers of hydrogen bond acceptor groups are
ciclosporin A and PSC-833. For the membrane-anchored
detergents investigated the estimated free energy of
transporter–water binding, of lipid–water partitioning and of
transporter–lipid binding was ∆G0tw = -24 to -54 kJ/mol,∆G0lw = -20 to -39 kJ/mol and ∆G0tl = -5 to -25 kJ/mol,
respectively, which is similar to the corresponding values
obtained for drugs (see Section 4.3). Because the free energy
of lipid–water partitioning of detergents was estimated on the
basis of CMC values [38], it may be somewhat overestimated
for cells with high lateral packing densities. As seen in Table 3,
the present estimation of the free energy of water–transporter
binding, ∆G0tw (or binding affinity of detergents dissolved in
water to P-gp) increases in the order: octyl-β-D-glucoside
< Triton X-100 < Vitamin E TPGS < Tween 80 < Pluronic
L61. As discussed in Section 3.1.2, the largest molecules insert
only into loosely packed membranes (πM ≤ 28 mN/m). The
cross-sectional area, AD, of the molecules increases in the
order: octyl-β-D-glucoside < Triton X-100 < Vitamin E TPGS
< Tween 80 < Pluronic L61. If the compounds exhibit large
cross-sectional areas the order of binding constants given
above may, therefore, change for membranes with high lateral
packing densities, πM.
In summary, the binding affinity of detergents from
water to the transporter can be estimated as the sum of their
binding affinity to the lipid membrane (derived from CMC
values) and their binding affinity to the transporter in the
lipid membrane (estimated as the sum of the potential free
energies of hydrogen bond formation between detergent
and transporter).
5.  Analysis of data
The individual experiments summarised in Table 3 are num-
bered from 1 to 23 (column 1). Table 3 lists the in vivo or
in vitro system (column 2), the detergent used (column 3), the
calculated LogP (KowWin) (column 4), the detergent concen-
tration (column 5), the CMC (column 6), the cross-sectional
area, AD (measured or calculated) (column 7) and the deter-
gent affinity to the transporter, ∆G0tw (detergent) (column 8).
For comparison the drug applied (column 9) and its affinity to
the transporter, ∆G0tw (drug) (column 10) is given. The latter
was derived from the concentration of half-maximum P-gp
activation [21]. The binding affinity of the detergents has been
estimated using the approach described in Section 4.4.
Column 11 finally shows whether absorption of the given drug
is enhanced by the presence of the detergent.
It should be noted that enhancement of drug absorption
observed in in vitro experiments with P-gp overexpressing
cells mainly reflects the direct interaction between the
detergent and P-gp. The enhancement of drug absorption
in in vivo experiments reflects the interaction of the deter-
gent with P-gp, with other ABC transporters, with the
metabolising enzyme, CYP, and possibly with other meta-
bolising enzymes. In the latter case enhancement of drug
absorption is generally coupled with a decreased plasma
clearance and an increased excretion of the nonmetabolised
drug [70-73].
∆G0tl Σ ∆G0Hi≈
(8)
n
i = 1
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5.1  Absorption enhancement by 
membrane-anchoring detergents
5.1.1  Absorption enhancement due to P-gp inhibition
An enhancement of drug absorption by detergents due to
P-gp inhibition is expected if the binding affinity of the deter-
gent to P-gp is higher than that of the drug (i.e., if the free
energy of binding, ∆G0tw, of the detergent to P-gp is more
negative than that of the coadministered drug). This applies to
experiments 1 – 8 and most likely also to experiments 9 – 13,
although the concentrations of half-maximum P-gp activation
and thus the ∆G0tw values of the drugs were not available in
the latter experiments.
5.1.2  Cells with plasma membranes exhibiting 
relatively high lateral packing densities
Hugger et al. [51] have shown that Cremophor EL and Tween 80
are less active in inhibiting P-gp in MDCK-MDR1 cells than in
Caco-2 cells. The packing density of the plasma membrane of
canine kidney cells (which may be similar to that of
LLC-MDR1 cells) is most likely higher than that of Caco-2 cells
resembling the IB (see Table 2), and, therefore, insertion of
Tween 80, which exhibits a relatively large cross-sectional area
(AD = 69 Å2), is more difficult in MDCK-MDR1. The
cross-sectional area of Cremophor EL has not yet been deter-
mined; however, due to the hydroxyl group in the hydrophobic
extension it may insert in a bent conformation, which would
lead to a relatively large cross-sectional area, AD, and thus also to
a reduced ability to insert into densely packed membranes.
Experiments by Wang et al. [74] (not included in Table 3)
showed that PEG, with fatty acyl chain extensions (small
cross-sectional areas) was more effective in the human colon
cancer cells, HCT-8, than Vitamin E TPGS (large cross-sec-
tional area), whereas Vitamin E TPGS was more effective in
mouse embryo fibroblasts, NIH3T3, exhibiting a lower
packing density than HCT-8 cells. This example may, thus,
also be traced back to differences in the cellular membrane
packing density.
5.1.3  No P-glycoprotein inhibition and no 
absorption enhancement
If the detergent exhibits a lower binding affinity to the trans-
porter than the drug (i.e., less negative free energy of binding
to P-gp) no absorption enhancement is expected. This behav-
iour is observed for the detergent, octyl-β-D-glucoside in the
presence of rhodamine 123 [75]. The low inhibitory power of
octyl-β-D-glucoside can be traced back to the low free energy
of lipid–water partitioning, ∆G0lw (see Section 3.1.1).
5.2  Absorption enhancement by polyethyleneglycols 
and poloxamers
5.2.1  Absorption enhancement by means of 
drug solubilisation 
Experiments 17 and 18 reveal an absorption enhancement of
taxol and digoxin by PEG. Neither PEGs nor poloxamers
show a strong tendency to partition into lipid membranes, as
shown in Section 3.1.2. Whether pre-emptive binding and
transport, as proposed for verapamil [76], could play a role for
highly water soluble compounds such as PEGs has to be
tested. Because taxol and digoxin are compounds with a ten-
dency to self-associate the absorption enhancement by
PEG-300 and -400 may be simply due to a solubilising effect.
The same may hold true for experiment 19, in which
poloxamer is used as a detergent.
5.2.2  P-glycoprotein inhibition by poloxamers 
Provided PEG or poloxamer can insert into the membrane (e.g.,
at low membrane packing density, πM > 28 mN/m, see Section
3.1.2), they are likely to be substrates for P-gp. A systematic
analysis of the P-gp inhibitory potential of a large number of
Pluronic block copolymers with varying length of EO and PO
segments was performed in BBMEC cells [28]. The highest effi-
cacy was obtained with copolymers exhibiting intermediate
length of ∼ 30 to ∼ 60 PO segments and a hydrophile–lipophile
balance, HLB < 20 (e.g., P85 with ∼ 40 PO segments and an
HLB of 16) [77].
No membrane insertion and no P-gp interaction in
inside-out plasma membrane vesicles of NIH-MDR1-G185
cells (Egli and Seelig, unpublished results) were observed for
Pluronic L61 with ∼ 30 PO segments and an HLB of 3.
Pluronic F68 (poloxamer P188) with ∼ 29 PO segments and an
HLB of 29 was inactive in Caco-2 cells and healthy male volun-
teers [78]. Pluronic P188 is a component of many laxatives [201].
Because talinolol used as a drug is highly soluble, the
solubilising potential of poloxamers played no role, as seen in
experiments 20 and 21.
5.2.3  Endocytosis 
The positive effect of CRL-1605 on amikacin [79] and
tobramycin [80] uptake is unlikely to be due to P-gp inhibi-
tion. The two compounds are highly cationic and very
hydrophilic, exhibiting large negative LogP values (XLogP:
-9.048 for amikacin and XLogP: -6.899 for tobramycin) and
are thus unable to cross a membrane barrier by passive diffu-
sion, even if P-gp is inhibited. Under certain conditions
poloxamers may form cationic complexes with highly charged
drugs, which enter the cell by means of endocytosis [81].
In summary, it has to be differentiated between detergents
that can insert into the lipid membrane and detergents that
cannot, whereby the potential to insert not only depends on
the detergent, but also on the the membrane. Compounds that
insert into the membrane can bind to P-gp, provided they
carry hydrogen bond acceptor patterns (Figure 3). If the bind-
ing affinity of the detergent to P-gp is higher than that of the
coadministered drug, the latter will act as a modulator by
keeping P-gp busy and allowing the drug to cross the mem-
brane by passive diffusion. The absorption-enhancing effect of
compounds that cannot insert into densely packed mem-
branes, such as certain Pluronics or PEGs, may be due to mere
solubilisation in the presence of self-associating drugs or to
endocytosis in the presence of strongly cationic compounds.
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6.  Side effects and toxicity due to detergent 
interactions with transporters and 
metabolising enzymes
In vivo, detergents commonly used as excipients can exert a
range of biological effects, some of which have important clin-
ical implications. Their use has been associated with severe
anaphylactoid hypersensitivity reactions, hyperlipidaemia,
abnormal lipoprotein patterns, aggregation of erythrocytes,
peripheral neuropathy and modification of the toxicity profile
of certain anticancer agents given concomitantly [82].
Anaphylactoid hypersensitivity reactions, which have been
observed with several ubiquitously used detergents such as
polysorbate 80, Tween 80 and Cremophor EL (polyethoxy-
lated castor oil) [83-85], may be traced back to P-gp modula-
tion. P-gp has been linked to the immune response and may
play a role in antigen presentation [86,87].
Massive hyperlipidaemia and artherosclerosis in rodents
was observed following treatment with poloxamer 407 [88].
Detergents including Pluronic L81, P85 and F68 and Cremo-
phor EL inhibited intestinal secretion of lipoproteins, includ-
ing triglyceride-rich chylomicrons in Caco-2 cells [89]. A
strong correlation was observed between detergent-mediated
inhibition of lipoprotein secretion and inhibition of P-gp
efflux implying a link between the two processes. The fact
that triglycerides display the characteristics of P-gp substrates
(see Table 1) suggested a direct involvement of P-gp or related
transporters in these processes [89]. Because many ABC trans-
porters play a role in the maintenance of the lipid bilayer and
in the transport of fatty acids and sterols [16] transporters other
than P-gp may also be inhibited by detergents.
Modification of the toxicity profile due to interaction with
CYP3A has been observed. P-gp and CYP3A also show over-
lapping substrate specificities and share a preference for com-
pounds with many hydrogen acceptor patterns (type I patterns)
such as PSC-833 [15]. Hydrogen bond acceptor-rich com-
pounds, therefore, generally have a significant impact on drug
metabolism and efflux, as shown, for example, for PEG-400
and P85, which are used as solubilising agents during in vitro
permeability assessment in excised rat intestine [90].
An overlap between P-gp and MRPs has been observed for
the Pluronics P85, L81 and F108 in bovine brain microvessel
endothelial, BBMEC, cells [91,92]. In contrast, none of the
detergents, TPGS, Pluronic PE8100, Cremophor EL, Pluronic
PE6100 and Tween 80, showed a significant inhibition of
MRP2-mediated efflux in MDCK/MRP2 cells [93].
7.  Conclusion
This review provides the tools for a systematic analysis of
the different factors that influence absorption enhancement
of drugs by different detergents. Many detergents fulfill the
requirements for intrinsic P-gp substrates, that is, they:
i) are noncharged; ii) reach the cytosolic membrane leaflet,
which is the site of interaction with P-gp; and iii) carry
hydrogen bond acceptor groups arranged in type I units,
which are required for an interaction with P-gp. The bind-
ing affinity of a substrate from water to P-gp can be consid-
ered as the sum of the binding affinity of the substrate to the
lipid membrane and the binding affinity of the substrate to
P-gp in the lipid membrane. The binding affinity to the
lipid membrane was derived from the free energy of micelle
formation. The fact that different membranes exhibit differ-
ent lateral packing densities, which in turn affects mem-
brane partitioning, was also addressed. The binding affinity
to the transporter in the lipid membrane increases with the
number of hydrogen bond acceptor groups arranged in
type I units (or hydrogen bond acceptor patterns) per sub-
strate molecule. It was, therefore, estimated by attributing a
free energy of ∆G0Hi = -2.5 kJ/mol to each hydrogen bond
acceptor group. If the binding affinity of the detergent from
water to P-gp (sum of the two binding contributions) is
higher than that of the coadministered drug, the detergent
acts as modulator of P-gp and enhances passive diffusion of
the drug into the cells. Examples for detergents with high
binding affinities to P-gp that work as modulators in the
presence of many different drugs include Tween 80 and
Vitamin E TPGS. The latter is, however, not highly water
soluble. Provided poloxamers enter the cell, they exhibit a
large binding affinity to P-gp due to the high number of
oxygen molecules that can be arranged in type I units.
However, their effect in inhibiting P-gp is limited to
membranes with low lateral packing densities. In combina-
tion with highly cationic compounds, poloxamers may
induce endocytosis. The modular binding approach predicts
the absorption enhancement of drugs by various non-
charged detergents in good agreement with published
in vivo and in vitro data.
8.  Expert opinion
Noncharged detergents that carry hydrogen bond acceptor
patterns directly bind to P-gp and modulate or inhibit the
interaction of drugs with P-gp, provided they can reach the
cytosolic membrane leaflet. As a result drugs can cross the
membrane by passive diffusion without being exported by
P-gp, which leads to an enhancement of drug absorption.
Experiments made with confluent cell monolayers of
MDR1-transfected cells reveal essentially this P-gp inhibitory
effect. In in vivo experiments the enhancement of drug
absorption due to P-gp inhibition by detergents is accompa-
nied by additional effects, such as decreased plasma clearance
and increased excretion of the nonmetabolised drug, thus sug-
gesting an interaction of detergents with other ABC trans-
porters and with the metabolising enzyme, CYP. Many ABC
transporters are charge sensitive; however, they most likely
share noncharged substrates with P-gp and CYP. Noncharged
detergents and drugs may thus interact with a larger number
of transporters than charged compounds. This may explain
their considerable effect on the ADME properties and their
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enhancement of the toxicity of the coadministered drug. With
this in mind, dosing of noncharged detergents used as excipi-
ents in drug formulations becomes a difficult task, especially if
one considers in addition the variability of the expression level
of the different transporters and metabolising enzymes in dif-
ferent individuals. Alternative ways to enhance drug absorp-
tion may, therefore, also be considered. As shown above,
decreasing the cross-sectional area of a drug molecule in its
amphiphilic orientation significantly enhances passive influx
of the drug and concomitantly reduces active efflux by P-gp.
Because detergents are omnipresent, not only as cleaning
agents and excipients in drug formulations, but also as food
and cosmetic additives, it is of importance to identify those
with strong inhibitory effects on ABC transporters and
metabolising enzymes and, moreover, to quantify their modu-
lating and inhibitory interactions. The present analysis pro-
vides the tools for an approximate and simple a priori estimate
of the membrane and P-gp binding ability of noncharged
detergents based on a modular binding approach. However,
much remains to be clarified in the field of the interaction of
detergents with other ABC transporters.
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The cross-sectional area, AD, of a compound oriented in an amphiphilic gradient such as the air-water or
lipid-water interface has previously been shown to be crucial for membrane partitioning and permeation,
respectively. Here, we developed an algorithm that determines the molecular axis of amphiphilicity and the
cross-sectional area, ADcalc, perpendicular to this axis. Starting from the conformational ensemble of each
molecule, the three-dimensional conformation selected as the membrane-binding conformation was the one
with the smallest cross-sectional area, ADcalcM, and the strongest amphiphilicity. The calculated, ADcalcM, and
the measured, AD, cross-sectional areas correlated linearly (n ) 55, slope, m ) 1.04, determination coefficient,
r2 ) 0.95). The calculated cross-sectional areas, ADcalcM, were then used together with the calculated octanol-
water distribution coefficients, log D7.4, of the 55 compounds (with a known ability to permeate the blood-
brain barrier) to establish a calibration diagram for the prediction of blood-brain barrier permeation. It
yielded a limiting cross-sectional area (ADcalcM ) 70 Å2) and an optimal range of octanol-water distribution
coefficients (-1.4 e log D7.4 < 7.0). The calibration diagram was validated with an independent set of 43
compounds with the known ability to permeate the blood-brain barrier, yielding a prediction accuracy of
86%. The incorrectly predicted compounds exhibited log D7.4 values comprised between -0.6 and -1.4,
suggesting that the limitation for log D7.4 is less rigorous than the limitation for AD. An accuracy of 83%
has been obtained for a second validation set of 42 compounds which were previously shown to be difficult
to predict. The calculated parameters, ADcalcM and log D7.4, thus allow for a fast and accurate prediction of
blood-brain barrier permeation. Analogous calibration diagrams can be established for other membrane
barriers.
INTRODUCTION
Brain-targeted drugs have to permeate the blood-brain
barrier (BBB) to be therapeutically active, whereas drugs
targeted to peripheral sites should ideally not reach the central
nervous system (CNS) not to induce central side effects.
Finding simple and unambiguous criteria for membrane
permeation that can be used for structural optimization of
drug candidates in the early stage of drug discovery would
therefore be desirable.
To assess BBB permeation, in vivo models have been used
for decades, and more recently, many in vitro assays based
on confluent cell monolayers have been established (e.g.,
ref 1). The parameters obtained from such assays are complex
because they reflect the resultant of different active and
passive transport processes and can therefore not be easily
translated into simple molecular parameters. Moreover, these
assays are rather time-consuming and are thus not applicable
to the early screening of a large number of compounds.
The most commonly used physical-chemical approaches
to predict membrane permeation are octanol-water2 or
hexadecane-water3 partition coefficient measurements, high-
performance liquid chromatography (HPLC)-related tech-
niques (ref 4 and references therein), and parallel artificial
membrane permeation (PAMPA) assays.5 Although predic-
tions of membrane permeation on the basis of these
techniques are generally successful for small molecules, they
often fail for larger molecules.4 This is due to the fact that
the membrane mimicking systems are either fully isotropic
(e.g., octanol and hexadecane) or exhibit a low anisotropy
(e.g., HPLC or PAMPA systems). As shown by Lipinski et
al.,7 the prediction of membrane permeation can be improved
by combining octanol-water partition coefficients with
additional parameters such as the molecular weight and the
number of H-bond acceptors and donors.
Lipid bilayers exhibit a fluidity which is comparable to
that of olive oil. However, in contrast to the random, isotropic
arrangement of the molecules in olive oil, the molecules in
a lipid bilayer exhibit an average structural order relative to
each other along their molecular axis and are thus highly
anisotropic liquids or liquid crystals. Using solid-state
deuterium-nuclear magnetic resonance, the packing of the
fatty acyl chains was described in terms of statistical order
profiles. For a given membrane, the average order of the
fatty acyl chains is comparatively high, close to the head-
group region, and decreases toward the center of the
membrane (for a review, see refs 6 and 8).
The lateral packing density of the bilayer membrane, ðM,
can also be assessed in comparison to that of a lipid
monolayer.9 It depends on the lipid composition and can vary
considerably (for a review, see ref 10). Insertion into a lipid
bilayer requires energy, ¢W, because a cavity has to be
formed in the well-ordered membrane which is large enough
to accommodate the drug. This energy, ¢W, is proportional
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to the lateral packing density, ðM, of the membrane and the
cross-sectional area, AD, of the inserting molecule (¢W )
ðM  AD).11 For molecules with small cross-sectional areas,
the energy is low; however, for molecules with large cross-
sectional areas, it can become prohibitively high. It should
be noted that the cross-sectional area, AD, of the molecule is
not necessarily proportional to the molecular weight but
depends on the conformation and on the orientation of the
molecule.12 The relevance of the molecular cross-sectional
area (rather than the molecular weight) was also demon-
strated by measuring the passive diffusion of linear and
branched molecules.13
The lipid-water partition coefficient, Klw, of a molecule
decreases exponentially with increasing energy of cavity
formation.12,14 To give a numerical example, doubling the
cross-sectional area, AD, of the molecule from 50 Å2 to 100
Å2 reduces the lipid-water partition coefficient for a
membrane with a lateral packing density, ðM ) 35 mN/m
(e.g., BBB) by a factor of 67. This is in contrast to the
octanol-water partition coefficient, P, which increases with
increasing size of the molecule,15 because the energy for
cavity formation is relatively small.
Most membrane-permeating drugs are amphiphilic and,
if brought into contact with the air-water or the lipid-water
interface, they organize themselves in an anisotropic manner
comparable to that of lipid molecules. Because the dielectric
constant of air ( ) 1) and that of the lipid core region ( )
2) are similar and much lower than that of water ( ) 80),
the amphiphilic orientation of the molecule is identical at
the two interfaces. Measurement of the Gibbs adsorption
isotherm, that is, the surface pressure of the drug in a buffer
solution as a function of the concentration, yields the air-
water partition coefficient, Kaw, the critical micelle concen-
tration, CMC, and the surface area requirement of the
compound, AS, in its amphiphilic orientation. If measure-
ments are performed under conditions of minimal charge
repulsion, the surface area requirement, AS, corresponds to
the cross-sectional area, AD, of the molecule perpendicular
to its axis of amphiphilicity.12
The three parameters, Kaw, CMC, and AD, have been used
to establish 3D calibration diagrams for membrane perme-
ation with high predictive values.12 For BBB permeation,
the calibration diagram was established with 53 drugs of
known ability to cross that BBB. It revealed that permeation
is only possible if a compound exhibits a cross-sectional area
AD < 80 Å2 [the limit of 80 Å2 corresponds to a rounded
value from the experimental cross-sectional area of spira-
doline (73 ( 5 Å2)]; an intermediate air-water partition
coefficient, Kaw; and an ionization constant pKa < 10 for
bases and pKa > 4 for acids. An analogous analysis was
also performed for the intestinal barrier.16
For fast screening of preclinical drug candidates, several
in silico models have been developed (for a review, see refs
17-19). The parameters used most frequently are the
molecular weight; the calculated octanol-water partition
coefficient, P, of the neutral form of the compound (ex-
pressed as log P) or the partition coefficient of the salt form
at pH 7.4; and the so-called distribution coefficient, D
(expressed as log D7.4). Further parameters are the number
of nitrogen and oxygen atoms, the number of heteroatoms,
and the number of hydrogen-bond donors and acceptors.
These parameters can all be calculated on the basis of the
structural formula. A second group of parameters also used
frequently, such as the molecular volume, the molecular
surface, the solvent-accessible surface area, the polar surface
area, the molecular shape, and flexibility, requires the three-
dimensional structure of the compound for calculation.
Because the cross-sectional area, AD, measured at the air-
water interface under conditions of minimal electrostatic
repulsion12 has been shown to be highly predictive, the aim
was to implement this parameter in the in silico prediction
of membrane permeation. So far, the cross-sectional area,
AD, of the molecule oriented at an amphiphilic interface has
not been used as a parameter for the in silico prediction of
membrane permeation. Although a related algorithm has been
described by Rohrbaugh and Jurs20 to assess the shape of
molecules from their 3D structure, using the projected surface
of the atoms toward three opposite spatial directions (“shadow
areas”), and has been implemented in a QSAR model,21 it
does not consider the conformational ensemble or the
amphiphilic orientation of the molecule. Therefore, (i) we
developed an algorithm to orient a molecule in an am-
phiphilic gradient such as the air-water or lipid-water
interface and to calculate the cross-sectional area, ADcalc, of
the molecule perpendicular to the axis of amphiphilicity,
taking into account the conformational ensemble of a
molecule. (ii) A calibration of the calculated cross-sectional
area, ADcalc, with the cross-sectional areas, AD, determined
by surface activity measurements yielded the cross-sectional
areas relevant for membrane permeation, ADcalcM. (iii) The
predictive value of ADcalcM for BBB permeation was then
tested using three data sets.
METHODS
Amphiphilicity Axis. Molecules in an amphiphilic gradi-
ent such as the air-water or lipid-water interface orient such
that the hydrophilic part remains immersed in the aqueous
phase and the hydrophobic part reaches into the air or the
lipid phase, respectively. The amphiphilicity of a compound
has been determined previously by two different ap-
proaches: (i) Fischer et al. described it as the sum of the
hydrophilic/hydrophobic contribution of an atom/fragment
as described by Meylan and Howard22 multiplied by the
distance between these atoms/fragments and the charged part
of the molecule;23 (ii) Cruciani et al. determined it by
assessing the center of the hydrophilic and the hydrophobic
domains. A closer description of how the individual contri-
butions were calculated is lacking.24 Here, we used the
principle of the latter approach.
To find the orientation of the molecule in such an
amphiphilic gradient, the axis of amphiphilicity, defined as
the line crossing the hydrophobic (Figure 1A) and the
hydrophilic center of the molecule (Figure 1B, purple line)
was determined.
We defined the hydrophobic center of the molecule as the
center of mass of all hydrophobic atoms (carbon, fluorine,
chlorine, bromine, and iodine); these atoms were weighted
according to their contribution to log P (logarithm of the
octanol-water partition coefficient) as described in the atom-
additive method proposed by Wang et al.25 They calculated
log P as the sum of the specific contributions from the
individual atoms. The contribution to log P further depends
on the hybridization state, the number of attached hydrogen
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atoms, the nature of neighboring atoms, and the adjacency
to ð systems. To find these contributions, the covalent
neighborhood of each hydrophobic atom (carbon, fluorine,
chlorine, bromine, and iodine) was screened and its electronic
state was determined. The aromatic systems were defined
as cycles or groups of cycles (found using the algorithm of
Balducci and Pearlman26) obeying Hu¨ckel’s (4n + 2)
aromaticity rule.27, 28
In a similar manner, the hydrophilic center of the molecule
was defined as the center of mass of all polar atoms of the
molecule. To this purpose, nitrogen, oxygen, phosphorus,
and sulfur atoms were weighted according to Ertl et al.29
(Figure 1B). However, we modified this approach by taking
into account the net charge, z, of the ionizable group, because
charged atoms do not penetrate into the membrane and
therefore remain in the aqueous environment. To a fully
uncharged atom, we attributed the weight, CO, proposed by
Ertl et al.,29 and to a fully charged atom, we attributed an
arbitrary weight of 100. The contribution of a given atom
corrected for charge, CC, was calculated assuming a linear
relationship from CO to 100 for z ) 0-1
Figure 1B shows as an example the influence of charge on
the hydrophilic center of GR91272 (V15) with an ionization
constant, pKa 7.58, which means that 60.42% of the species
is protonated at pH 7.4. The ionizable nitrogen thus strongly
contributes to the hydrophilic center of mass and dominates
the contributions of the uncharged nitrogen and the oxygen
atoms.
To determine the ionizable atoms and their ionization state
as a function of the pH, we embedded in our algorithm a
pKa determination module, based on the approach of Sayle.30
The algorithm finds the ionizable atoms of a compound and
attributes to them a user-given (if available) or a calculated
pKa value.
2D and 3D Structures. The positions of the hydrophobic
and hydrophilic centers of mass, and thus the calculated
cross-sectional area (see below), depend on the three-
dimensional structure of the compound; multiple 3D con-
formations for each molecule were therefore required. The
2D structures were either imported from SciFinder Scholar
(American Chemical Society) or drawn using ChemDraw
(Cambridge Software). The 3D conformations were then
calculated with MOE 2005.06 (Chemical Computing Group)
using two different algorithms: (i) the systematic search
which covers the whole conformational space by systemati-
cally rotating all rotatable bonds by discrete increments,
without energy minimization, and (ii) the stochastic search,
which samples local minima of the conformational space
using a random approach and an energy minimization with
the MMFF94X force field and chiral inversion in order to
cover the whole conformational space. The hydrogen atoms
were added to the structure (if required) and the partial
charges were calculated prior to energy minimization. The
3D structures generated by the stochastic search algorithm
were finally exported as MDL SDF files.
Calculation of the Molecular Cross-Sectional Area. To
determine the cross-sectional area, ADcalc, of the molecule,
the amphiphilicity axis determined for each 3D structure was
oriented perpendicular to the plane of the lipid bilayer surface
(assumed to be parallel to the plane of the paper) as seen in
Figure 1C, and the atoms of the molecule were then projected
onto this plane. The van der Waals radii of the atoms31 were
taken into account, and the contour of the projection was
smoothened using a water probe of 1.4 Å radius (Figure 1C)
following the definition of the molecular surface, according
to Richards.32 The area inside this smoothed contour was
then defined as the calculated cross-sectional area, ADcalc. The
current procedure was applied to each individual 3D structure
generated with MOE, which leads to a range of ADcalc values.
To assess the difference in the calculated cross-sectional
areas, ADcalc, obtained with the two different algorithms within
MOE, we used verapamil (55) with 13 rotatable bonds as
an example. The systematic search generated 257 647
conformations with calculated cross-sectional areas, ADcalc,
varying from 63.43 to 131.61 Å2 (Figure 2A, black bars).
The stochastic search generated 79 conformations if the
Figure 1. Calculation procedure of the cross-sectional area of GR
91272; the purple line represents the axis of amphiphilicity of the
molecule crossing the hydrophobic (A) and the hydrophilic (B)
centers of mass. (A) Determination of the hydrophobic center of
the molecule, (B) determination of the hydrophilic center of the
molecule, and (C) top view of the molecule (perpendicular to the
amphiphilicity axis) and projected surface area smoothed by a water
probe of 1.4 Å radius. The structures were rendered with Pymol.40
CC ) 100z + CO(1 - z) (1)
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energy cutoff was set to 7 kcal/mol, the failure limit was set
to 20, and the RMS tolerance was set to 0.1 Å (Figure 2B,C,
black lozenges), and 1232 conformations were generated with
the failure limit set to 50 (Figure 2B,C, open triangles) [The
energy cutoff means all conformations with an energy greater
than the global minimum (the minimum energy value of
those conformations generated) plus the value specified in
this field will be discarded. The failure limit specifies how
many contiguous attempts, k, should be made to generate a
new conformation prior to terminating the search. If k
contiguous attempts at generating a new conformation all
result in conformations already generated, the search will
terminate. RMS tolerance means if two conformations have
a heavy-atom RMSD less than the specified value, then they
are considered duplicates. Molecular symmetry is taken into
account in the superposition (definitions taken from the MOE
manual)]. The calculated cross-sectional areas for the con-
formational ensemble obtained with the stochastic search
varied from ADcalc ) 63.57 to 130.56 Å2 (Figure 2A, gray
bars).
The dashed rectangles in Figure 2B and C represent the
experimental cross-sectional area, AD (with error range), of
verapamil determined by means of surface-activity measure-
ments at 24 °C and pH 7.4 (50 mM Tris, 114 mM NaCl)
(Li and Seelig, unpublished result; for experimental details,
see ref 12). Figure 2A highlights the fact that the repartition
of calculated cross-sectional areas for conformations obtained
with both systematic search and stochastic search is similar,
varying from ADcalc ) 63 to 132 Å2. Moreover, Figure 2B
and C show that the stochastic search with the failure limit
set to 20 is sufficient to cover the whole conformational
space, leading to much fewer conformations (93.75% less
in the case of verapamil) and, thus, a much faster processing
of the calculations. Figure 2B further shows that neither the
smallest calculated cross-sectional area (ADcalc ) 63.57 Å2,
Figure 3A) nor the one having the smallest potential energy
in vacuo (which has a calculated cross-sectional area,
ADcalc ) 88.65 Å2, Figure 3B) corresponds to the experi-
mental value. For membrane insertion, two conditions have
to be fulfilled: (i) the molecule has to be amphiphilic,
whereby the hydrophilic or charged portion remains in the
headgroup region of the lipid bilayer,6 and (ii) the molecule
has to be as slim as possible for energetic reasons.11,12 We
therefore searched for the most amphiphilic conformations
Figure 2. Calculated cross-sectional areas of verapamil (A-C) and fluoxetine (D). (A) The 257 647 conformations generated with the
systematic search (black bars), and 1309 energy-minimized conformations generated with the stochastic search (grey bars); three of the
latter conformations are shown in Figure 3 as an example. (B) Calculated cross-sectional area versus the potential energy of conformations
generated with the stochastic search, with the failure limit set to 20 (77 conformations, black lozenges) and the failure limit set to 50 (1232
conformations, open triangles); the cross-hatched rectangles represent the experimental cross-sectional area with the error range. (C) Calcu-
lated cross-sectional area versus the quotient of molecular length (oriented toward the amphiphilicity axis) and the distance between the
two centers of mass. Symbols are identical to those in B. (D) Calculated cross-sectional area versus the ratio molecular length/distance
between the two centers of mass. Symbols are identical to those in B.
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with the smallest cross-sectional areas. This was achieved
by plotting the calculated cross-sectional area versus the
quotient of the length of the molecule (oriented in an
amphiphilic gradient), LM, and the distance between the
hydrophilic and hydrophobic centers of mass, Dhh (Figure
2C). The quotient, LM/Dhh, reveals the tendency of a molecule
to regroup its hydrophilic fragments on one side and the
hydrophobic fragments on the other side, creating a long
distance between the two centers of mass, relative to the
molecular length, while keeping the cross-sectional area as
small as possible by eventually folding the structure (as, e.g.,
for verapamil, 55, Figure 3C). Hence, the relevant conforma-
tions are those with the smallest value for the calculated
cross-sectional area and a quotient LM/Dhh < 6; for verapamil,
this led to a calculated cross-sectional area, ADcalcM )
82.52 Å2, which is close to the experimental value (AD )
82 ( 2 Å2) (Figure 3C).
For the evaluation of the cross-sectional area, ADcalc, we
therefore always generated multiple conformations using the
stochastic search algorithm with the failure limit set to 20.
The number of conformations varied from one conformation
(e.g., tranylcypromine, 34) to several thousand conformations
(e.g., 5105 conformations for amiodarone, 36, which has 11
rotatable bonds). We then chose the smallest calculated cross-
sectional area of each data set having a ratio LM/Dhh < 6,
ADcalcM. Comparing the calculated cross-sectional areas versus
the quotient LM/Dhh led to the observation that nonfoldable
molecules, like fluoxetine (9, Figure 2D), show a relatively
small variation in both parameters, whereas foldable mol-
ecules, like verapamil (55, Figure 2C), show a much broader
variation of the quotient.
Correction for Missing Hydrogen Atoms. Three-
dimensional structure-generation software often omits hy-
drogen atoms in the output file. To be able to also use the
output files lacking hydrogen atoms, we assessed a correction
factor for the missing hydrogen atoms. To this purpose, the
cross-sectional area with, ADcalc+H, and without, ADcalc-H,
hydrogen atoms was calculated for 46 compounds (most of
the drugs of Table 1). The plot of ADcalc+H versus ADcalc-H
yielded the following linear correlation with a coefficient of
determination r2 ) 0.995 (Figure 4)
Because we used the MMFF94X force field to generate
multiple conformations of each compound, the hydrogen
atoms were always present in the structures used for the
calculation of the cross-sectional area. However, because
hydrogen atoms might be absent when using other modeling
software, eq 2 was implemented in the algorithm to correct
for missing hydrogen atoms in case no hydrogen atoms were
found in the processed structure.
Octanol-Water Partition Coefficients. The octanol-
water partition coefficients log P were obtained with Kowwin
v.1.67 (U.S. Environmental Protection Agency).
Distribution coefficient log D was calculated using the
following equations:
for acids,
for bases, and
for zwitterions.
Figure 3. Three-dimensional conformations of verapamil. (A)
Conformation yielding the smallest cross-sectional area. (B)
Conformation with the lowest potential energy. (C) Smallest
amphiphilic conformation, corresponding to the membrane-bound
conformation (ADcalcM). All figures were rendered with Pymol.40
ADcalc+H ) ADcalc-H  1.13 (2)
log D ) log P - log[1 + 10pH-pKa(acidic)] (3)
log D ) log P - log[1 + 10pKa(basic)-pH] (4)
log D ) log P - log[1 + 10pH-pKa(acidic)] -
log[1 + 10pKa(basic)-pH] (5)
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Calculation Speed. The algorithm for the calculation of
the cross-sectional areas, ADcalc, can process hundreds of
compounds within a few seconds on a normal desktop PC.
Moreover the speed of computing can be enhanced by
decreasing the contour resolution, which has only negligible
effects on the final result. The computational speed can be
further enhanced by omitting the hydrogen atoms of the
structures, which strongly decreases the number of atoms to
be processed, and then correcting the obtained cross-sectional
area without hydrogen atoms, ADcalc-H, with an average
correction factor, f ) 1.13 (eq 2), to obtain the cross-sectional
area, ADcalc, with hydrogen atoms.
RESULTS
Comparison of Calculated and Measured Cross-
Sectional Areas. To validate our algorithm, we compared
Table 1. Molecular Weights, log P (calculated with Kowwin 1.67), pKa and Calculated Cross-Sectional Area of the Membrane-Bound
Conformation (ADcalcM), and Experimental Cross-Sectional Area (ADexp) at pH 7.4 and pH 8.0 of a Selection of 55 Compounds (Fischer et al. 12)
Used for the Validation of the ADcalc Algorithm
ADcalcM [Å2] ADexp [Å2]
activity no name MW log P pKa(base) pKa(acid) pH 7.4 pH 7.4 pH 8
BBB+ 1 amitriptyline 277.4 4.95 9.441 53.75 56 ( 3 52 ( 4
2 apomorphine 267.32 2.78 8.9242 9.43a 50.61
3 chlorpromazine 318.86 5.2 9.343 48.44 42 ( 3
4 chlordiazepoxide 297.74 2.42 4.842 61.48 67 ( 4
5 clomipramine 314.85 5.65 9.544 52.92 64 ( 8 50 ( 4
6 clozapine 326.82 2.84 7.642 51.29
7 diazepam 284.74 2.7 3.442 60.17 48 ( 2
8 flunitrazepam 313.28 1.91 1.845 64.57
9 fluoxetine 309.33 4.65 9.6246 57.55 51 ( 7 51 ( 1
10 cis-flupenthixol 434.52 4.07 7.847 14.96a 59.43 63 ( 1 60 ( 2
11 haloperidol 375.86 4.2 8.6643 13.85a 56.67
12 hydroxyzine 374.9 2.36 7.145 14.4a 60.94 71 ( 7 62 ( 1
13 perphenazine 403.97 3.82 7.9441 14.96a 52.13 55 ( 4 55 ( 4
14 promethazine 284.42 4.49 9.141 57.75 59 ( 3 63 ( 1
15 roxindole 346.47 5.71 8.64a 10.15a 62.07
16 spiradoline 425.39 4.78 9.85a 69.08 73 ( 5
17 thiopental 242.34 2.87 7.5541 42.66
BBB+ (sometimes
described as
BBB- because
of low-dose
administration)
18 thioridazine 370.57 6.45 9.542 60.56 56 ( 8 56 ( 8
19 clonidine 230.09 1.85 8.0548 37.64 34 ( 6 34 ( 1
20 mCPP 196.68 2.19 8.72a 29.99 30 ( 1 30 ( 1
21 desipramine 266.38 4.8 10.441 47.71 36 ( 3
22 doxylamine 270.37 2.37 9.349 51.34
23 imipramine 280.41 5.01 9.441 47.86 39 ( 1
24 lidocaine 234.34 1.66 8.0141 42.83 49 ( 4 45 ( 1
25 mequitazine 322.47 5.66 10.43a 62.89 45 ( 3 45 ( 1
26 metoprolol 267.36 1.69 9.5650 13.89a 40.83
27 naltrexone 341.4 1.41 8.451 10.351 62.76
28 noxiptilin 294.39 4.29 9.07a 55.32 63 ( 2 52 ( 2
29 piracetam 142.16 -1.4 -0.62a 15.67a 30.49
30 promazine 284.42 4.56 9.3641 55.78 57 ( 2 57 ( 4
31 salbutamol 239.31 0.64 9.352 10.352 57.23 44 ( 5 27 ( 1
32 sumatriptan 295.4 1.05 9.49a 11.31a 54.00 26 ( 2
33 tamitinol 226.34 1.18 9.06a 8.11b 52.40 55 ( 4
34 tranylcypromine 133.19 1.57 8.78a 27.71 38 ( 1 45 ( 1
35 zimelidine 317.22 3.18 7.91a 50.22 44 ( 6
BBB- 36 amiodarone 645.31 8.81 6.5653 58.08
37 asimadoline 414.54 3.52 8.1b 14.95b 76.89 76 ( 5 81 ( 1
38 astemizole 458.57 6.43 6.7154 92.97 94 ( 5 94 ( 3
39 domperidone 425.91 3.35 7.943 79.82
40 ebastine 469.66 7.64 8.7855 89.51
41 loperamide 477.04 5.15 8.6656 13.85a 100.33 102 ( 10 147 ( 9
42 terfenadine 471.67 7.62 9.5357 13.32a 94.04 110 ( 7 92 ( 11
54 methyl-â-cyclodextrin 1303.3 -3.87 n.d. 243.61 243
55 verapamil 454.61 4.8 8.9245 82.52 82 ( 2 90 ( 5
BBB- (not surface-
active or strongly
charged)
43 captopril 217.29 0.84 9.853 3.753 47.07
44 carmoxirole 374.48 6.07 8.66a 4.47a 72.91
45 D-mannitol 182.17 -3.01 13.542 41.23
46 furosemide 330.74 2.32 3.6558 61.25
47 pirenzepine 351.4 1.68 8.259 11.29a 57.17
48 acrivastine 348.44 2.08 8.88a 1.99a 59.41
49 ampicillin 349.4 1.45 7.0654 2.654 64.10 67 ( 5
50 carebastine 499.64 2.83 8.48a 4.16a 89.41 141 ( 9 78 ( 5
51 cetirizine 388.89 -0.61 8.2760 1.5260 61.45 57 ( 2
52 ICI204448 465.37 4.05 8.42b 2.89b 73.38 73 ( 5
53 penicillin G 334.39 1.85 2.7442 48.58
a pKa calculated using Advanced Chemistry Development (ACD/Labs) software v.8.14 for Solaris. b pKa calculated using ChemAxon software
MarvinSketch v.4.0.1.
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the calculated, ADcalcM, with the measured, AD, cross-sectional
areas for 55 compounds (Table 1), covering a broad range
of molecular weights (130-1300 Da).12 The experimentally
determined cross-sectional areas, AD, were obtained from
measurements of the Gibbs adsorption isotherm, that is, the
surface pressure, ð, as a function of the concentration of the
drug in a buffer solution (for experimental details, see ref
12). Measurements were performed at pH 7.4 (Figure 5A)
and pH 8.0 (for cations) or pH 6.8 (for anions) (Figure 5B).
The latter two pH values were chosen to minimize electro-
static repulsion between the compounds in the air-water
interface. The linear regression of AD (pH 7.4) versus ADcalcM
yielded a coefficient of determination r2 ) 0.903, a standard
deviation SD ) 12.22, and a slope close to 1 (AD )
1.027ADcalcM). As expected, the correlation under conditions
of minimal electrostatic repulsion (Figure 5B) is slightly
better than that at pH 7.4: r2 ) 0.948, SD ) 8.67, and
AD ) 0.962ADcalcM (Figure 5B). It has to be noted that the
pKa values of cationic (anionic) compounds in the air-water
interface are distinctly lower (higher) than those in a dilute
solution.14 Therefore, charge repulsion minima are generally
reached in the range of pH 7.4-8 for cations and around
pH 6.8 for anions. (No good agreement was achieved
between experimental data by Fischer et al.,12 and experi-
mental data by Suomalainen et al.33 This is due to the fact
that drug stock solutions in the latter case were prepared in
a buffer, not in pure water,12 which can lead to molecular
association in the solution and hence generally larger
apparent cross-sectional areas.)
Packing Density of Molecules at the Air-Water In-
terface. For compounds such as the phenothiazine mequita-
zine (25), the calculated cross-sectional area was larger than
the experimental cross-sectional area (ADcalcM < AD). The
measured value was 50 ( 5 Å2 in the range of pH 7.4-8.0
(Li and Seelig, unpublished data), whereas ADcalcM is 62.9
Å2 at pH 7.4 for one single molecule (Table 1). As shown
in Figure 6, packing several mequitazine molecules in an
antiparallel manner can lead to distinctly smaller cross-
sectional areas. As calculated from an ensemble of 12
molecules of mequitazine, the cross-sectional area can be
as small as ADcalc ) 56.2 Å2 (Figure 6).
Calibration Diagram for BBB Prediction Using the
Calculated Cross-Sectional Area, ADcalcM, and Calculated
Octanol-Water Distribution Coefficient, log D7.4. To
establish a calibration diagram for the prediction of BBB
permeation, we plotted the calculated cross-sectional area,
ADcalcM, and calculated octanol-water partition coefficient,
log D7.4, for a data set of 55 compounds (Table 1), comprising
35 drugs able to cross the blood-brain barrier (BBB+) and
20 peripherally acting drugs which are not able to reach the
brain (BBB-) (for details, see ref 12).
The plot of log D7.4 versus ADcalcM (Figure 7) shows an
excellent discrimination between BBB+ and BBB- drugs,
suggesting a limiting calculated cross-sectional area of
ADcalcM ) 70 Å2 (ADcalcM of spiradoline, 16) and a limiting
range of octanol-water distribution coefficients of -1.4 e
log D7.4 < 7.0 for BBB permeation. When these limits are
used, the only misinterpreted compound was pirenzepine
(47), which is not surface-active and was therefore predicted
correctly on the basis of surface-activity measurements.12 The
prediction accuracy based on log D7.4 and ADcalcM was thus
100% for BBB+ drugs and 95% for BBB- drugs, leading to
an overall prediction accuracy of 98%.
Figure 4. Comparison between the cross-sectional areas calculated
with, ADcalc+H, and without, ADcalc-H, hydrogen atoms for 46
compounds. The straight line represents the linear regression of
the data, and the dotted line, with the slope of 1, was drawn to
guide the eye.
Figure 5. Plot of the measured versus the calculated cross-sectional
area of the membrane-bound conformation. The labels refer to
the compounds in Table 1. The dashed lines correspond to a slope
of 1. Measurements were performed at pH 7.4 (A) and pH 8.0
(bases) or pH 6.8 (acids) (B).
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Validation of the BBB Permeation Diagram on the
Basis of Calculated Cross-Sectional Areas. To validate the
approach using the calculated cross-sectional area, ADcalcM,
together with the calculated log D7.4, for the prediction of
BBB permeation, we used a second data set of 43 com-
pounds34 (Table 2), comprising 24 drugs able to cross the
BBB (BBB+) and 19 drugs which are not able to cross the
BBB at the concentrations applied and have a peripheral
target (BBB-).
Figure 8 shows a plot of log D7.4 versus ADcalcM where the
dashed lines represent the limits defined above (ADcalcM <
70 Å2 and -1.4 e log D7.4 < 7). Again, a good discrimina-
tion between BBB+ and BBB- drugs was observed. The two
parameters, ADcalcM and log D7.4 were able to correctly predict
96% of the brain-targeted compounds and 74% of the
peripherally targeted drugs, leading to an overall prediction
accuracy of 86%. However, all of the BBB- compounds
which were incorrectly predicted have an octanol-water
distribution coefficient log D7.4 e -0.6. By increasing the
limit between brain-targeted drugs and peripherally acting
drugs from -1.4 to -0.6 for log D7.4 (Figures 7 and 8, red
dots), we increased the overall prediction accuracy of the
validation set to 97.7%, whereas the prediction accuracy for
the calibration set decreased from 98% to 93%.
Three other published models used the same data set of
43 compounds (Table 2) either as a training set (Deconinck
et al.35 and Crivori et al.36) or as a validation set (Narayanan
and Gunturi37). The prediction accuracies obtained with our
model were comparable to those obtained by these three other
models, with overall accuracies of 97.7%, 81%, and 95.3%
for the models of Deconinck et al. (1639 descriptors, 150
classification trees of size 4), Narayanan and Gunturi (324
descriptors, three- and four-descriptor models), and Crivori
et al. (72 descriptors, three significant principal components),
respectively (Table 3).
To further test our approach, we selected all of the
compounds that were mispredicted in at least one of these
publications. This led to a third subset of 42 compounds (15
BBB+ drugs and 27 BBB- drugs) from which three
compounds were missing in the data set of Deconinck et
al.,35 nine missing in the data set of Narayanan and Gunturi,37
and covered in totality in the data sets of Crivori et al.36
(Table 4). It is worthy to note that, in the publication of
Deconinck et al., all compounds were present in the training
set, and we considered the results of the best discrimination
tree of size 4 obtained with the Gini index as a split criterion.
In the subset of 42 compounds (Table 4), 10 compounds
were present in our calibration set and seven compounds in
our validation set. The 25 remaining drugs were modeled
using the same procedure as described before; the log Pow
values were calculated using Kowwin v.1.67 and the pKa
using ACD/Labs v.8.14. We also used the limit of -0.6 for
log D7.4 and 70 Å2 for the calculated cross-sectional area as
Figure 6. Possible arrangement of six molecules of mequitazine at a lipid-water or air-water interface. The figure was rendered with
Pymol.40
Figure 7. Log D calculated at pH 7.4 versus the calculated cross-
sectional area of the membrane-bound conformation calibration
diagram. Open circles are BBB+ compounds; closed symbols are
BBB- compounds. Labels refer to compounds in Table 1. The
dashed lines correspond to the limits set between BBB+ and BBB-
compounds (calibration set). The dotted line is the limit defined
after evaluation of the validation set.
Figure 8. Log D calculated at pH 7.4 versus the calculated cross-
sectional area of the membrane-bound conformation validation
diagram. The dashed lines correspond to the limits set between
BBB+ and BBB- compounds. Refer to Figure 7 for the symbol
legend.
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defined previously to discriminate between BBB+ and BBB-
compounds.
Our model was able to correctly predict the blood-brain
barrier permeation of 35 compounds out of 42 (83.3%), with
Table 2. Molecular Weights, log P (calculated with Kowwin 1.67), pKa and Calculated Cross-Sectional Area of the Membrane-Bound
Conformation (ADcalcM) of 43 Compounds Used as a Validation Set
activity no name MW log P pKa(base) pKa(acid) ADcalcM [Å2]
BBB+ V1 BRL52537 355.3 4.37 9.84a 48.66
V2 BRL52580 403.34 5.15 9.55a 58.22
V3 BRL52656 354.41 4.04 9.07b 48.50
V4 BRL52871 409.37 4.97 9.58a 54.32
V5 BRL53080 409.37 4.97 9.41a 55.52
V6 BRL53087 383.36 5.24 9.82a 56.36
V7 cyclazocine 257.37 4.09 9.15a 10.21a 44.18
V8 EMD60400 353.46 0.97 8.56a 60.11
V9 GR45809 413.34 4.52 9.07b 57.64
V10 GR85571 398.33 2.07 9.54a 52.92
V11 GR88377 393.31 4.52 9.49a 52.84
V12 GR89696 414.33 2.92 9.00b 52.73
V13 GR89696et 428.35 3.41 9.00b 54.30
V14 GR89696pr 442.38 3.9 9.00b 53.48
V15 GR91272 409.31 2.98 7.58b 14.95b 53.99
V16 ICI197067 357.32 4.41 9.09b 48.25
V17 ICI199441 391.33 4.71 8.49b 56.77
V18 nalorphine 311.37 2.46 7.39a 9.49a 59.06
V19 RP60180 395.56 5.55 9.80a 65.35
V20 sankyo 370.32 2.59 5.00a 12.07a 52.54
V21 SB201708 393.31 3.21 9.29a 53.35
V22 SB204484 394.3 2.39 9.26a 54.87
V23 tifluadom 415.5 5.87 4.50a 14.13a 84.65
V24 U50488 369.33 4.78 9.91a 53.64
BBB- V25 BRL52974 393.31 3.21 9.53a 13.79a 71.46
V26 GR94839 414.33 0.53 8.51a 14.95b 59.95
V27 GR94839A 413.43 0.2 8.40b 14.95b 55.33
V28 GR94839B 391.53 -0.16 8.40b 14.95b 67.95
V30 GR94839C 381.42 -0.36 8.40b 14.95b 62.57
V30 GR94839D 375.46 -0.68 8.40b 14.95b 58.96
V31 GR94839E 390.43 -0.94 8.40b 14.95b 72.30
V32 GR94839F 375.46 -0.68 8.40b 14.95b 52.19
V33 GR94839G 390.43 -0.94 8.40b 14.95b 64.01
V34 GR94839H 345.44 -0.76 8.40b 14.95b 53.02
V35 GR94839I 409.54 -2.32 8.40b 14.95b 76.11
V36 GR94839L 423.53 -2.19 8.40b 14.95b 78.16
V37 ICI204448 465.37 4.05 2.89b 8.42b 73.38
V38 ICI205640 493.42 5.03 9.56a 4.60a 87.52
V39 SB204454 439.34 1.38 9.72a 9.44a 57.37
V40 SB204457 439.34 2.28 8.86b 79.25
V41 SB204459 409.31 1.68 7.65b 14.95a 76.96
V42 SB205563 416.34 0.48 8.56a 66.12
V43 SB205605 409.31 1.68 8.50a 13.79a 75.48
a pKa calculated using Advanced Chemistry Development (ACD/Labs) software v.8.14 for Solaris. b pKa calculated using ChemAxon software
MarvinSketch v.4.0.1.
Table 3. Comparison of Different in Silico Methods to Assess Blood-Brain Barrier Permeation
source set descriptors
number of
compounds
(BBB+/BBB-)
compounds from
training set
(BBB+/BBB-)
correct
prediction
(BBB+/BBB-)
prediction
accuracy
(%)
Table 1 calibration 1a 54 (35/19) 45 (35/10) 83.3%
calibration 2b 54 (35/19) 50 (32/18) 92.6%
Table 2 validation 1a 43 (24/19) 0 32 (23/9) 74.4%
validation 2b 43 (24/19) 0 42 (23/19) 97.7%
training28 4c 43 (24/19) 42 (24/18) 97.7%
validation29 4d 42 (23/19) 0 34 (16/18) 81.0%
training27 3e 43 (24/19) 41 (23/18) 95.3%
Table 4 validation 1a 42 (16/26) 10 (3/7) 30 (15/15) 71.4%
validation 2b 42 (16/26) 10 (3/7) 35 (15/20) 83.3%
training28 4c 39 (14/25) 29 (11/18) 74.4%
validation29 4d 33 (15/18) 6 (3/3) 10 (3/7) 30.3%
validation27 3e 41 (15/26) 5 (4/1) 14 (11/3) 34.1%
a Cross-sectional area ADcalcM. b Cross-sectional area ADcalcM and log D7.4. c Starting from 1639 descriptors, 150 trees of size 4 were built. d Starting
from 324 descriptors, three four-descriptor models were developed. e Starting from 72 descriptors, a model based on three significant principal
components was obtained.
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a prediction accuracy of 93.3% for BBB+ compounds and
77.8% for BBB- compounds. On the same subset of
compounds, Deconinck et al. obtained an overall prediction
of 74.4% by correctly predicting 29 out of 39 drugs,
Narayanan and Gunturi an accuracy of 30.3% (10 out of 33
drugs), and Crivori et al. an accuracy of 31.7% (13 out of
41; Table 3). We should mention that several mispredicted
compounds, like mequitazine or mefloquine, showed an
alteration of vigilance and sleepiness; these symptoms
observed in double-blind crossover placebo-controlled trials
suggest that these drugs reach the central nervous system if
applied at higher concentrations. For example, mequitazine
is applied at 10 mg/day, whereas the structurally related
CNS-targeted phenothiazines are applied at 100-200 mg/
day (see ref 12).
DISCUSSION
To determine the optimal membrane partitioning confor-
mation of a drug, we first generated the conformational
ensemble for a given compound using MOE, combined with
a stochastic approach to reduce the number of conformations
and thus the computational time. We then assessed the axis
of amphiphilicity and calculated the cross-sectional area of
the compound in its amphiphilic orientation. To obtain the
optimal conformation for membrane partitioning, we then
calibrated the ensemble of the calculated cross-sectional
areas, ADcalc, with the cross-sectional area, AD, measured
under conditions of minimal charge repulsion. The calibration
revealed that the measured cross-sectional area corresponds
well to the smallest cross-sectional area in the case of
nonfoldable compounds and to the smallest cross-sectional
area of an amphiphilic conformation (LM/DHH < 6) in the
case of foldable compounds. The amphiphilic conformation
with the smallest calculated cross-sectional areas (from
various conformers), ADcalcM, led to an excellent linear
correlation with the measured cross-sectional area, AD
(coefficient of determination, r2 ) 0.94, and a slope close
to 1). Only a small variation of AD between the different
Table 4. Calculated Cross-Sectional Areas of the Membrane-Bound Conformation (ADcalcM) and log D7.4 (Kowwin Used for log P and ACD/
Labs for pKa) of 42 Compounds Mispredicted in Some Other Works
name ADcalcM [Å2] log D7.4 exptl. BBB this work Deconinck Narayanan Crivori
alprazolam 64.19 2.12 + + -a +
astemizole 84.44 6.34 - -a -a - +
BRL52974 71.46 1.08 - - +a + +a
carboxymefloquine 37.59 -1.76 - - +a +
carebastine 78.87 -2.91 - -a -a + -
carmoxirol 72.91 1.86 - -a +a + +
cimetidine 64.31 0.49 - + -a -a +
clonidine 37.64 1.11 + +a -a +a +
corticosterone 78.86 1.94 - - +a -
cp102 55.96 -0.66 - - -a +
cp107 46.66 -0.12 - + -a +
cp41 55.73 -0.92 - - -a +
desloratadine 58.35 1.76 - + +a + +
difloxacin 75.91 -0.96 - - -a - +
dopamine 29.88 -2.34 - - -a - +
ebastine 90.06 6.24 - -a -a + +
EMD 61753 77.23 2.34 - - +
fexofenadine 92.5 1.08 - - -a + -
GR85571 52.92 -0.07 + + +a - +a
GR89696et 54.3 1.8 + + +a + -a
GR91272 53.99 2.98 + + +a - +
L364,718 79.87 3.06 - - +a +
L663,581 44.41 2.1 + + -a - -
loperamide 96.95 3.87 - -a -a + +
loratidine 72.35 2.6 - - +a + +
mefloquine 58.36 1.21 - + -a + +
mequitazine 62.63 2.63 - +a -a + +
morphine 48.01 -0.2 + + +a - +
nalorphine 59.06 2.46 + + +a - +
naltrexone 54.84 0.37 + +a +a - -
nordazepam 55.22 2.87 + + +a - +
oxacepam 56.13 2.24 + + -a +
ranitidine 42.47 -0.77 - - -a -a +
SB201708 53.35 1.31 + + +a - +a
SB204484 54.87 0.52 + + +a - +a
skb-i 77.19 6.02 - - -a +
tamitinol 46.52 -0.57 + +a -a +
temelastine 78.24 4.96 - - -a - +
terfenadine 92.57 5.49 - -a -a + +
thiopental 42.69 2.64 + + +a ( -
tifluadom 84.65 5.87 + - +a - ?a,b
tiotidine derivative
(BBCPD 16)
33.32 -0.58 - + -a -a +
total 42 39 33 41
correct prediction 35 (83.3%) 29 (74.4%) 10 (30.3%) 13 (31.7%)
a The compound belongs to the training set in the original publication. b The prediction for tifluadom could not be found in the original publication.
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stereoisomers of racemic compounds was observed (data not
shown); thus, the stochastic conformation search within MOE
was configured in order to cover the whole conformational
space, including racemates. The quality of the calculated
cross-sectional areas, ADcalcM, as a descriptor for the prediction
of blood-brain barrier permeation was then tested on several
data sets.
Limiting Values of the Cross-Sectional Area and log
D7.4 for BBB Permeation. The calibration and validation
procedures yielded an upper limiting cross-sectional area for
BBB permeation ADcalcM ) 70 Å2. This is in good agreement
with the previous calibration results obtained from surface
activity measurements which yielded a limiting cross-
sectional area for BBB permeation AD ) 80 Å2.12
The cutoff for passive diffusion across the BBB is due to
the rather high packing density of the lipid bilayer, as
discussed above. Because of the high expression level of
efflux transporters in the BBB, which efficiently export the
slowly diffusing (large or charged) molecules, the cutoff is
even more rigorous than that in a simple lipid bilayer. If the
rate of passive drug influx drops below the rate of active
drug efflux by multidrug resistance transporters, the drugs
no longer reach the cytosol or cross the BBB.38
For the octanol-water distribution coefficient, a lower and
upper value of -0.6 e log D7.4 < 7 was assessed. This agrees
well with the intermediate range of air-water partition
coefficients.12 If compounds are small and soluble, the lower
limit can be reduced down to -1.4 as shown in Figure 7
because partitioning into the lipid bilayer can be easily
enhanced by increasing the concentration of drugs. The upper
limit is more difficult to overcome because increasing the
concentration of hydrophobic compounds may lead to
aggregation. As mentioned above, hydrophobic compounds
with large cross-sectional areas tend to be substrates for
multidrug resistance transporters. Provided the drugs will not
aggregate in solution, increasing the concentration may help
to modulate or inhibit the multidrug resistance transporters
and to enhance passive diffusion.39
Prediction Accuracy. The quality of the calculated cross-
sectional area ADcalcM and the calculated log D7.4 as param-
eters for the prediction of the blood-brain barrier permeation
have then been evaluated with a first data set of 55
compounds and have been validated with a second indepen-
dent data set of 43 compounds and a third data set of 42
compounds. It is interesting to note that the calculated cross-
sectional area alone can correctly predict 83% of blood-
brain barrier permeation for the first data set, 74.4% for the
second data set, and 71.4% for the third data set (Table 3).
Together with the calculated log D7.4, the prediction accuracy
for the present set of 55 + 43 + 42 compounds (total of
122 different drugs) increased to 85.2% with the lower log
D7.4 limit set to -1.4 and to 90.2% with this limit set to
-0.6 (87.3% prediction accuracy for BBB- compounds and
92.4% prediction accuracy for BBB+ compounds). However,
the limits between BBB+ and BBB- compounds should not
be set in a too restrictive manner because, depending on the
concentration applied or the formulation10 used, the experi-
mental outcome may vary.
Comparison of Different Prediction Methods. We
compared our method to predict BBB permeation with three
methods described previously.35-37 All three methods are
heuristic approaches and start with a large number of
descriptors (72-1639) and then filter out the most relevant
descriptors. The latter are related to (i) the size of the
molecule ( shape index used by Narayanan and Gunturi37
and the sum of topological distances between N and O atoms
used by Deconinck et al.35), (ii) the charge of the molecule
[an electrotopological descriptor (SsssN) used by Narayanan
and Gunturi37 and a descriptor yielding information on the
atomic charges and atomic polarizability (BEHm4) used by
Deconinck et al.35], and (iii) the hydrophilicity/lipophilicity
of the molecule (log P used by Narayanan and Gunturi37
and a hydrophilicity index used by Deconinck et al.35). In
the third approach,36 the most relevant descriptors are not
revealed.
The present approach is based on clear physical-chemical
principles developed on the basis of structural and dynamic
investigations of the lipid bilayer membrane and drug
partitioning measurements performed with lipid monolayers
and bilayers (cf. Introduction). They revealed that partitioning
into an amphiphilic lipid leaflet is not a random process but
requires conformations in which the polar and nonpolar
groups of a drug are arranged in an amphiphilic manner.
Because cavity formation in an anisotropic membrane
requires energy, the partitioning of molecules with small
cross-sectional areas is favored, and because the hydrophobic
core of the lipid bilayer exhibits a low dielectric constant,
molecules can only diffuse in their uncharged form. For the
prediction of membrane permeation, we therefore chose (i)
the cross-sectional area, AD; (ii) the ionization constant, pKa;
and (iii) the octanol-water partition coefficient, P, as
parameters, whereby the latter two were combined and
expressed as log D7.4. As expected, the parameters found to
be most relevant in the three heuristic approaches are related
to the parameters based on physical-chemical principles
used in the present approach. The main difference is,
however, that we investigated the full conformational space
of the molecule, defined the cross-sectional area in the
amphiphilic direction for each conformation, ADcalc, and chose
the most amphiphilic and at the same time smallest cross-
sectional area, ADcalcM. The last step, that is, the determination
of the cross-sectional area, ADcalcM, of the membrane-binding
conformation of the drug, was possible by a calibration with
measured cross-sectional areas, AD.
CONCLUSIONS
The full conformational space of a molecule was inves-
tigated, and the cross-sectional areas of all of the conforma-
tions were calculated perpendicular to their axis of amphiphi-
licity, yielding a large number of ADcalc values. For calibration,
the cross-sectional area, AD, measured at the air-water
interface was used and yielded the conformations relevant
for membrane partitioning, ADcalcM. This calibration revealed
that the most amphiphilic conformation with the smallest
cross-sectional area had to be chosen from the ensemble of
conformations, which is in accordance with the physical-
chemical principles for membrane partitioning. For several
compounds, including verapamil, the conformation which
meets the above demands is folded. A plot of the measured
cross-sectional, AD, versus the calculated minimal and most
amphiphilic cross-sectional area, ADcalcM, yielded an excellent
linear correlation. The present data reveal that partitioning
into a membrane requires a specific conformation and
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orientation. Membrane partitioning thus clearly differs from
partitioning into an isotropic solvent and resembles to some
extent receptor docking, which also requires a specific
molecular conformation and orientation. The predictive value
of the parameter ADcalcM, for the BBB permeation, was then
tested with different data sets, revealing that the calculated
cross-sectional area alone (when excluding highly charged
compounds) correctly predicted 83.3% of blood-brain
barrier permeation on the first data set, 74.4% for the second
data set, and 71.4% for the third data set. Together with the
calculated log D7.4, the prediction accuracy for the present
set of 55 + 43 + 42 compounds (total of 122 different drugs)
increased to 90.2%. This high prediction accuracy obtained
with a model based on two descriptors only (calculated cross-
sectional area, ADcalcM, and distribution coefficient at pH 7.4,
log D7.4) can be explained by the fact that these descriptors
fulfill the conditions required for membrane partitioning.
The simple and unambiguous criteria for membrane
partitioning should help for the structural optimization of
drug candidates in the early stages of drug discovery.
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Dr. Manfred Kansy, F. Hoffmann-La Roche Ltd. (Roche), Basel 
PUBLICATIONS & AWARDS 
Deleuze-Masquefa, C., Gerebtzoff, G., et al. Design and synthesis of novel imidazo[1,2-a] 
quinoxalines as PDE4 inhibitors. Bioorg Med Chem 2004 12(5) 
 Gerebtzoff, G., Li Blatter, X., et al. Halogenation of drugs enhances membrane binding and 
permeation. ChemBioChem 2004 5(5) 
 Gerebtzoff, G, and Seelig, A. In silico prediction of blood-brain barrier permeation using the 
calculated molecular cross-sectional area as main parameter. J Chem Inf Model 2006 46(6) 
 Seelig, A., and Gerebtzoff, G. Enhancement of drug absorption by noncharged detergents through 
membrane and P-glycoprotein binding. Expert Opin Drug Metab Toxicol  2006 2(5) 
 Gerebtzoff, G, and Seelig, A. A high quality descriptor for the prediction of drug’s passive diffusion 
through biological membrane. Winner of the Basel Award for the Best Poster at MipTec 2005 
EDUCATION  
2002-2006:  
Biozentrum, University of Basel 
Ph.D.: Division of Biophysical Chemistry, laboratory of PD Dr. A. Seelig 
In silico prediction of blood-brain barrier permeation and P-gylcoprotein activity 
2001-2002: 
University Montpellier II, Montpellier (France) 
Fifth year postgraduate certificate: "Interface between Biology and Chemistry: molecular 
systems with therapeutic aiming", passed with distinction 
1999-2001: 
University François Rabelais, Tours (France) 
Degree and Master's degree in Biochemistry, passed with distinction 
1997-1999: 
University Louis Pasteur, Strasbourg (France) 
1st and 2nd year of Biophysical Chemistry (University diploma awarded after two years of graduate 
study) 
1996: 
Lycee Jean Mermoz, Saint-Louis (France) 
General Scientific Baccalaureate (equivalent to 'A' level), with specialization in mathematics, 
physics, biology and chemistry 
EXPERIENCE 
January 14th - June 28th 2002: 
Centre of Structural Biochemistry and Organic Chemistry Laboratory, Montpellier (France) 
Determination of potential inhibitors of phosphodiesterase: purification, activity measurements, 
establishment of structure-activity relationship, molecular docking (FlexX, working under Unix 
on a SGI station) 
June 12th - September 29th 2000, June 11th - September 14th 2001 and 
July 29th - August 30th 2002: 
F. Hoffmann-La Roche Ltd. (Roche), Basel 
Automation of screening tests on a robotized pipeting station, adapted for use with a 
spectrophotometer, implementing transgenic cells overexpressing the human P-glycoprotein 
(Schwab, D. et al. J Med Chem, 2003. 46(9)). Programming of software to convert data from ASCII 
into Excel format (Visual Basic); laboratory notebook converted to HTML form 
July 2Qth - September 30th 1999: 
Wunschheim & Partner GmbH, Basel 
Realization of a website (HTML, ASP); data-processing maintenance (on Microsoft Windows NT4 
Workstation) for the Hoffmann-La Roche Ltd. Company 
 
October 9th 1996 - July 31st 1997:  
Novartis, Basel 
Part-time employee in the electronic mail department of the Information Services division. 
Programming of automation systems for the monitoring and the maintenance, with Microsoft Visual 
BASIC and Microsoft Visual C++, under Microsoft Windows NT 
September 9th - October 4th 1996:  
Ciba-Geigy, Basel 
Employee within the Information Services division, department of data-processing support (using 
Microsoft Word, Excel, Access). Duties included programming of Excel and Word macros in VBA 
July 1st - 6th and August 8th - September 1st 1994:  
Ciba-Geigy, Groot-Bijgaarden (Belgium) 
Employee within the pharma division, department of maintenance and data-processing support 
(Microsoft Word, Excel, Access) 
August 1993:  
Baden-Wurtemberg (Germany) 
Agricultural operator on a pig and cereal farm 
August 1992: 
Canton of Bern 
Agricultural operator in the agricultural federal service 
GENERAL AND BIOCHEMICAL SKILLS 
?  General biochemical techniques ?  Scheduling                ?  Inquisitiveness 
?  Pharmacia FPLC ?  Teamwork                 ?  Problem Solving 
?  Cell Culture ?  Flexibility 
COMPUTER SCIENCE SKILLS 
?  Programming Languages: VB .NET, VBA, HTML; occasional use of Perl, C++, PHP, ASP, MySQL, 
SVL, C# 
?  Software and OS: Microsoft Office, Windows XP Pro, Unix … 
LANGUAGE SKILLS 
?  German: Good oral and written, several jobs in German-speaking Switzerland  
?  English: Good oral and written, linguistic course in Reading (UK), 1995  
?  French: Mother tongue 
EXTRACURRICULAR ACTIVITIES 
?  Paragliding: confirmed pilot's licence, federal two-seater qualification  
?  Deep-sea diving: level 2; climbing; badminton (Badminton Club Aesch) 
?  Former gymnast member, in charge of the young people commission in 1996-97  
?  Webmaster of the website for the former students of Biochemistry in Tours 
    (www.biochimie.fr.fm) made with PHP and MySQL 
REFERENCES 
Dr. Marie-Paule Strub Prof. Dr. Jörg Huwyler Prof. Dr. Anna Seelig 
LBC, National Institute of Health Institute of Pharma Technology Biophysikalische Chemie 
50 Center Drive University of Applied Sciences Biozentrum, Universität Basel 
Bethesda, MD 20892-8013 (US) 4132 Muttenz (Switzerland) 4056 Basel (Switzerland) 
+1 301 451 4071 +41 (0)61 467 46 89 +41(0)61 267 22 06 
strubm@nhlbi.nih.gov joerg.huwyler@fhnw.ch anna.seelig@unibas.ch 
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